var title_f28_54_29536="Non-continent cutaneous diversion PI";
var content_f28_54_29536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Non-continent cutaneous diversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 653px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts one option for people who have a cystectomy (removal of the bladder) for bladder cancer. With this procedure, called a non-continent cutaneous diversion or ileoconduit, urine is diverted from the kidneys through a segment of bowel to the skin's surface, where an opening (called a stoma) is created. A bag is attached to the stoma to collect the urine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29536=[""].join("\n");
var outline_f28_54_29536=null;
var title_f28_54_29537="Asthma control test adults";
var content_f28_54_29537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Asthma Control Test&reg;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 578px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For information on the interpretation and scoring of the Asthma Control Test&reg; (ACT&reg;), visit www.qualitymetric.com/act.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kosinski, M, Bayliss, MS, Turner-Bowker, DM, Fortin, EW. Asthma Control Test: A User's Guide, Lincoln (RI): QualityMetric, Incorporated, 2004. Copyright &copy;2004 QualityMetric.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29537=[""].join("\n");
var outline_f28_54_29537=null;
var title_f28_54_29538="CDC weight for age boys 0 to 36 months";
var content_f28_54_29538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, boys, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 656px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29538=[""].join("\n");
var outline_f28_54_29538=null;
var title_f28_54_29539="Anesthesia machine";
var content_f28_54_29539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Anesthesia machine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    GE Aestiva/5 Anesthesia Delivery System.",
"    <div class=\"footnotes\">",
"     MH: malignant hyperthermia.",
"    </div>",
"    <div class=\"reference\">",
"     Used with permission of GE Healthcare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29539=[""].join("\n");
var outline_f28_54_29539=null;
var title_f28_54_29540="Assessment of optic disc A";
var content_f28_54_29540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Assessment of the optic disc in healthy and glaucomatous eyes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Optic nerve photography: small central cup in healthy eye; enlarged cup and loss of inferotemporal neuroretinal rim in glaucomatous eye; B: Retinal nerve fibre layer photography: uniform reflections in healthy eye; poor reflections in inferotemporal region (arrows) in glaucomatous eye. Reprinted with permission",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     from: Weinreb, RN, Khaw, PT. Primary open-angle glaucoma. Lancet 2004; 363:1711. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29540=[""].join("\n");
var outline_f28_54_29540=null;
var title_f28_54_29541="Cochlear implants";
var content_f28_54_29541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    The internal and external components of a cochlear implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 556px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIsAgkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorl5/Hnh+G6uLc3F5JJbytDJ5On3Eqq6nDLuWMg4II4NN/4T/QP+empf+Cm7/8AjVAHVUVyv/Cf6B/z01L/AMFN3/8AGqP+E/0D/npqX/gpu/8A41QB1VFcr/wn+gf89NS/8FN3/wDGqP8AhP8AQP8AnpqX/gpu/wD41QB1VFcr/wAJ/oH/AD01L/wU3f8A8ao/4T/QP+empf8Agpu//jVAHVUVyv8Awn+gf89NS/8ABTd//GqP+E/0D/npqX/gpu//AI1QB1VFcr/wn+gf89NS/wDBTd//ABqj/hP9A/56al/4Kbv/AONUAdVRXKf8J/oH/PTUv/BVd/8Axqj/AIT/AED/AJ6al/4Krv8A+NUAdXRXKf8ACf6B/wA9NS/8FV3/APGqP+E/0D/npqX/AIKrv/41QB1dFcp/wn+gf89NS/8ABVd//GqX/hP9A/56al/4Kbv/AONUAdVRXK/8J/oH/PTUv/BTd/8Axqj/AIT/AED/AJ6al/4Kbv8A+NUAdVRXK/8ACf6B/wA9NS/8FN3/APGqP+E/0D/npqX/AIKbv/41QB1VFcr/AMJ/oH/PTUv/AAU3f/xqj/hP9A/56al/4Kbv/wCNUAdVRXK/8J/oH/PTUv8AwU3f/wAao/4T/QP+empf+Cm7/wDjVAHVUVyv/Cf6B/z01L/wU3f/AMao/wCE/wBA/wCempf+Cm7/APjVAHVUVyv/AAn+gf8APTUv/BTd/wDxqj/hP9A/56al/wCCm7/+NUAdVRXK/wDCf6B/z01L/wAFN3/8ao/4T/QP+empf+Cm7/8AjVAHVUVyv/Cf6B/z01L/AMFN3/8AGqP+E/0D/npqX/gpu/8A41QB1VFZWgeINN19Lh9Lmkk+zyCKVZIJIWRioYAq6g9CD071q0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcn8O/+QfrH/Yav/8A0oeurrlfh3/yDtY/7DWof+lD11VABmjNFBoAM0UUUAGaM00mml6B2H5o3VCZKYZR60rhYsF6aXqqZfemGWlcpRLvmUnmVS833pvne9LmK5C/5lL5grO8/wB6abjHejmD2bNMSCl3j1rJN1jvSLdFun3fWplVUVdh7Jmv5gpfMrI+0ncAOR39qVbgnowNZfWEHszW3ijeKyxcH16UouDR9YQezZp76UNWaJ+etSLP71SrJi5GX9wpaqLLUqvmtVNMlxsTUU0NTqskKOaKKACiiigAooooA5Xwr/yN3jT/AK/bf/0khrqq5Xwr/wAjd40/6/bf/wBJIa6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlPh3/yDtY/7DWof+lD11Vcp8O/+QfrH/Yav/8A0oeusFABig0UUANNMY09qrytikxpCPJioHmqKaTrVV5OahyNowuWmm96YZfeqZk96Y02KhzNVTLhlphl96oPcY71A9171LmaKmabTgd6ia496y2ufeo3uQO9Q5mipGm9zjvUDXRLBVyWPQDqarwwSzEFz5SH+91P0FX4oktwdoC88s55bisZ17bCfLESOJmG6f8A74/xqYygFQeAfWqstzbRLme4Hfv60z+1LXAC7mGONozmsHzSd2Rqy2WCIQG24OCfWhn8tVIJwx5BHSqR1S3x/qpcdf8AVN/hSnV7YfeSUY9YyMfnRyyDlfYvByN2FY4x361IHznB/wDrVnxapZM5HmhXP96rcciSY8uRT9O9TZoTRMH6Hr6VIH96r4wcAdOlKpO5skYoUrCsW0kI71PHL71RBp6titY1GiHE1ElzUyvmstJKsxy1106plKBfBpahRs1IDXUncyaHUUUUxBRRRQByvhX/AJG7xp/1+2//AKSQ11Vcr4V/5G7xp/1+2/8A6SQ11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJ/Dr/kH6x/2GtQ/9KHrrBXKfDr/kHax/2Gr/AP8ASh66ugAoNFJQA1qqz9KsueKp3LYFSy4IoztiqMsuKku5cZrIuJ+vNYSZ204lmSfFVpbn3qhNce9U5bj3rJs6FE0JLr3qBrjnrzRaafcXQEjDyof77Dr9BW5Da2mnRl8ZcA5duv4elZSqdEDnGBQtbC5nAL/ukPduv5VZDWtiR/HNyB/Ex9cY/pUD3MtyNkBMcB6uerfT/PfpT4YkiHyjk9SeSfxoVNy+IhuUtx7XV3cEbFWBPVuWqL7JuOZ5ZJCeuTgH6461NvApplrRQjHYFEWO3ijx5caLjoQKkOBVczUhmqirExIxUTtUTTVC8tK40gucYrImYwsWiJQ/7Pf8KvSy5yKzbtsg1mzWK7lm18UTWhVLk+Yg43d66nTtUtb+IPG4wRXl2ocg1kW2p3WlXYmtpCvPI7Go5U9yKlFPWOh7wtOrmvC/iCDV7VWgYCZRmSAnp9PT6V0UbhxlT3wfas503DXocV9bPclBqWN8VBSqaIysDVzRhkq2jZrKjfmrsL120qhhOJcFKKYpzTq60zIWijNIaYjlvCv/ACN3jT/r9t//AEkhrqq5Xwr/AMjd40/6/bf/ANJIa6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfh1/yDtY/7DWof+lD11Vcr8Ov+QdrH/Ya1D/0oeuqoADTTS01qAIpWwDWXeTYB5rQmXIODWXc2rPnEgH4VjOaRtTSMW8myTzWTcS9ea330sMf3kzf8BGKfBp1rCQyoHYc7m5Nck6qOyM4xRzVvYXV42Y02Rn+N+B/9etqy0m3tCrMpnmz95hwD9O1Xn/ejblozn6E0y5nW1gaSZlBAyx7D3rBylN2CVRsZeTpaxO8zbzzjI6Z7VjM73cvmT9M5VO34+tZsuoG+ufMOQgPyKf5n3q2kvFbwgolQg92TalcPbabdTQtCskcTOhmbbGCASNx7L6n0ryDR/iHq2gi4/wCE0OqNfRWL3htvKtngnAK4aGSLBC84+bdx3yMV6tMyyo6SKrIwKsrDIIPUEVmWOh6PYNO1hpWn2rXAKzGG2RPMB6hsDn8a0UktypU29UzB1Tx5qOmaRYXd7pulrdX677W0i1CaZ5VCBjt2WxJIyM4GOc7q5m0+IL6h4i0zXPONnpsvh+e6a0uLplgEizhAWIU88Y3BScHp2rqLrTvBtnqNjosujaRHc3hea3txp6bXKD5m4XaCAepwaqLf+GF1nTtEh0NEku7eeKLdpwhRYlOXQhwDtJOcAFT1p3XYlqV9y74F8dnxPfavZzaebKfT/JJIeQrKkillYCSONh07qOxGRXVPc89aw9P0zS9JMh0vTrKyMgAf7NAse4DOM7QM4ycfWsxfFdnJrWpaYIrzz7CSCORkgaRSZVLLjZkgADksAB61m9Xoax91e8zrDN71G0/vWcZ8DrUbXOKm5pYvyTcdaozTZzUEt18vWqMs+e9IpIW8cEGufvhzmtKebNZlydwNIpkGmajcaXfJc2rlXU9M8GvddJuxqOm217CQGkQHH9CK+fpRhq9l+GJk/wCEYi8zoJWxnPTA/pXRQs3yPZnnY6NoKot0dfFIHHow6g9qkqu6nOU4dehP8jUsbiRc9D0I9DXPXoOk/I56NVVF5kqnBqzC9VBUsbc1EJWZpJGpE2anU5qhC9W0bivQpyujmkrEtFAorcg5bwr/AMjd40/6/bf/ANJIa6quV8K/8jd40/6/bf8A9JIa6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfh1/wAg7WP+w1qH/pQ9dUelcr8Ov+QdrH/Ya1D/ANKHrqTQAVG5pzVDIaiTsUkRStVSQ5zip5T1qpIw5zXFUkbxRDI2CuWA/rVeVmjjc9V6AIORnvU0oPy8AoOSDUOPOV8SMAeOO1crZqgkVERHcZZOFPfNec+LdfF5e/ZLdw0UbfvCAfmb/Adq3fH2t/2VpLCNiZX/AHSENgjjBb+n515VYyMzFnJJJySa2hHlVzWlDmfMzs7Gb5RzWmk/HWubs7jCir6z8daq518pwlp8PLyDWtSZNRjh0pUum0lIs+ZaS3CgM2MYwuDjBzz2qhp3w41C20fULOfy3N3bxwSeTqXkpKUYHeVW168HJbeTkgk9a9M873pGnwOtX7RmXsInnGn+ANQttT0LULu30C6ksZZ/NhWBYVMb48vBSIBnQ5Odi8+nWqD/AA91ZGgYro94I/toaK4lcJ+/OUP+rOSvXtyOD3r1Fpqheb3o9ow9hE8zv/AGs/YpreC9srk3Gkx6fJJPI6FXRw2RhW3LxjnFWbrwVqUmpXNws9mElutOnALtnbbptf8Ah6k9P1xXfNPUTSk96XtJB7CJZebHeoXn9KgZvU1WllArM3sTyTZ71WeT3qJnp8FvLcvthQufagZGWJpohebIiRnb0UZrpNP8O7iGuCWAPRThcfX/AArdhsreBQigDjGF4H/16EmJyRxtp4fUTLJqMoWMEEonzFh6Z7V3OneJooBFbR2uyBBtUBvm/PpnNVrq2XbgAYrBvIvLOVOCDVKcoO6M50YVVaep6bp2pW2oRZhYh16o33h/9arR/dt5n8PRvp615nbXwg8icSCOR2AU5xl/T+dek6fcC80+GdRjeOnv0NddOf1iDhNank4rDfVZqcHoXBTlPNV7djsKnOVOOf0qcV5jTi7M3TTV0WYm5q7E1Z0Z5q3C1dVGRlNF5TTqjQ1JXdF3MGct4V/5G7xp/wBftv8A+kkNdVXK+Ff+Ru8af9ftv/6SQ11VUIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5T4d/8g3WP+w1qH/pQ9dVXK/Dv/kHav/2GtQ/9KHrqW6UmAxjUEhqVzVeQ1hNmkSGQ1VcAHoSSc1PL0NVpcfKScYNcc2bxIzy27ccDqtRu4SAsmBn7vHc9KV1WQMFOOecetZviS6FlpF1Mz7VihZi3XGRtB/Un8KyjHmlYp7Hi3j7WP7U8ROkbI0Ft+7Rl6npnP5fzqjZNgCsRZWmuJJXOWdixOMZJOa1rQ9K6JHdTSWiNyCXAq5HOccmsmN/ep1k461mbmmJ/egz1niT3o8z3piLjTGmNLmqpemmTFFwLBkprSH1qs0tPggmuWxEjN9BQAjS5pYIJbl9sSFif0rodK8MvKQ9ycL6V1tjpltZIBGgyO5FNRb2IlUSOT0zws74e5OB6f55rK8SeM7Pwx4lj0JbW0Vvs4uPPv7v7LG+SRtj+RlZuD94qO2a9Hmk2jiuN8U+GIfEizw3mo6ilnOAJbaNo2jbAxxvRihxnlCp5NaRjFPUym5SXuip4w0y4vWsIpZpbtAvmpBbyTJCWGQryIpQH6muc8RfEC0tdH1Z9KZjqtla/alt7y1mhyucbirhSRnjipG8I2mkX902k3d9Y2t1jzrWJ1MbkLtzllLqcY5Vh0rmofhxotpDdk3V4Fms2tJXYxKfLLByxIQZbI+82eOtNOINVLaHfQeMNLKabb6hLPb3l75ccZazmWGSV1BCLKV2E/wDAvarGoREhsVxWheAtA1TVLXU47+6nKTw3cEiSRSKTF90B9hbYccqGx6YwK9Jv7fapOOtTNLoXSck2pHNQW0F3ayQXSgrHKsinOMHqMH8K9H8IMzaY6n7olIB/AVwEmlpeRmKYvteVWCqcbtp4B9s/yr07RLT7Dp0cLcv95z7mtMLzOfkjmzOUY0kurf5FnlbkMej5X8ev+NWBVebPllh/Cc/l/nFWBWWMhy1L9zhw0rwt2JE61ZiNVV61Yj7VnTZtIvRGp1qtEeKsLXoQehzyOY8K/wDI3eNP+v23/wDSSGuqrlfCv/I3eNP+v23/APSSGuqrUgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvK/2hLzUrXRfCcWkXVzbzXniSztHWC9ktPORxIDG0sfzKp4yQCR1wSBXqlFAHzbofxI13wz4NvCRcXGpnxG9nd22qTm5/sSFs7FeSWVDIuF+V3kRTk/MMc7emfFvXryfRLXVZ/C3h+K7guJZdZuZVu7KR0k2rFGYrgIr7cMQZTj3r3eigDw5Piz4il+JbaALDSIrKPU4rEpc3EVvNPA2B9oiL3AZ8kgqixNkHG8niuf034ueJND8BeE9R/su3vLfW7a7t7Vd1xPINQW4dYleSWV3ZGGOCc8HDAYA901TV7iHxboekWixkXMdxdXRZSSsMaqowc8EySx9c5Ab6jdoA8K1b4reK9N8ePoE+naJF9kmtIpRdTxWpu1kUGWSFpbhTgHO1VSX0JB4PWfCbxX4p8X3utXWrQaJFodpeXNjB9mEouWkjkABYMSu3bnoc57AV6TRQAUUUUAcp8O/+QdrH/Yav/8A0oeuoauX+Hf/ACDtY/7DWof+lD11DUmNEL1BJU71A9c0zSJWlPB4qqw2sWY8HtVqSqsuFHXGT1NcczaIxSNxXbtx0PrXMePiR4a1hgxUiADIXPc10c7ASrkHA5yKo65YjULK7tGJ/wBJgKDHqM4/nRQ+O3qOTtZ9mvzPma1PNa9u2Kz72ym02+ltrhGR0PQjGR2NTwS9K1lqd8NDXR+BzUqvVGKQVKHqDZMubhS7qrK1TQpJNIqRKWZiAAPegY8tUlvBNcyBIIyxrUtNFAdRduWlJ4hiG4n64robSxKKqyNBax/3M5P4gZ/Wmk3sRKaRj6f4e3Ya4fccdB0H4966K2gtrVQFRc9eBgflV62t7d/3aXsXmHgB1K5P1NYmqefY3jRXClT19iPUGtOTlV2Ye153ym1FcbmwKvJ8y1h6RFcXrgW8bMO7fwj6mutt7GG0i8y8dGx1LHCD8/61tTi5HLXqKGl9TJmQMOOa8k8eX3i+11vXBoTX62trp0U9qsNksqyzmQBkyUJb5STgHI617Tc+J9HtWEf2xD7RAsB+VULnxVo86YmiuJPYwHIHqD9PSqcYLqjNVptWszwjX9T8bQS6vHFFd3EMVzaeVcPahXEUkZaUR7YyG2thfuuR3BNZs9/4plsLKC8kuzbTfaUnuLSwcyH5f3SMrwggEnBYIAfUc17Rqsun3kbrZXipkZCXIMbD8Twa5aO7Vx96sJSt0O2EedaSZ5p4dk1rQ7eymh02+V7fQQMwWiCcTfaPuB3Q8hTnYcjvtJr0f4Z6x4k1t9Wt9dS6kVZIvsTzweWzKyncM+VEGwcAnYMU6acKODWn4V1mOy1KMyn5RyMn9KTmpaMr2ThrF7dD0DQ9Hgt7hnmlimuo/wDlmhBEf4etXbx9TGrWiWqW39mlWNwzk+ZnHyhe3Ws7w9oWnWerahrGnyTPLqDFpA7ZCnOSAO3NdC3P1xXoxpwgrU9jwatac5uVTV7CT/6th65p8BzEh9VBqOTAiZj6NUsIxGg9ABXDjt4m+E2ZKtTx1CtTR1zQOlluKrK9KqxVaTpXdTOeRzPhX/kbvGn/AF+2/wD6SQ11Vcr4V/5G7xp/1+2//pJDXVVuQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB6UgNQX84t4Nx7nFU475T3pXCxqZoqol0p71YjcMARTAfRRmorq4itbWa4uHCQwoZHY9FUDJP5UAcr4d/4mPj7xPqZw0dmsGkQn0KL50pH1MyKfeP2rr65b4YQSx+CtPurtCl3qW/Up1bqr3DmUqf8Ad3hf+A11NABRRRQAUUUUAcp8O/8AkHax/wBhrUP/AEoeuoauX+Hf/IO1j/sNah/6UPXUNUsaIXqvJVh6ryVzzNIlaU8GqzttQseasyVWkBPA7evSuOZvEjBJIJ4z2prgyICAVZTlc+tPK/Pu3HGMY7VB50Kuf9Ij5OSCwrHm5Xcq11ZnFeNfBEWvyi8sWEN5nEikdf1rzW88K6vp7gTWcmCxAIGc4r395baQ/wCujDdirjNOKSYOCkins2R+o/wrrVWnU3dn+AozqU9EuZfcz54h0+84/wBGm5O0fIetaNnoOp3X+ps5SM7ScdP/AK1e5LGAcm2GfUYNEhjkiaOaNjGwwQUOP5VpGlCX20OWOmtqbPJ7LwwEP+lzB3/55xHPP+93+g59q6ew0disq2lsQAMMifuwT7sRk8dcYrsLaGyhx5MMUZAwCFAP59anLr18xR+NaRw8erMamPm9o/1/XmYlv4eRA6ySgRMuCkQ2ZPqT3/Gr76ZZuE328Z2oY1OP4T1q358Q48xPxNOVkkHysDXTGnBbI4p16st2cH471XS9GiWCGNTeHaCF/ugcKf0rB0vx9ex2qR3ltb3Sr90yD5gPrU/jDR47vULgXbSRzrI7o4G4FSSelYyaBBFzLcyOozwsRHI7Zrz5VWptrQ9ylh06aT16nSR+ONT1Fhb2EFvaKOsgBbaPbtWde3ZmYDUbyS4UEAGaT5c+w6e1VrqG1ZfICFIGG0Ioxuwf68c+1cHr9jqukSqsQnvtHjXcq7t80A7+7qPxYe9VCpKo7voYcijPRWS+87aK+8jVzaEbLedBH8nG09mGPQ1djedV2glr6xOQP+esXp+Rx9K5jR4Z9S0uC8s7mOSRGDwSI27IHbP1qTVHu9M1RL65WddFvgsckmzDWbsu3k4+4Tjk9DjseMa1NuV0VUXVGrqrGEJdWzebat+9RH5A/vIR6Ypb3QvP3XGlkx52kRScAg85B9K56K31w/8AEq8qVtcs28+JDHiPUYOjduD0BxwGwehrvvDsTa7pdvc2MEvloBEQ+EeORCVdGBPDA5BB70QpzSslc0o1YJNTaRxUtrqCOY5LWfcPRCw/MVf03Rbh50a6jwob/V55Y8ce3WvQ7Xw1eSf8fM6xR+m7c3XPbHoO9b2l6NaWG1o13TAcu/b6Dpn9a2hQqS3ViauOo09nzMi8OWctjpqrPkSOxdlI6ZAGP0o0nSJbLVdSun1C4uYrt/MWGT7sPsvP+HStjqcdqQKR+NehGCikl0PEnWnJyb+1uRT/AOoIHU8D6mrI6VBIoZ407Fv5DP8ASrAFefjXeaR14VWg2OWpkqAVPHXNDc6GW4qtJ0qrFVpOlehT2OeRzPhX/kbvGn/X7b/+kkNdVXK+Ff8AkbvGn/X7b/8ApJDXVVuZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHLePr37HZWgBxvlP6CuUg1vjJb9a0PjLL5On6ac4zK+fyFeYrfkKpzjPNYylZmsVdHpkOujj5/1rq9BvhdWisDnkivBG1Vl/iPPvXpPwz1P7TpbFj92Zh+gNRUqcsLjULux6KZQADnviuW+Jsxn8KPpUbES6zPFpYx12SuFlP4ReY34Vo3NwVEfPVuK5q/uf7R+Iui2mcxaVbS6i4z0lk/cRcf7puPypUaymgdPQ9DjCqiqihVUYAAwAKdVO1nD5welWlbNdCkmZNWHUUA0VQgooooA5T4d/8g7WP+w1qH/pQ9dQ1cv8Ov8AkHax/wBhq/8A/Sh66hqljRC9V5KsPVadlRSzEBQMkmueoaRKlwyopd2CovJJPFZEt9LcNttQI0/56MOT9B2/H8qLuR76ddwItByBnG4+ppzhUCoE+UnkAc14OJxmvLA6IorGx8wsZJHlbv5jZH5dBUpt4kVQo3c4IA6D8Kl3YBO3IHOKp+erFpg0gLD7nQD/AArznNy1ZRJJbw5/1ZP1x/I1UdbeEnBCH/YIH8hVW91IIdo6njGf51W0+zur8HaWEOeZH6fh60QhKT03GWnvxF/q7iX6ZzU8F3qE/MEczj1YAD8zUqWdjp0RlnwWA+/Jj8wOg/GsO/8AHFojFbL99IFwCvQHHr/+qvTo4So1eUmNJy2R0sS6kwzK0UY92yR+lJIZ1Us2oRAf7Me7+Rrh5/EN1cxs80ghiUFmYtwo65yemPyqPSNT0/Wg8tlqFtfqvDNBOsgXPY7Sa644VLdv72X7J9Wdr9qHQ6nET7x4/m1QvdxDrdxP9IQf/ZqzIYYe65+pNQ2mo6Tc6veaXAyNf2aI88XlkbA4JU5Iwc4PQ/WtFho+f3sfs0t2aE17bFsmSJjxg/ZAev41WkuIZOPPRVOR8tttPvyDVtYbf/nlH/3yKkEcOPuJ+QqlQS/4dj5Y7alWyubG3QqQGBxj5cZH0qj4immuLSNdBv49OnDku5iL5Ude3HNbWyLB+Rfypki28cbO6RhVGSdo7V0qclHlRisPTUubX8P8jlJLI2N0t5oOoLY38mPtqvAZbW7cjmQxB0KvnncrD/azxhL2+125tZre71PQZbeZWjkjfRZmVlIwQR9r6EVFqGrbmbywAM9uK5rVtXeFAC3LGnGtNuyZjKlR7Fo2WrnR7GwbxBYNPp8olsr9rCQTw88LkzHK7SUIbOV65PNadmNXtvEFxqlrrOgQm7QLc262c3lyuuAsmPM4fHy5B5GM5wCOKOtN/eP51JFrZJwWrZymhKjSl3PVoJfE0wzBqmgA99tpMcfUeccfjV+FfGQUDz/D0/cP5c0efw3N/OvLbTWmjZWjkZGHQq2CK9V8G6//AGvaeVKFFxH3HAYev1qqdW75ZGNfCuEeeGqJ7UeLTPF9oGheRuHmeX527bnnGe+K4HxdrPiC3+K2u2mjyedbJ4YM/kT38kEcLeYwMqBUcGTgDov+8K9gjO35mbA96yL7xPpthql5ZajPBZpa2y3MlxcXUCIqM20ZBfevPG4qFPQEnitjjXc8JT4rar4c8B+GzFdRXuqNpP26VdRhLmceYVJ85rhCWwPuqsjcZxjONm8+JGt2d1rEukWtk1xNq+mWUSXs1xJGBcQbzx5hCYOB8igY5Kk17FoOsabrENxJpWpWV8EkKyfZp1l8s9lbaTg4HQ1zFz8UNGt2uJ2tNSbR7a9Gnz6ssafZY5shSD8+8qGIBYIVz3rzak+abtG56EI8sVqSeNfEuveFPh9Fqdza2FxrIaKK6eESG0tyxw0pH3zGv1B9xXH+Lfipreiz6fbaRd+G9WjubeWZdWTZDZySqcCAM90FVhwWPmMcMMIea9R/4Sjw+tzc27a5pQntt/nxm7j3RbMb9wzlcZGc9MjNFv408LPZy3i+JdENpCypJOL+IojNkqC27AJwcA9cGs6e+qLl6nz740vpdT1/Xb+4jiimum8OTukUqyorNkkK6kqw54YEgjkV614N+JWpax8TLjw7fPpfkeZcfZ101Uux5UY+VpZ0uCYmJz8rwr0xnNdq3jHwxBbW9xP4j0aO3uEaSGV76ILIqnDMpLYIB6kdK6KznhuraK4tZY5oJVDxyRsGV1IyCCOCD613QZzs53wr/wAjd40/6/bf/wBJIa6quV8K/wDI3eNP+v23/wDSSGuqrUkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8w+OnOnaQvZp3z9NteRSSHr68V6d8cbgtf6VbA8LG8mPckD+hry67jb91BCC8rkKoHUkn/Guap8R0Q+Ezrq4Pzc8nivTPgzcGXS7gdcXR4/4AK8z1/wAP6tp0/lzCMsV3LtOQ30Ndx8AJy9hemTgrd4IPb5KxxaaoyuVSactD1LUp8XNsnTG44/KuU8IXJutY8R6uek959jhP/TO3Gwj/AL+mb86k8cawbS1v9QSYxJZW8kgYKDnaM9D1zjFcx4BlvtL0u20zUiGeNcM2ACJTy+cdcsWNcuHhONLmZspRbUT1rQ7wSzzrnlQp/nW9HLXnfhC8Mut6jHnhIo/5n/Gu0jl961jXsyJ09TXVwaerZqhFL70+GcGu6lUUjlnGxeopEOVBpa2IOU+HX/IO1j/sNX//AKUPXUNXL/Dr/kHax/2Gr/8A9KHroLy6WGMkDc3pUTkoq8ikriXUscETSSsEQdSa5m7vWvpO6W6ngHq3uaxPGmvHTtKv9Susz/ZYXlSBTgMwHCj3JwPxqKO/nljT9yVcgEqpyFPcZr5zGYydX3aatH8zphC25uzTBYyEYK3bvVW4vdqrtZTzyBWLNNcAndE4P+1x/Oq0f2qViEUsSeAOT9OK83kfY1NS61EKhYqSB261my3ZaVtpO6Q44zz7Vbt9GvbggyKUXuZOMf1/St7TtMtbNsjEk69XYdPoO1b08NKW+iAzNN0Xftmv+mNyw9Cfr/h+fpWjqd9Bpti11PIscKpwrcKuO9XYC0kru20qPlUgc15V8adXYJDYRSSKZDlwOjKOMH8efxr1KFGMdEC1ZyfiTxPd+ItQYBmS0VjtQNnPXk1a0qIIASK5zSFAcE10bTmC0lljQyOiFgi4yxA6ckD8yK7H2OqCsix4ishqfh69sWt3uFnQIYo5RExGR0Y8AjrzxxiuTg0jxjHpupRWM10kI8lIPtMkEd68SsS8YljJA4OAS30xTvD/AI/jbQ9JvNetpLV73zcTRqvk/u8n++WGQMDPcHtg1oP8RtPghMslhqgVLSO9k+SPKRO20Ejf7jgZ4NWlKOljOThP3rkPiq08T3NpFB4b0/WbNBBIRNPq7vOkueFI+1bdp4+Yl8c/LT20zxVDPrV9HYNPeXtnp8RIvfJZnRT5pDRyIcgnpuUN61oyfEPTYY70y2eoLLaTwQPFsj3EzDMbD58YI9SCO4qST4hafFY3NzJa3UbWtw1tPDLJBG8bqM9WlCtnPG0mneXYlxg3e5tfCuLXrHSNQt/E0lw8v26RrVribzH8ghdvO9yOd3BYkep6124lHrXlQ+KOki3WaCz1K4j+wf2ixjSMbIvMMZzucchhyBn8a3dB8UrqviDULOGTdDBBbzoPI2HbIpI+bed3TptXHvSfNu0XFw0SZ3BlArnPGGtxWVqsDSBWl5IHXb6fian1PVIdPspbq5fbHGMn1PsPevJWurnXtVkup85c8LnhR2Aq6VJ1fQzxFRU1bqzok1ZWBZLdmHqzYrntduzc3G/bsAGAuc1r3Ci2t9vGcVyuoT5Y11Qw0KbulqcDlcqSzEZ5qut0VfrUFzL15qp5vPWqkhxZ0NreM0igGvS/BWoNaajZuOxweex615LouWl3Hp0r0TRA3nQbU3ncML61xVny7HfQXOmnsfQuFYfOM8/yrzjx98N/+Eq1LWrgat9lbVtNh00J9m3+X5cwlMmd4znGMcfXtXojMcY9Otc14+1688N+DNU1zTrL7bdW6L5URyVALAF2A52gHccdl7dR01p8kdN2ePRi5S8kJ4U8Hr4f8UeJNYS8Eq6wLX9wIdnk+TGU67ju3Zz0GPeuduvhU82mX2gprfl+Fb2/+3zWP2TM3LhzEs2/AQsAfuE9s15/448Wav4st7XSXn0i802PxNp9kNRtbZ2tL8SKz7dnmncqMuHXcd2RyuOfRvi1d3mkaX4bgguJtN0Fr6ODVLuxzCbeALwAy8xoTgFgeBgZrz7STWur/Q7rpmdr3wisZ9A8aAg3epa3eNeRT21rEtxCpdGEKs7qGXKZILKDnsar+G/AHi/UpvEuoX+qSeHLvU9QtZwsCbTNFDGUKOsM5KK2Rwk2RjrUmt+Ok8OjS7Twzq9rJo10buT+2tZlku4FeNAwgjlLqX3NkBi7dwM42hnh/wCIHjnxVrVrpml6bo2mGTR4tRuRfRzGWPezKTGFYbs4DKp28Hk1rT5+pEuU0/DfwRXSZLJm10TpbQ6hFsNmcMLpcdWkJ+X3zu9RXpvgDw7/AMIn4O0nQvtX2v7BAIfP8vy9+O+3Jx19TXh3wo8X6rcWHwyttQ1ZNUury8vbe63XFwLi3KIzBJ8TYkfgEeYnCkYAPzH6QHSutJ9TFnL+Ff8AkbvGn/X7b/8ApJDXVVyvhX/kbvGn/X7b/wDpJDXVVYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDxD4wy7/GkSn7sNmg/EsxritMaMa7ayXDoioxkJc4AwOP6V1/xhDDxuoI4e2jP4AtWXpenJeeGb+VkBeOdSrEc9P8A69YJXmb3tA1fE0aXOnW8vDFGwD7Ef/Wqr8KIRa3+tRqAFN1FIB/vJz+oNSxkzeHNrHLR4H5Nj+VS+Bl8u91M9N3kn/0IVGMV6MhYf4y9rWnxapa/ZLrf5LFGYIcbtrhsH2OMH2JqldQY1F2DbdyiT6n/ACKnvrmWPUoyjny44wxTs2Sc5/AVV8VSGBlK90OPwNR9mxcNy/8AD9nGuakZesiBhz1AIAr0BXrzbwHkeKLzcePJcAeg3LXoua83FL2dSyOik+eN2W45MVWt7vDsM9CR+tCtWGLjbczDPSRh+prowdS7aM60TvbB/Mtlb6/zqxWb4efzNNVv9o/zrSr1ou6ONnKfDv8A5B2sf9hq/wD/AEoeuiuLVJhhsj6Vzvw7/wCQdrH/AGGtQ/8ASh66ntUyipaMEzgvHmnWks3h7R44gz6jqcRkzz+6gzcPn2JiVT/v4rsTGqDCqAPQCubGNS+KMrcNHo2mBB6CW5kyw+oS3T8JPc11DisXCMVaKLTb3KsgqrLgcZwatyrkcVA4455rmqI1iypIMqQxwfaq7oAYsbySeSB1+tWioLZx7c1DNlGUjPGcKD1rmZqhsPzM2VCgHAAP8/evD/jJEy6/A5V9pVhkn5c57V7jEu2RsKFUgH6muA+L+hPqGmrdwIGlgy3fJHcDH4VdJ2kXF6nkWmHBFdDAQVwQCCOlcvZsVPpjtW3aTHj0rZnZHYpaj4L0690ODSbYtbWKXS3DRlnlGBnKpub5M5PTjk8c1uXnh3R7+S5e6sw7XMC20uJHUNGpyFwCAMEdsU5JRgVOk1HO+4vZx7GT4g8G2Gp2862rGznuZ7eaeVSzlxCMKMbht44yMevNWv8AhD9C2wgWbh4pnnWUXMol8xxhmMm7ccgDOSa00lqeNx3p877i9lG97GVa+DNAigaGPT9sbWhsSPOk/wBSXLlfvf3iTnr71taXpGmaRPPfW8KwO8McUsjSMR5cYwo5OBgd/wA6UTpGpZiAByTWXqdrc67iBpXgsc5Maj5pPqew9qTqJfGzOrKFFXtqcx4o1qTxFqKwWu4WETfIP75/vH+lbGkWC2dtucc4rotL8IafaIGxIG9S1c94lvorZnit5N6jjNeth6kJRtFHjznKcuaRi69egswBrlLufkmpr66Mjkk1kXM3FbMlMhuZuTzUMZLtheSarysWbitbRIYzG9xvVyjbAoOfm9DWUkt2XFu9kbmjW2HRMfd5P1r1DwHYC+121iYNsU72I9uf5Zrh/D9m7ldql5GPAAySa9w8A6G2lWf2mUH7XcqPkP8AAvqa8yTU53ex6jfsaOm729TrmG5imOo+b2HpU2e1MRQgxnJPU+ppw4rnrVXVlc5aVNU42HA5NPFNUYp681miySMc1ciFV4lq5EtddGJlNkyCpKaop1dqRgct4V/5G7xp/wBftv8A+kkNdVXK+Ff+Ru8af9ftv/6SQ11VUIKKKKACuStviF4fufER0GF9UOrDaWt20e8UopbaHYmLCpn+MkL711tcRa+E76H4tar4oaW2On3ekx2CRhm80SK5Ykjbjbj3z7UAdvRXz/o3wQ1DRPhzp2lWMXh+bXZLlJNWlu83EU8aPKYxD58UqRsFlIz5Pdvqa2k/AzW002xstYuNGvYbTSdRsI1lkeQI8zs0LLmMYCkg5ABBHAoA+iaK8Gk+EniN77wvdGTR5bzTLOzs7i5vpxexssWC/lwS2xKsSOHWVD34NQ6Z8D7+G70WW+XQplguNVe/+8xuYrhf3CHMfzhG+YhuB1GTQB7L4g8T6X4eiuZtYkube3trc3Us4s5niSMHBzIqFd2f4M7sc4xSQ+KdGm1ux0iK83ahfWf2+3i8pxvgyBvzjA6jgkH2rxmX4Ka/e+HrDTtRv9Lkkg8My6Ozs8kg8/7QJYmGUHyAKoz1BAwDitSD4S30WveGdUg0zw1ZPY6W+nXEdsx/cSlspdwt5I3SDJbBCEMT83egD22ivnHTfgZ4gtdB1yza7sjf32mvYfahfYiuCZQ6vLEtorFuvztLIw6ZI6et6B4BsdG8LWWj6bc6hpqxHzpmsrx8yzMBvYs+SQSM44oA7OiuV/4Q3/qY/Ev/AIHf/Y0f8Ib/ANTH4l/8Dv8A7GgDqqK5X/hDf+pj8S/+B3/2NH/CG/8AUx+Jf/A7/wCxoA6qiuV/4Q3/AKmPxL/4Hf8A2NH/AAhv/Ux+Jf8AwO/+xoA8/wDjfH5fiSwnx9602fk5/wAar+DV8zwtqakZJkJ/8cql8ZvDP2S/0j/ic61OHSTma63EYI6ce9U/Anh4XNheodY1mPa65VLrAOQevHtWS+M1fwGlZn/QL5PQk/8AjoNW/B67dTuh2ZIz/wCPGqlgm2O8QknCY578GrfhZturye8OfyYf41GKV6Uh0PjQmoLtvQT/ABRD9Cf8ao+LW3wWp/6ZkH8lrodas1e5ZSSrI7qCPQmue8Vj/R4fbd/IVlB80EyluX/B6eX4kVv+ekTf0P8ASvQq8p0zX7HS9dsPtchTMQDMQQoyvHPT0r1C1uYrmMPC4ZT6GuHMYSVRNrob4ZrlsTVylzIVvrgZ/wCWjfzrrMVx2pZGpXH++azwmkmVW2PQ/CLbtFjP+03862awfBJzoSf77VvV7sPhR58tzlPh3/yDdY/7DWof+lD1D/wntnP4g1DStM0rV9SGmzJBfXVpCjRWztg4ILh3IByRGrEVP8Ov+QbrH/Ya1D/0oes2w8D6joviPWr7w9ryWWn6zdre3lrLZCZ1k4DmGQuAm4D+JHx2piNnTtT8NDxHqNjp+p6W2uzyCS7tY7pGnLIiplk3bhhVUdB+tc141+KOhaDpn2nTL3TNZnS8htJ7e31CPdAHfaXfbuIwexA+orHtfgtFHeWcdxrkkmjWN3d3ltBHbeXc77hSGDz7zuAycYRT0yTint8KdRfwTpvhWbxDZnS9NuYZ7V00spNiOQvtkbztrEg4yFXnnBqWkUmbeu+PtNtW8Oto8lprFtq+qLpn2i1u1ZIWKsxbKhgxGPu5HXrWmfFHh95r2Fdd0oy2SM90gvIy0CjqzjPygdycVya/CUJqz3v9s8N4lbxEYxa4+8hXyc7/AHzv/SsXSPgnJoibdM8RPFJBDPDY3hina5tRKSTjNx5PU84iUnrkN81YThFlps7qLxb4cuLJ7yDxDpEtmkixNOl7GyB2+6pYNgE9h1NaFpd2t/aR3VlcQ3VtKN0c0Lh0ceoYcEV5Ufge8sGrpf8AiL7U2p3NjcTGW1kk3G3DAhjLM7Nv3d246AYwB6vZ6fa6faxW1hbQ2trCu2OGGMIiD0CjgCuSpCK2ZtFt7kbxo6rnIB4JzinyxxzwtGcFen0qVlHAONvYGorhAyFWzg9h1NYbGh45498EyWVxJfaan7s7nkTJJJJ/h/OuLglKkq2Qw4INfTEkSSxBXXK46HtXEeI/h9Z3zPNa5hnIJ3L/ABE9yP8AD8q3jUT3NYVLbnlkcx9anSYitDUPB2r6ez7IxcIvePqB6kdqw5vMtl3XKNEuM5cbR+tVY6FNNXNFbg+tTJOzMFQFmPYVy02sFm2WibvV26fhWno9zqLOoURhc8jZ1/rWywtaSvFfectbGRjpDVnU2NjLO4MnJ7DsK6W0skt03PjNZunaoltCPtUQU/3k/wADXPeKfFRdWigYpH9eTRRwE1K9Tc8yc3N3bLfizxKkUbW9o/HRnHf2FeXalfGZySabqF+0zkljisiaXrzXrQgoKyJEuJevNZ00hJxTp5c0+ws5bydUjUsSaAJtH0572454jXlmPQCuq0/wjN4ivlfTrWSIRkRrcRfKwHue/rg5r1XwB8NorbTEl1mIZfDeU/GPTI/pxXqFnY2lmuyJIwV7AAf5P15rzsTior3YnXRppe9JHlnhvw1q3hKRLnU9M/ty0XkXFkMTw8dWgJxIPdDn/ZNem6FrWma1DI+kXsVwyHEiA4kjb0kQ4ZD7MAa0SzYyBxjPPrWLrHhbS9ZuEvZYpLbUkGI761kMNxGPQOOo/wBk5U9xXA58+jNm23ck1DxT4e0q9+xatr+kWd8AMwXF5HHIM9PlYg81b0TWtO1v7f8A2Zcef9hu5LG4+Rl2TJjcvzAZxkcjI9683vNC8R2XxZ1vWrS21w6beW9rEkumSWBMpjHzCQXByB/ugHr7Vh3vhHx5bRap/ZAnt7W68UX1/PBbXAWW4tpFTynUrNEcAhsp5iHpnpiq9nHuRzPse7gVFpl7Zai1wLC7t7k20rW83kyq/lSL95GwflYZGQeRXkFhoXjKGTRBrp8S61pcOnvDLDaX8djd/afOYrJKUuQHHl7QMSt0yRnNZcfgTxhp1p4otdDg1q0ur7xEL2C+t9XAV7NnXPDS58wAHcWXLcDLdKqFON9xSk7bH0TFHVTXNf0vw8untq9z9nF/eR2Ft+7Z/MnkzsT5QcZweTgeprxvxL4Q8f2t9fWug6l4g1CJba1j0a/fVhGLZ1fMzXab184sM4Ox+MDAqPxH4M8c6t4vt59Rtr/UEtvFNnqFvcLqCLZxWEf3gsBlGJATydhY84Y557oRSMJM+gRQK8S+Hfh74i2XjqC78V6jqstus1yLgxukllcowPlnDXWY8HbtCW6ns2R8w9uFakHK+Ff+Ru8af9ftv/6SQ11Vcr4V/wCRu8af9ftv/wCkkNdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5H8dGAudGJ7LKf/Qa5/wCHM+26vICfvxq34qf/ALKug+PIw2jN2PmLn/vmuA8N6h/Z2pw3DfcPyv8A7p/w/pWDdp3N0rwOit3xe6jHnoD/ADNO8Ny/8Ttk7m1kP5MlZ8TyW+valHcKB5kTSRsOjDr/AFpvha5WTxdFED960m/9CSnX/hsmj/ER3viKMx6gzfwyEMPrjB/p+dcf4n+ZUUfwqWP4kf4V6BrMQudMmZs5jw6sOo5FcJrVsYo5WdjIJAMMe3tXl4LEKVNRe6OmVN3ujFbQxq7WUcRUSXEeCH+6xCHGfToBmmeENVvfD+t/2VeNIImJWNX6qR1U1seGpCL/AEn/AGXVfzGP61S+LUSWOu2d/Eu2QGOY47kNg/oBXpSl7Wf1eWzV16nPFckfaLoz1azuVuIg6nrXIavIRqtyP9utfTmNrdGI/cPSsLXDjWLn/eH8hXkYfSbOuprE9F8BPv0H6SsP5V0dcr8OH3aHKP7s5/8AQVrqq9yn8KOCW7OV+HX/ACDtY/7DWof+lD11WK5X4df8g7WP+w1qH/pQ9dVVkngWk/F/xRLc6NLPp2mXttqNzqlqtnaQSRz77RCybXMjAl+BjaOfrxlWnxw8US+FNd1Z7Lw+Xs9OS8ijE0fmRSmdI2jkgW5eUqFf75EfIwVGRn6SoosB4V4t+Ivjvwg2lQaxpOiXd1rVs8enDT0mdPtplURxuWIJXy3UngEkNg9qjvfil4ntviGfD82n6PDHb3tvayx3M0dtJcxuMNPCZbhWOW+6ixvkcFs8V7xikK1Lih3KLxe1V5YsgitQpmonjB7Vzzo3NFMyXj5Ge1REAsAfvdRVu/ntbQBrqeGHPTe4GfpXM3/iqxiZhaxS3LjgEDav5nn9DXHUgo7mqqLqbDqWYYbGDyKpX+pWulQmXUrmOFCeC7Yz9B3/AArlbrXtVuyRblbZD2jXJ/M/0xWaulyTSeZOzSOerOSxP4msE+Z2irkusuhD4m+KVupMGg2JupRkCe4Uqg9wvU/pXm96NU8QXQm1OZpmzwuMKv0Ar1g6TahD9oSNlxzuArD1L+zbM/6Iw9wOQPxr2cGopW5bP7znnOUtzmdO8OogBkAFazC3sY+MDFZ9/rixghDXK6nrEkpIBr0b2M7GrrWtjlUauOvbtpWJJNRXNw7k5rPmkPepbHYWWT3qlPJyQKJHZjgZrX8PeHLrV7lVSNtpPXFTcLGbpmnT6jcLHAhYk19FfC74dw6TBHfakgN2eUQ/we59/b+vSr4V8GQ6TArGMGXHXHSuoWzYDjNcOIrOS5IM7qOG+1I7QI2QSRkdwOtJ5Y434bHOSK5KO3lU8M4+hNXITdoRtnl/Fs/zrzvYS6HQ4LudEchmIXqM9e9SR/MAcVlW9xcjiTD/AFGDWjFJuAwCD6Gl7KUd0ZtE+K57xp4rs/COnJe38EksLEg7Li3iIwM/8tpYwfouT7V0KAmsrX/COkeJJ7CfV7WSSexZntpYriSB4iww2GjZTggAEZwacIXepDehydl8W9EvbvQ7fTtK16/k1e2F3CLW0Enlx+aYiZAGyoVgSTyAB16CrGi/F7R9T0W51W30XXIrC3YIbi8W3tIZDuZSEllmWNiCnIDZ5HuB0/hrwB4d8PXdjdaRp32eeytGsbdvPkfZC0hkK4ZiD8xJycn3xQPhv4W/4R+x0QaY6afY3X221WO6mSSGfcW8xJQ4cHLE8NXbTpRWyMJSbOYt/jn4TbT7K+ki1OCzu7e6mjmkjj2l7cEyQ5DnMmMEAZB3DmvTdGvhqmk2V+tvPbLdQpMIbgASRhgCAwBIB55AJrgPEXwf0DVNN0TS7SNLTSrDVf7VngcPcPcsc7k8x3yoYn5uucdq9LroSsZ3CloFFMRyvhX/AJG7xp/1+2//AKSQ11Vcr4V/5G7xp/1+2/8A6SQ11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVLUtUs9MiEl9OsQb7oPJb6AcmuWv/H9tHxZWU859ZGEY/qf0FZzqwh8TNIUZ1PhR21FeZP8QtQBJFlbAehLH9c1Ja/EiTzALuxjK9zG5BH4HNZLF0n1Nngqy6HpNFYOj+K9K1MqkU/lTMcCOb5ST6DsfzrereMlJXiznlGUHaSseXfHm3Mmk6VLnAS4ZD+K5/8AZa8lzhVr1z48ztHommwrj95cE/iF/wDr14/IdqKo5Kj9axqfEbU/hN6Vn1TQQYCBfWXygk/ejPH/ANb8qxvAMksfxEihuFwy2zjr1zg/0q14fufs+qxh2xHJ+6bPoRj+eKh0txB8WLUAjDRgce4YUTfNSYorlqI97ljWXSHQD/WQ4/EiuHv0E1hgjqK7jTWJsY9/I21yE0eIpYz1R2T8jivnKDs2j0aXVHGeH71U8TWlj5TB0uFBYnjGQRj8MVY+M/729tIF5Z41UD3Ln/CovIEHjDTbgDAeRFP1Df4H9Kl8Tn+1fidp1p1SO5jBHsg3H9c17WGm5VlUf2Ys468FFOK6s7/UE8udHHauZ1pwdWuD64/9BFddqa7kri9YONTlHsv8hXBh9zWpsd78MZc2V7F/dkVvzGP6V2tec/C6b/Tr2H+9GH/I4/rXo1e3Rd4I4Z/Ecr8Ov+QdrH/Ya1D/ANKHrqq4XwNJOLTWVjk2r/bN/jCjP/Hw/rXSE3DYzcSH8h/IVbmkQa2aa8iRjMjqo9WOKyHiaTh3kYehc4P4ZqM2an+BfyqXPyAvS6xp8QJa7iOP7p3fyrJuvGFjCSIorib3CgD9Tn9KmksI3GHVSPcVl3uiR4LxED/ZNVGae4FC+8c37BhZ2UMfoZGLfoMVzOoaz4h1AMsl/KkZ/hiAT9RzXQmxjXqBUbxxRjoK3SQji4tMvN+/z5cnqSxNbNhGYsC7Acf3gMGrl1cIgO0ViXt65ztqZ0Kc/iQrs3Z7yxtVzvDH0XmsHUfFCxgiBAvueTWDeSyvnk1j3EbMTnNEKEIhctal4gmnY73Zv5VgXeoSSZ5OKmlg9qqvB7VstNEBmzsznrVSWMmtdoPamG1LdBRcDnpozVYWckrYVSSa7Kx0Oa9nWKGNndjgKq5JPpXrngn4ThPLudYXYOohHU/U9vwqW7bgeT+CPh3e61cK3lERA/Mx4Ar3/wAO+DLTRrZUiQGTHLkcmu1sNNtrGBIbWJI41GAqjAqyYh6VjOTlp0NINR1OaOmAdqYdOA7V0xiHpTTCPSsuQ1VVnOLp/tUqWA9K3fJHpSiIelHIHtWZMdkPSrMdqB2q+I6eEqlEh1GVktl9KlWHbU4FLRyInmYwLTgKWimlYkKKKKYBRRRQByvhX/kbvGn/AF+2/wD6SQ11Vcr4V/5G7xp/1+2//pJDXVUAFFFFABRRRQAUUUUAFFFFABRRRQAVjeJtZGk2i+WA91LkRIenuT7CthjgEk4Arz24kOsaxNdN/qgdkXptHQ/j1/GsMRUcI6bs3w9NTleWyM4Wc19O1xeO0sr9WapJdMRV6VuBVjXAqGQg5rznBdT0VUfTY5W508AHArGu7LBJxXbzRBgayb214PFZygbwqdzjpBJF06V2HgzxzLYyJaao7TWnChzy0X+I9uvp6Vh3ltjPFYN3C0b7lohUlTd4l1KUasbSO9+PUiS6JolzE6vF57EMpyCCuQf0rySF/MKk/wC8a1NfurvUNChsxIWjtpDKsZ5xkc4/nisHTS87hIlZ2PAAGTXoRqKquZHkzpOi+Vk12flqeI+V8S9Hl6GVYM/jgf1qa4tYbNPP1OVURf8Alkpyze3tXP2eoPe+L7TUZBsUXEQRf7qhhWlrRaZne8lY+ndIc/ZgpGcZx+dYGpLt1G6XGAxDD8R/+ut7TDttFJPdsfnWJq5J1BGxwyFQfof/AK9fNU3aq16nfD4jj9YRY5oJycCCZJM+gB5/TNU/ARbUfHF5qdwuRBGxJ/uySEn+QNXPFzrDYvu/jIX8Op/QGtP4V2Rh8OG8f799K83uADtX+R/OvXg/Z4Wcu+n+ZlWXNWiu2p1t3hlYYPAzntXD64MarJ7qp/SuzkZvunf9znd9T+tcb4j+XVh/tRKf1NclDSQVNjY+Hdx5PiWJc8TI0Z/LP/stetV4Npl21jf29yn3onDflXu0EqTwxyxMGjdQykdweRXsYaXutHFVWtzlG8CWgurua21fXLRbmeS5eK3vNqB3YsxAxxkk0v8AwhCf9DD4k/8AA7/7GutorosZHJf8IQn/AEMXiT/wO/8AsaP+EIT/AKGLxJ/4Hf8A2NdbRRYDkT4HjPXxD4k/8Dv/ALGoz4Atz117xEf+37/7GuyopgcS3w7s26654hP/AG/f/Y1G3w109uus+ID/ANvv/wBau6op3A4Fvhdpbfe1bXz/ANvv/wBao2+FGjt11PXT/wBvv/1q9CoouwPOm+EWht11HXD/ANvv/wBamH4PaAet/rf/AIG//Wr0iii7A80Pwa8Onre62f8At9P+FIfgv4bP/L3rX/gYf8K9MoouwPMv+FK+Gv8An71r/wADD/hQPgv4bH/L3rX/AIGH/CvTaKLsDg9N+GGmaYxOn6trsDNwSl5yfx21ojwZjp4j8Sf+B3/2NdXRSA5X/hDf+pj8S/8Agd/9jR/whv8A1MfiX/wO/wDsa6qigDlP+EM/6mPxJ/4Hf/Y0f8IYP+hj8Sf+B3/2NdXRQByn/CGD/oY/En/gd/8AY0f8IYP+hj8Sf+B3/wBjXV0UAcp/whn/AFMfiT/wO/8AsaX/AIQz/qY/En/gd/8AY11VFAHK/wDCG/8AUx+Jf/A7/wCxo/4Q3/qY/Ev/AIHf/Y11VFAHK/8ACG/9TH4l/wDA7/7Gj/hDf+pj8S/+B3/2NdVRQByv/CG/9TH4l/8AA7/7Gj/hDf8AqY/Ev/gd/wDY11VFAHK/8Ib/ANTH4l/8Dv8A7Gj/AIQ3/qY/Ev8A4Hf/AGNdVRQBjeHPD1voRvXgub26mvJRLNNdy+Y7MEVBzgcbVArZoooAKKKKACiiigAooooAKKKKACiiigDH8VXJt9HlRCBJP+5X8ev6ZrnbeNba3UDg4q/4qkE2rWVvz+6QyEf7xwP/AEE/nWHq12IsgHpXnYifvvyPRw8PcS7klxdAHGar/agT1rl77WIoXHnSBc9B3NNt9ctJMfvtp/2wRXG5NncqVkdckwaklQODWRDdcAg5B6EGr1vdK2ATTUrkOFtile2vB4rn7+168V28kaypxWLqNpweKUkXCZwU0bQyblrF1KaexdVslKx3DdEGSW9K67UoMAjFZEB2ShXx8rblJ7H1rShU9nIWIpe1hpuZy+CPEOqKtxPEsatyFkbmsvVfDWqaNLDNcLGUWRclGzjmvd9Jv21Hw/DK/E0fyNj2rmPHEAk0W4IHzAZH1r1uVNaHiczT1PR9Nx9jjLdOT+prK1sZiRwPuy4z7EH/AOtWpCuNLtwp5Ea5P4VBrEYj0eUHluGJ+hzXyHN+9v5npxetzyj4l3PlwrCvXYW/EnA/rXpOg2yw+GtMgiACx2yIePRQD+ua8q8ZML3xTaWx5HnRIfoBuP8A6FXq+hkS6FAPTchHrya9vFrloU4fP7zKHvVJy+QXDbWCAjC5AU9a5XxauzU7c/3of6mulud+5SRjAGU6965/x0NmoWJ9YyPyP/165KOkkVPYxG4r1P4baqLvSTZSN++tjwPVD0/I5H5V5kE3pVvQtRl0bVYbpMkKcOv95T1FehSnySuc048yPcqKgsbqK9tIri3YPFIu5TU9ekcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXz74S8Z+NtX8TMtle6nqCw+Jrmxu7d9NjSyg0+Mn5vPEQ/ejoB5hJ4yPUA+gqK8V8P/ABp1XV9C0bUW8GfZE1y9jsdLabVFMU7lpBIXZYy0YXyx1Qli3A4zV/RvjBNrt3pGmaToEZ1u+nvIHiur4xW0ZtiN5WYRMZM5GMJ65xQB63RXky/Fu9k8ZTaFa+Er+8SzvYbC/ntPOl+zu4y0gxBsMSnuzoxHIXFJbfFvUJLrWLWbwjdQ6lZ28tzbaS8kwvrtEkCBkQwCMqeTlJHOBwDQB61RXkFh8YptQn0/TrLRrGTXLy4uYDavfzQJbGCISSLM0tsrq/OAoQjj71M0T4zXfiLUvDdp4c8JT3p1ew/tCTzL5IDbItwYZCQy4cLtLAg5bjgdQAexUVhav4i/s29Nv/Y+s3eFDeba2vmJz2znrVI+Mv8AqXPEn/gD/wDZUAV9WIbX7p852hV+ny//AFzXF+Ibg735q1feKy2o3zHQte5c8Gz5H15ri9d8Rb95/sjWF6/etsf1ryK6bb9T2MK0rX7GcAb7UHYnKqdo/rW7b6WrL0rk9E1naQf7L1Rs8/Lb5/rXWWviAAD/AIk2tH/t1/8Ar1kos6J1EWI7Oa0O+Bseq9j9RWlZziYcfLKo+Zf8Ko/8JAGXH9ia3/4Cf/XqhcayVcPHo2tqwOQfsvT9abgyFUR2ljc8hWq3eRq8Jb2rh4PFG7BOjayJB1Atf/r1ox+LN6pGdF1s5PP+if8A16qEW9GRUaWqI9WtSAeK5e6iwCw610uq68JImI0PXBx3tP8A69cjfawRn/iU6sPrbf8A16Xs3e5pGrGyR2Pw+uy9reWzHkEMKs+KV3aPcD/ZNcP4O8R/ZNYYf2XqriRcbUt8n8s122p3P23Qp5vs9xb7gw8u4TY4+or1aLvBXPIxCtUdjs9Kl8zRLbJ5aIYqee3M0TxOQQUIx+GKoeGm36DYOq5AiFam4Kjt3YcV8dU0kztjseHwn7d49gbqE82Q/gCo/pXqXhZ8adcq2cRylsD6D/CvMfCiiTxndnrstXI/GQV6P4Wk2XF7EehVXH4ZH9RX0GYfEo9kicPrTcu7LUqRtKsZ3kgnJxg8c1i/ERMf2ZIBwC6/+g1txk+dKxlwgGAO4rJ+IwP9mWUhGCs2D+Kn/CuGm7TRUvhZg2pyoq29uJlyBzWfZNlBWvbHpXXexgaXhPXptBn8m4DPYyHLAclD6j+tepW1xFcwJNBIskTjKsvQivKDAky4Iq3o95e6JKTaNvgY5aFvun6eh966aOI5dJbGU6d9Ueo0VmaTrNtqUY8tvLm7xOeR/jWnXempK6MGrbhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVNP02x02OdNOsra0SeVp5VgiWMSSN952AHLHuTyat0UAZLeGdBfRE0Z9E0xtHQ5WxNpGYFOS2RHjaOST06mo7rwp4du9LttNu9B0mfTrb/UWslnG0UX+6hGF/AVtUUAYU3g/wAMz3ttdzeHdGku7VUWCZ7GIvEE+4FYrlQuBjHTtUUHgbwlb29zBB4X0KKC6UJPGmnwqsyhgwDgLhgGAPPcA10VFAGC3g3ww2lLpbeHNGOmLIZVtDYxeSHPVgm3GffFX7fRtLtruC6t9NsorqCD7LFMkCq8cOc+WrAZCZ52jir9FABRRRQBw2qLt1i+X1bP5gVxXiGHcko9Qa7rXVKa/N6MikflXH68PvD1zXj117z9T2sK9F6HLaBGCqH2FdPGduMVzehnaqD04roh0FYo6J7mtanenNTPArjmq2mndkelaParRzvRmJeWpgYSR9RSQTZmDrwAOnoa1LoBomz6VzaXAhuSH4RzjPofWjbUpO9kdBcyiS0x3JArm9Xg+UnFam8hkQ9OtR6ggaI1tD3omM/dmcdo8v2bxDbN0BfB/Gu18S/8eM/oVP8AKuFuP3OqQt6SA/rXb+JSP7LZvVP6V24b4Wjkxi99M6PwW6/8IrY+vlgVqJFmFmfgDpWH8PyZPDVt0+VcVvzFnUxfdyK+Urq1SXqbw+FHiXgIb/E+ose1qo/NhXb6dN9n1dRnAlRk/TP9K4r4e/8AIx6kP+naP+ddRqD+RfWz9hIM/TPNe/mCvXa9PyHhf4J1NoT5hcIpLMEz7daz/HEBl8MOclmhdXye/OP61qxgxwKSCd/y8HFN1O1F3o19axksxRlGf72Mj9a81O0kymtDznTmygrbtj0rnNOfAAretm4FdjMDWhNW0PrVCBulXYzkVIx+BkEZVgcgjjFbmn+Ibm3AS5H2iMd+jj8e/wDnmsTGaCCK0hUlDZkyinud9Y6tZ3mFhmAkP8DcN/8AX/Cr9eYEZGCMirVtql9akeVcSbR/Cx3D8jXZDF/zIxdHsei0Vx1v4quVOLi3ikH+zlT/AFq6niu3P37aYfQg1sq8H1M3TkjpKKxF8S2BHPmr9U/wp3/CSad/z0k/79N/hV+0h3FyvsbNFY//AAkWn44eQ/8AbMion8TWo+5DO34Af1o9rDuHJLsbtFc//wAJPFn/AI9pfzFTReIrNv8AWCWL/eXP8s0lVg+ocj7G1RUFtdwXS7oJUkH+yeR+FT1pe5IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBynixPL1K2l/56IV/I/wD2VcfrkeQSBXe+LoN9lFOOsL8/Q8fzxXG6khaLIry8VG02erhJe6jz/T2MV3JEezn8s5rp4zlBXO6jCbfU1lX7snB+oroLQ7oh9K5LndM0tJbEpU9xWqRxWVpX/Hz+FbeBitI7HNN2ZTuFxGfpXJagm6LPqSa7G8H+jyY7Ka5e6UeQo74qmvdCD98i0m5NwgRz+8jGD7itGc7ozmubgc290ZV6A4PuK6AyCSIOpyCKqD5UhTjzNs47XV2XAYdjmuu8Qtu0CN/WMH9K5bxCMsTXSay2fCdqe/l4rtwz3OPGL4WdF8O3C+HrbnHauhucGZdxwK5H4cK0miRrzw1dXcsGBTHzLXzGJ0qy9TWn8KPFfApMfiy9U/xWyj9RXWa8m5eK5/wjBs8eanbEfObSQKP9pZVx/KukvmWfBQ5GK9zHSvXv5IMI/wB3Y7CFvMs4pk/iVWGenOKfbFw2JGXLEkADqPWqejsJPD9vnadqFPm6ZBI/pViLaPKGxRJkkY6CvMktWanmmqWh07Wrm3wQivlP908irdq/Are8e6eXgi1CMfNFhJP90ng/mf1rlbaXBFdlOXNG5zyVmb0D9K0IXrFgkq/BJTBGqjVMMGqcT5FWUapGP2ZpPKqVTUoApcwWKnk0nkiru2l2iq5hWKYhp6xVa20oSqUhWK4ip4iHpVgLVa+YsUt0OC4y5HZe/wCdNSE9Cs8ruSLVFZVOC7HjPt60wXDRkfaYwF/vpyB9RUsUbXcrRxsY7eL5SV6k+gpt1bvZjdvaW3PDbuq//Wp3I13LKoUZZIWKt1VlP9a1LHxBPAQl4DLH03Dhh/jWHpzeVObcnMTjdH7HuP6/nVuaKtadRx2E0pI7a0u4buLzIJA69/UfUVPXAW8kttMHgZkYdxXTadrSTAJcjy36bux/wruhVUtzGULGzRSKQwyCCDS1qQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFXVYPtOnXEQGSyHaPccj9a4Nl8y1I7ivRq4bUYfsupXUB+6W3r9Dz/wDW/CuPFx0UjswktXE4PV7cujqB86ncv1FLp8u63Vh6VqatFtk3AVhQfuLySP8Ahb51/Hr+tebses9Vc6LST/pI+lbx6VgaJzOT6Ct4nitIbHNPchuuLSY/7Jrn7mDci49K3L9sWcvuKolAQBirfwEw+M5byTumBHf+lSabMVR4GPTkfStNrcGSb61j3UZgnDjtVtaIIPVmdrZzmt3U2z4OtT/sVg6t8wJHetnVDt8F2g7la6cL1OfG7ROn+F/Gi4966ucIJQT3rmfh3CYtCRiPvCt+dmKjI4FfNYp/vJepVNaI8ov3/sf4t28oG2KWZoj6ESJn/wBCb9K2nUx6ncRn7pbcv0NUvjJpsqNZapb8MAACOzoSw/Qn8qtQXkWpxQ6hBgJMgkx6Z6j8D/KvWrPnp0q/dcr9URQfLNwOq8NAiwlQ/wAMpx9CB/XNXYwykAngDLseM8dap+H/ALko7EA/zq2saKrjeGWQ85OMVxT3Ol7j/LjmtzbzYlVkw2RwwrzjX9Il0a8OAzWjn93J6ex969Gi3q5VXXy0OMFaWeKG8tmhuYw8bryCODThNwZMo3PNbWbIHNaUEnSnav4YuNPLTafuuLfqU/jX/Gsu3uecHgjsa6lJSV0YtNbnQwSVejf3rCgnBxzWhDOMdaTGaqNmrKHIrMjmFW45QaljLY607NQK4p4akBKDTgahLgDJIA9TUDahGP8AVK8p/wBkcfmatEsv5rJknGLm4Pc7V/3RT5LyZ0KxwMjMMBiw496rXS+TZqoGQmDj1xVruZyd9jX0+LybSNW4fG5vqeTVh0WSNkcZVgQR6imROsiK6HKsMg+1SDrU3Lsc3kwhDITutpcE+oB/qK6BxWHqSbrjUU9Qp/8AHRW3bMZbaGQ9XQN+YrWJmuqIynNORKl205VroiSy3ZXM0HCP8v8AdPStm3v1cASLtPqORWHEKuRCuiMmjNo20dXHysDTqzYzgZJxio5dXt4SVWRpXH8MYz+vT9auVWMFeTsRyt7GtRmucm1u4Yfu444h/tHcf6AfrWfNfyOSZriRs9i2B+QrhqZpRjpHU0VKT3OukuIY8h5UBHbPNR/bYj90lvoK5FLog7Y4nP4Y/nV63mlPLgL+NZLMnJ7WH7Kx0QuQ3RT+NSK+ayIpwOrCrsMwboa7KWI59yHGxdopqNmnV1ogKKKKACiiigAooooAKKK+YtbvfiFc+Kfib/wjerXT6VFM1rMZLog6YixiTzYAW4JAkTCYOWU9uAD6dor5u0L4h67o+lafcxWtzrd7F4Gi1QiW6uJHllN0IyzJvKEAEsW2byARuxxXS6r8SPES2/hiDwzrPgzxBqGtXjWpkhilS3t28oOFfbNI2c8nIBxxtHWgD2yivEbL4qeIz4vtdJvLPSjcNrn9kT6TDHJ9sSEICb4MXx5OckfJjH8Wa5e3+LmueKtAlsbpdFuU1LSdX+2W9hDIs2nCGNxG8jGRhtfAABVeTwTQB9LUV80eFviX4j8J+ELPS4tOsNTitfCNpq9n5UUivGGlSEiX5zvVQS5KheB+I35/i74gWO4ishoeoomvWOlQ6xbQSfY7pLhWLlF80nfGQAcORz2oA94or57vPjP4ptbFopdO0oXMOt3+kT6js2Wi/Z1QoSstxGELl8fNKPunG4/LXrXhbXdZ1zwBYavHY6W+s3EQY266gDbFg+1sTxCUYwCRgN2BxyQAdVXL+Mbfa9vdKP8Apm5/Uf1pv27xx/0L3hv/AMH0/wD8h1Q1qTxreabNE/h7w4ONwK65OTkc8D7HWdWHPBo0pT5JpmLqUe6ImuT1MeW0U46xttP0P+RWibrxXLBgaLoZBH/QXl/+Rq5/Un8S+VKj6Ro4yD01SU/+29ePKLPbpzVrHaeHV3K7+vFbhU4rifDU3itNPRo9G0R1b5svq0qnn2+zGtWS98Wgc6HoP/g5m/8AkWtIwdjnlP3jT1Pi2I9SBTG28VzWo6j4pKANo+iDkdNXlP8A7bVnz6z4lj5bStFH/cVl/wDkelLZIqC1udQuC8v+8aydXjGCQKwY9f8AEJJxpejHJP8AzFJf/kenT6h4jnX/AJBWjf8Ag0l/+R613ViErO5XvMmIg/StnxQwtvD9han/AFhUcfWuK1nUNZtZojd6dpqIPnG3UJDkg/8AXDt6Vt+HP7U8a+IIZniItLcgtJtwuBXVRXs6bqSOTFT55qK6HrPhuP7PokKYxxx+da8Q3xguueKdbwRxwJGANqjFTHC/L0FfLVHzTbN46Kxg69pX9tafLZOQBtyjH+Fh0NeOaLfTeGdXfT9QUpbmUgBukbd1Psf89a9xZjHcttPykZNcz428Ix6/A9wgRLoLjkfLIPQ+/oa7cBioRjLD1/gl+D7mdWDupx3Rf8PSxuriNtwC5B9Rxira7Z1UDfgksRgDiuB+HUWoaNqN9a36zGOONQiSfeUZ7How9xXbx3yXXyW02XV8bejAY7ita9F05WTuu5rTnzq7LDnz4InY7Dk4wCaV9z7Xjl7bcNxkiiSPzuf3qtGT2xke1MlVpmVCFEgGePryP5VgaFlZSuFc5YcMB1z2rO1TQbHUmZ9vlXH/AD0j4J+o71ZRh5shj3yEKFYdj2pVxCiIJM4Y4OeooV1sLc5C78P6jZZaJRcxjvH1/KqAuXibbKrI3owwa9DjnygZsICcYY85pZVinG24hR19HUNj6itFVfUlw7HCw3w9auxXq8c1uyaJpNyRi2VSRn92StRt4Z04g7GuEx6Sf4iq9pEXKygl6v8AeqT7coGSeKsDwzZ44uLr/vof4Up8PWEa7nuLkgdcsP8AClzoLFXz1ceZOfl6qp6fjSfbC/Ee1F9T/hWl/ZFhIpP7xwvX5zRJodkwAUzKT3ViaftUtET7O+rKKPMeVlRj6EYp5kEymOQFX9DSTaI0Q3W4SYf98mqbZ3eWzvHIvRXHI/OtIzuZyjY0NKufIf7JKcc/uyf5VtLXLSx3DqPlWTHOVODWjp+oyomy8hlyBw4Gc/WqsCl0Yy6G/UL4D+4ufyrS0aUTabDjAZB5bD0I4/8Ar/jWHb3qM9yJCVlkdmwwwcZ4/TAqfQL2K3uZ4Zm2LJhlY/dz059O1WmQnqdCBTlWq819BGdqyI7+gbgfU1XlvIV5ln3E9FQ4FOWIhT3Bq5qb0iXdIwUe5prXzEf6PH/wOTgfl1rNgeNlMiqqYOD6/jU8FtdXpyv7iH++w+Y/QVl9cq1Xy0kLkS3G3U+Tm6mZ88BO3/fIqe3s7qePeEW1hAzvl4OP93/HFaNrZWenIZiBuUZMsnLf5+lY+r6n9pI82UW9puAAZgNx7fjUVaMaS58Q7t9ATvpEq3JimmMFo0s7L9+RjtUfgOn480uYYCFJLyHoqjJNNsop9SmNppgEUKn95Ljhf8TXY6VpNrpqfuE3Sn70r8u34/0rPDYWeJfMlyr+thymo6GFa6bqNztIjS2jPeQ8/kP61qW+goozcXEsre3yitoUV69LAUafS78zB1JMqw2FtEMJCv8AwL5v51ZVQowoAHtS0V1xio7Ii9woooqgCiiigAooooAKKKKACiiigAooooAKyvDHh7S/C+jx6XoVr9lsY3d1i8xnwWYsxyxJ5JJ61q0UAFFFFABRRRQAUHmiigDzy8gNpqNzbkcK5K/Q8j9DXO6uuZSo6twK7fxjAIr22ugDiRTG3pkdP0J/KuRukEmqW6+rZ/LmvHrQ5ZtHs0J80FI6KxgWCzRFGABiqd7NtU4rRmOyEfSuc1ObGeac3ZCprmdzK1S6CjJPSuJ1XU3mlKoeM1o+Ib04dVPIBNc3axmR8+tc72udsVubenRO9srEmtCJ2j4JqTSoh9hTipJISe1dnLZHC53Zq+GtOstWu3i1C3jniVN21xnnNeg6dZ21haGKygjgiHRUXAri/A8P+kXTHsgH6/8A1q7yA7bZd3piuOcm24vYxr25rohfeqkg9OanMgaJWYdaQKskZ2frSsuyArjJrypxsxp3E8uMox65HeqyEpblDnbn5TUoUJECT9RSiSGSMoCOKz3K2IJYUcIGUEbDz+IrlNd0N5JVNpIS7H5cnaQfZhXWxhhDk/wngeoqKVTy6sOxHGePau/DVpQScQcVLRnAi91vS3VZpZJo4j0nBYf99j+taEHi5So+0WUsDbtzPGRKMd/eun2K29BG2Gf5iTj34qhd6VbXQmaW0jWUfdkHycfUV1+2pT+OH3Eckl8LIrTXNOvHXybyKNmyGic7ev171omO3LJHHIflycjnOfeueuvCsEkYNuxL/wC1iQf0P61nv4XvrNgbF/3mfm8mYoV/A8frR7OjL4Z29Q5prdHZt++hWXymJXhVz196HKq6rtaMsud2eQTXGtN4g06UGSWVwo4EkQk49ytSw+JryBwt3awTHJPEhUj8Dml9Vn9lp+jH7VddDr0VkbaxDIBzIx9ewoXJMZwQF4OZO3rxwa5yHxHbSKouYLi3bjICb14+hrQi1bTbyMRwXIjKHjzAVz+dZSozjui1OL2ZqIdzEblLK+CXUD6YqlearZWN5a2VxmO5vSxhTZkEjtnpmr0E0FwAUdHUd89xXiF3NrXjPX1sJrhJlt5pDG6KAqLnk5HUcDFFOnzvUtK+p6c3jjR4ruxgYyK12M8AHy2zja4ByDmuhkjCyeYFdmyPuntXnsvhB9HslMawFupkeHJJ9ck8Vd0DxfHZxy2et+b5iEukqguGX09ciqnRtrEzVSLdjtlDiV9xJUkFcHGKZc20N9EYrpV8xejL1X6GorWW2vrGK5tW822mUFCucgE1KxHmKq79wwQWHQd6yWhTOfuY59MkKs+V6oezD+hrRtNSR1A4JrQ/cTQeVMAyHpxzxWZNZrbT5Kgjs2K6qcrnNUjYqalam5lDRgK2cg+lWY7GNUO5QWIwatRkdamjXeea2UTG5m6cEjZrOO0ikmJLeZLghV/H0pWsbXzC7ShY1PLLhd59vQU7WIUeMjo3Y1TjMZtpL+5j8m0T5QMklyP4VJ565ya56tNytGKLUu5t6bHCyGaXZDZRnChjgMfekufHGhWjEPeByOyDNcbLBfa7cLdapN9k0qIjyrdP4wO3sP8APvV0Q6YFCxaasqL0LRbgPpkfyrrpRjQSite9jNyctizc+MrfUpkAlVY/4I93X3PqaraksPiBYtNmtre5jncKI50Dp9SCMVBdW+mX0LWzw+SCMBQNmPoOlUdBM/hPWbe7u3N3pyMRuI+eNSCC3vjPT8fpx1MKqs+fn69e3kUp8qs0d/Y/Dfw/YWyR6Wl/pjqAN+nX01sCfUojBD+KmrI8O+ILQj+y/GF26gcR6pZw3Kj8UETkfVifeunglSaJJYmDxuAysOhB6GphXuxslZGDMTQz4mS7Meuro01rsJFxZmWN92eB5TBhjGed/wCBryzwPriXGuatJ4s17VofGUOrypb6JHeSIGhGfLRLb7jxsnJkKnH3twxmvbx1ps0scMLyzOscUalndzgKByST2FWI+f8AS/jV4lntTPHpGn6xO2m3N7Np2nRSLPpckblVjuCWYnI/2UPoCOai8V6/d+Jn+Gt3F4i8Oapevr0DBtNt28u1doWO2RfPZmIPbKHjoO3t+meKvD2qvMml69pN68MXnSi2vI5DHH/fbaThfc8VDD408LT2RvIfEuiSWYlWAzpfxGMSMMqm4NjcQDgdTQB4Ra+O9V1zxV4R8Q3emw3GrWFnrsf2WyDBbh4VXAQMSRuwBjJP8q1dE+Nesz+HtY1LV10e3it7OG4iktUjuZIZGdVaKW2S7LgfNgSO0QB+8AflPs0fi3w3JbTXEfiDSHt4fK82Vb2MqnmjMe47sDeCNuevbNTW/iPRLnWZdIt9Z02XVos+ZZJdI06Y65jB3DGfSgDwvTfjL4w1f7FYaXZeHm1W51qXS0lnDiB0EQkjf91LIAeedruD2PevoSz8/wCyQfbPK+1bF83ys7N+Pm255xnOM1LRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGR4qtvtOjTFfvRfvR+HX9M15zE27XbUN6H+VetyIskbI4yrAgj1FeQ3K/Y/EEUb5/dStFk/iM1wYuOqkd+DldOJ0962Iq5DWZdisa6u8OYfwrhvFEmyBzXJVZ24dHFXshnmnOeMVJp0PTioLUb1nP0rW0+PkVEtEjoi9Zf10N3SY82airhg+XOKbpCf6Iv1NaojBSu17Hl31JfA8qjUbqBgCWQMPwP8A9eu4ZQUAxgV5rYyNp+txTqMjoR6+1egRXSPGGViUbkGuCq1GWvUKsW9UTJsgV2kYKvqTUTahbZ4Zj9FNZ14Liadm2M8Y4XbyBUQjkHWGX/vg/wCFL6vTlG7ZjztM2UMU43xMDVeSEiXeBz7VQAKfP88ZHflTU0d5MDncsg/I/mK5amDe8NTSNXuW5ceV8h5700qQAV+ZT1HpTftyFDvRg3qBmlj8mRN0RYnuK53CdLVo0jJPYQhX4PUc8jkVHLCzBdsrLt/HNWWHyhZFz/Soo1DykIXCAc5P+NWqy6l3GrGUclSNpGAuOBTTbjZIpdmDnPJ6Ub1EhzNtUd2xVW81W2tIy8s6qo/ikIQfrWkHz/CO5ZNuM7hgkLtAI4qOexhmO6WJJScZD8iuS1Dx9YwMywvJcEdBFHx+ZrHl+JU4P7vTWI9WlAP/AKDW3s5LqWqcn0O6l0KycqfJVQCchPlzn6VC3hy2AIjaQAjkE5yfyrj4PiWcjz9PlUf7Lhv6Cro+JmnquXtrkn0CAf1q06q2YnR8hPiNpd3beGHlsbrYkTAygfIWQ8YyD6kcd65r4UxXFrrqk2s2yVMFthwOhzWhq/iFvGun3lpZxPDGi7olY8yOuGxgewOPfFa/w9vfEF3bxteysbVMIvmjDEDv/wDrrojzRh7xnJpQcUdX4nlJttrcLivKdRH+lpJgHD5+owa9V8UbfsG9+UBAOPc15Ta3sOovcRNH5U4zwTnI9B6VVN31Zz8rauiX4feI5tO1OKwurlxYOxVYyu4KxPGPQZr1ncodnQswxxg5HJryHwUNOj8RMuqHYzcQO33Vf3rvdR0S+g3yWUjnPP7psH8u9Z1IQc7XsdEm7J2Oh+YNtCEAZAwMA96mSNXTbIFGRjBPNcKviPVdPYxajALlACoX/VSdfToa29K8VabeSCOWXyJd3Ecw2H/A1X1epDW2nkYupF6GlPbPAcjJT+VIkm0Vpq4ZcfLjPJ7Yqpc2YY5iIB9KuLMpRMXUZiTWDf3Mt/Lpul5KxeYxyp52g7mP9Pwrc1GF0zkGl0NA2jynaPMDNzjkc1VKfJO7IkrqxJp8Ed7JJcXH/HpB8qR9iRTzc3d0rSWcUaWy8Bj3+lM0j59DmgBxKrMD+ZrD15ItW0S10x4rpJonBUwTSQsrDIyGQg9/WldJAWLuQXTG3uoxHcDlSvf3Bqko+32VzY3B+Ygrn+RrJ1XQ7+0urVdP8Q6h5nH7u7VLlF49SA/5vVS3n8S2mqy7rXTNRAUbjBK9s3U9FYOP/Hqh6SumPoepfB+/nn8OvYXbbp7CTyuTk7CMrn8K70V4R8KfF8dlqmvTatpurW0RkVS8Vk9yiYHG4w78cDqcCvXNH8WeH9Yl8nTNa0+5uM4MKTr5qn0KZ3A+xFerC9ve3MTdqrrFn/aOk3tl5nl/aYHh34zt3KRnHfrTtRvrXTLC4vtQnjtrS3QySzSNtVFAySTWX4b8WaP4kZhpM9w5EazKJ7Sa38yM8B08xF3r/tLkdOeRWgjzdfgZbyWVnaXeuyvDB4dbQGMNsI3fMvmiXO84weNmDnnnmoB8CYprSKHUNVs53F5ZXM8ptLmRrpLYMoikE11IpBVsDAAAyMEYA9srn7HxXY3njXU/DEUVyL+wtorqWRlXymWToFOc545yBQByGrfB/Srzx9pWv2dwun6baiA3GkW9uqw3LwbvIbIIChdw+UKQQo6daq+FPg5B4d8V22qR6kl5a2t5PeW0dylyZoDMCHCsLgRc9yYckcHPBHdeHPFNjr+ra9p9nFcpNo10LS4aVVCs5UNlMEkjB7gVv0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeYfEW3NrrIuFXAcLJkeo4P8AIV6fXF/Eu28yztJgPus0Z/EZ/wDZa58TG9N+R0YWXLUXmUvME1orKcgjNcJ4w4hIro9DuS1isbdU+Uj6Vg+MY825Iry5u561JcrOL05f3c31FbmnqMisfTxhZRWzp55FKey/rqaLeX9dEdJpI/0Nfqf51pR9KydLnSONopTtIJrRE6Y4Nd19EeY1qxwtRctIuOQtWdN1RrF/JuyB/tN91vqex96fowLyyv8Aw4xn3p2pWiSqQwrmqRVzeHvKzN+HUbZ4xjdHn2yPzFH2uJZApnXYe5OK82vLW4tnJtZ5YvZWIFQJeauOBeSH6gH+lc7gh/V09menS36KSsciMPUGmrc25XMqRs3rsz/SvNzdaww/4+3/AAUf4VGzaq/3ryf8Dio5Nb3ZSwvmelm8sh/ywBP/AFzqGbUYol+VRGn0C4rzY2t/Jw91cH/toaQaI8hy5Zj7nNJ0lL4m2UsPFdTu7vxXYQR4NzbjHpJvJ/AVz2o+PIwClpFNOT6Dy1/PrWXHoH+zVqLQlH8NONGC2RapQRj3XiHWb1j5BW1Q/wDPNct/30eazjp090++6lklc/xSMWP612sekIvapP7PRe1aWZacVsccmkqo+4KR9PUD7g/Kuukt0XtVKdFwaTNEzk57NRn5R+VZd5bgK2BXVXaLzWLeICDSRYvgwFLdmQlXSfII6g4GDXb3Op3mnILuzQPbj5riFR9z1ZR/d/8AQfpiuK8IfLeXUBIGcOv8j/SvQobdjGrLwRXfTipwszwq94VWaVtrFpqOniSRd9s67ZlHJA7H8DXmlzaaVZas72+rZKvna0J/LNdVBajT7xpbYiNJD+8hPCHPcf3fp0+lcT4xsjDem6jyEbAZSMEehqFDkdjahKLla+5Pf6fAz7zcoqyfMuUbkexrofDev6jpkYhe6iv7YD5UkJDL9G5/WuHs9UliiETqk0QOQrjOPpW1pF9pc10Dq8cghYYzESDGfUe1KSjJao6tY2i43R6APE1jdp5eo6WTGTk42yDPrziq8ugaHrSgaddCCU/8sZRnP4N835Gq58Ns9uLrRL+O7tz0DsM49Nw4z9cVnMJbaQR31u8L9twwD7g9DRSsv4crEypU6hNLY+IvDfMEsv2ccAD99Fj6Hlf0rT03xwCFXUrUoB1mgO9T9R1H61Lpmr3VuoQSieE9Ul+YYqxPpuk6sdwQWl0ecE4Un/e7fjXRz3/iRv5o4p0JQ+Fmgt5Z6rAXs5kmUddp5H1HaqthizuZIX4jk5U1iSeHL/Rrh7qwu5YnYYIkUNFIOwJAqy+tQeRs1lPssw4LAHaT6r6/hms5Rje8Hcxu+pfuLeezuWntAHV/vp6+9Vpr+6IIitSrnuQBToLwumbK5gu4/wDZcEj8qSW4uiD+5A9yQKzldaAZxga333V24aYjj0WqDTLpunXGo3Z2luFB6+w/manv9T0+1bdqF2ksoPEEJ3tn3/8Ar4rQ0LQLjxfeW11f272+lwMHCPkFiO2P8/h3cKLbTktBOXRHU/CrTntNAku5YzHLfSmbaeoXooP4V0us6FpGuReVrWl2OoR4wFuoFlA/76Bq9HEsaKiAKijAAHAFSAV6MIqKSRmcZ4p+H+n6p8P9b8MaUW02HUY8KyszrG4wRhSeFyoyowMZ9awvE3hTxl4o8EDRNQk0KyMH2ciO3nmeK+8tsukpMa+XGwAG0K/1wMH1HtTq0EeDR/B/XEaCdv7CmsE1ibUT4XeWQaaI3QKEDeV1U5YfutuT0o8YfBrU9fk8RXFtaeHdOlvNNsrbToYpHKWM0MgZijCJdq7cgFQCc4IANe80UAeEeIPg/wCItSfWpI9UsQt5rcOp/ZmkJS5iSLYUl3xOuc8jKSL6g1l638FfE154as9Fs20NbOC3nRPtc6XFxbyu5ZfLnNmCsXP3EWMjs1fRdFAGb4ZsrnTvDek2V/Ks15bWkUM0isWDuqAMQSATkgnJrSoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArA8bx79BkP9x1b9cf1rfrL8UJ5nh++A7R7vy5/pUVFeDRdN2mmeWW7fZL0Z4jl4/HtT9ftvtFk+Bk4zUtzbia1yOoqWwlFxAYpf9YvDD+teKe2n1POIIzHJIpHatGw+8K0tb0preZpkX5D+lZdrlH5py+FFRd5M6VQDaHIBPHP41sPHGJrVVRRk5OB1rCjkzAqjuwFbMcm69h5+6pNXHb7zCa1fyNyHAXAAAqO45pI24pJDmlfQSWpk3kIaqiW4B6VrzKDVfaAaRoiJLdSOlSC2X0qeMVMqilYLldLdR2FTLCvpUwAHU0jSIo5Ip2FcaI1HakYAVBPexIPvCsu51XzH8u3VpHPQKMmlcaTKniyfGo+GoEcjzdSy2Dj5Ugmfn2yqj8RWlPeIvcVy2pWd/feL9AgkxERHc3IH3iAqomcD/rqB+NdXF4W3N/pEsrnGcEhR+OP8aU5xVk2JOKbuZVzfx8/MKzJr1D/FXZp4Z01cF0RuM8bjn9f6VOvh/Ss7fs6Z90HP6Vk6kS1VSPNrm5Q55rMnkVu9etS+GdKkGTbxc+q4/lisy+8CadOuYA0Z9Uc/1zQpx7lKujyy2uvsOpQ3Q+6pw/8AunrXrGjXEc0IAbIIyCD1FchrXw/vokY2comUfwuNp/Pp/Kq/ha7u9NnXTdTikhnX/U7xw6+gPfFdmHqJaHHjIKfvxO1sBBrFzqkaq8f2K6+zbic+YfLjcsPQfPj/AIDnvXO/ErT47DR4GUsxdyo54HQ1pfDi5V7DUrg/8t9Tu2/75maP/wBkpPiuhl8OxyryI5AT7Z4rsmlys4aP8SJ5hbw7gKupbn0qKxdSorUiZTXGe8kO0q6vdLn87T52iY/eXqrfUdDXfaT4usdSj+zazCkErYBZhuib8/u/55rh121IIlfqAalwUtzOdNSPRLrw3CVE2nzCHIyFLbkP0br/ADqmY7mycJeQlR0DdVP0Nc5o+pX+lMPskxaHvC/Kn/D8K7nSfEdlqCeVdr5ErdUk5Q/Q1cZTh5o5pc0d9R+m30kSgI+6M9UbkVoPp+laqpSaBYpG6gcA/h0P5UyXR4jh7Q+USM4zlTUaxy27hZ0KnsexrojyzOaajIz3+HVtG7tZXRg3HOFBA/LOP0qlH8MR5/myXzlt2c5PX8MV2lldugAY7l/UVrROki5U1ahZ37nPKKRwkfwp8M3Egm1WxS9uR0mclZF9MODvH/fVaaeDrnT0C+HvEusWCKMLBcOt7EP+/wADJ+TiutA4py1pGKSsiGcos3jbTx+/tNE1uMdXtpJLGU/RH8xSf+BrVvSPFDXeoR2N/oOuaXdSZC/aLUSREgE/62EvGOAfvMPTqcV0Qp1aIk8x8L/FE6/4x1PQ1t9AszY6rNpvl3Ot7bycRnmSK38n5gfTf2bnioPBHxg0u78B6Pq/i+6gs9TvIZrmWGytZpVihSd4vNYKHKJ8oBZiBnPPauj8OeA4/D2s6nfaVr+sxQalqMup3ViwtmhklkxuGTD5gXgDAcdOvWuaT4D+FI7TSoYpLzzdPt3tUnnhtblpI2laXDrNC8eQzthgoOOM1QjrLv4g+Hobu6tLa4ur+6t4lllSwsLi6WMMu9N7xRsq7hyMnpXM6B8bPDNz4H0rxH4keXQUv2kjWKaCeRdyZyEkEYDjAzkDGTt6jFbuk/Dyx0bV7i+0fVNSsI7sRC8s4FtxBc+WgQEqYiUyowfLKe2Ko6L8J9I0m38OW8Wp6vNbeH7t7vT4pnhxGXByhIjBZcsTyc89ccUAacHxJ8Jz6nDYRarumlmjtkcW03k+c67kiMuzyxIQfuFg3bGa5qf4t2Fz4+0DTNGubabQLqG+kvb+W3lRF+zpuzFK21HUENuI3DjqK1bj4U6FPrct89zqItJdUXWpNNEkf2ZrwDHmn5N/PUrv2n0rPsPgp4ctDYxSXurXWnWMF5bW1hPJF5UUV0GEqArGHI+YkEsSPWgDrfDHjXQPE91NbaLevNcRRJcGOW3lgZon+7IokVdyHsy5B9a6OuJ8AfDfR/A9w8ukSO+6EW48y0tEYICDzJFCkj9B99mz1OTzXbUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVT1lQ+kXqnvC//oJq5UV3H5trNGOroV/MUmroadnc8wsfnt8e1Z9xm0uxKv3c/N9KuaOSYcHqKXUIg6nivDZ7i3LTxpd2boQDuUgVz50JLu1WWBtko4ZfcVa068NtIIZThM/KT/Kr5hmEry2UqqJOWVhxn1FaQakrMzleEro5BhNZXSxT/wAJzWtZ3QN3uz/BSeKLUQaa8hJaXOS57mub0a9LAFm56UXWyKs2rs9DguAVHNSPOAMk1g2lyCo5re0vTnvTufiMcnPT/PtUCk1HVlCa7difJjeTH91SapzXk8fL28yj3Q13iWlrAqhIlY46tz/9amPbwSNgQoD/ALPH8qynVjEzVdPoefLrG04IIqQa2Ogzmu7k02ArkKT/AMCqMWVsrAY5Puah4mCL9quxxJ1C7l/1NvM3uENKtrqt0cbVi9mbJ/IZrtZVsoB8wUt9Sf502KQsv7tFKjnC1lLFr7KD2vZHOWXhl5SGupWk9R90fpz/ACrbttMtLNAqov0AwP8A6/41N57BySOnYHj8TUfmM8m75WI7YJA/Ks269RX2X3GcqutmzE3L/wALItyqAfZdJl6dvNmj/L/U/p7V0khJDMQxbJbA7jHH+H4VyenSST/EPXJshVhsbODkcA753bg+odfyFdfPcwmAM7pHjozHA/8A1VL/AHckr9P+CTF31KoIwvJXLZ65wfSmCQHcPmJByRwPTn/PrVOfW9KhOHugT6xEv+oqB/E2mr9wTynthMfzxXQoyeyL5kaqQhHJUsCOjE8fWlOQoOwqehUH+Vc3ceL41JEdiSD/AH3/AKYqD/hL7luFsYce7Gq9nPsTzo7FHYnC/MM98evIqreWNnqMW2eJTu5BI5+v+ea5pfF04OHsYj9GIqTUPF9pFo99cSxTQSRQPIDnIyFJ6/h6UKnNPQOeJi+BtPuYPBum3sH72K5ja6wOoEjFwc/8CrT1V11PR7mxn+SR0IAfjB7Vq+BPJh8JaLZ280cn2eygiK55XbGBjHXtWzJbwOf3luCe3pXUsW4tqSMvYJ2cdD52tobuK6e3EErSoxUqqknIrptO0HWbtlCWckee8vy/p1r2FYbZMBIuo3dyKkWReVjCKx52jg9OlQ8Qnsjs9q0jgLDwLfuAbm5ji/3V3fzxWmngiRB/x9lj7IP8a63c5QHjO3JYHPOPSl80rGWXkDjIPvUqtJkOpLuci3hS8jPyOrj3GP5ZrBt4b0eJtVs5k/0e0htyAFzh28wsSfps4/xr1SJ2Lck/Nzj0rnvCe248R+MJ5Fyov4rdSfRLWE/+hOw/A1vTqvW5nKq9LlLTLy7s8CCZtn9w8j8q6iy1mK4UR3cO3PUjkH/Co77Ro5My2oAbuo6Gs6GIq2GGCOorqhaWpnK0tjpkto2G+1cMv93NTQ5Q8ZBrItC0ZBUkVsW8gkA3jDetdMEc07ovxSBsA9amFVFUirEbY4NXYzJaWkFLTRIorx342+IvGml6gLbwXZ675q2X2hZra1We1lkD/wCqKi2lYvtzwXiXHfPX2KiqEeHS6j8Tr3VPGl7Be31jYaZpkc+n6f8A2Mrm8uJLFiVikZdxKT4JXD5OFOBwamr6r8S9L8HaGXvNe1DXNSt3u2ntdKiiismMCFbeaMW87lg4bnEQJYgsoHy++UUAfPGpeLviXFqPhDTRM9veeK9OhRFks41fTbmN0NzIUZMkeVubDZAJ4AxivoZQQoBYsQOp6mq0um2MupQ6hLZ2z38KNHFctEpljU9VVsZAPcA1aoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKDRRQB5LJMLDVru2MckkvnOFjjXJIB6+gHI6+tSG7SV/KkjlglP3UlXG76EZB/A07xqZbHxp5ttbyzSSIr7FGAyHhvmPAOU/zmqZvI75o5JZUEcb7vLjVjtYf32x8uPTivHqQs2j14TukypfRYYjFFhey25CuSyfyq7dKH5HIqosOTWSVje9y1ryi90iULydteY2jtbhweCrYr1GCMrEyn7prldR8PGa7YRcbzuq4ivYf4Xla+vY4sEqOWHsK9ZAW2t0hTty31riPBWmpYXWyVRvbkN647f1/Cu1OD8zjc5PA9K5a9TlVkYV3zSsN3s+5v4FHFEcnnEJGNq9Wap129yAM4xRMYyjRkfKykHHHFee9XuZ7GfcXLN8sbHYP4j3qud0gDDzHHqCQP8KvSpa28DTOyoqjO+Q8D865bUvF8Kgx2cUlwf733VP9f0rrjKK0pQv5sjlb+JnQw2juu5URR/tH/DNDTi13ANknq2MCuIl8R6tONsbR2yf7C5P5mqckU94+65mkmP8AtNkflVypVqqtJpLyHHli77nZT61pllHkTRSSj+FTvI/nisqfxbMx/wBDtWb3k4A/AVlwWCqB8tW47UDoKpYWG8m2HM+hzWj6jqd7r3iW5MwiL3ccR2LjhYIzwTyOWP61qm0eQ7pneRvVySf1qDwXAJINUuD0l1K5Gf8AckMX/tOumEI9OK6XGMXoiVdowEsS56cVOLE4worfSEVPHAp7UXHY5lNLycsM1L/Z5x0wK6j7MvpS/Zh6UXCxyh089hiuf8d2bR+ENYC5DyWzxKR2LjaP1NelfZR6VzHxAtgdDhgAybi/soT9Dcx7v/Hd1XB6ol7FBbVodvl5TaMDbxitOz1vULTAeTzkHaQZ/XrWjLbKO1VpLPI5FS4qW407bGpZeIbWcgTq8EhGM5yv5/8A1q1k2zIXt5UcdnGGz7VxclnjoKjRZoH3wu6OO6nFZvDr7JaqPqdxHGq7SE2AjGSSOfTFORic8KWB5KCuatfENzCNl5GJk6bgMH/CteDWrGYZyydOeoH+fpUexmuhSknsaEZBlGxQWA755z7fjWD8Ph5kOtXLgEzavdc56+W/k/p5eP0rcju7NyCtwoJHBPB/WsL4atDL4Rtpmkjzcz3NyRu/563Ekmfx3VrBNJ3REtzsbc4UZHX8qhv7NZCJUGG71KrxjkyIPQg097iLy9obcTxxXTRTuZSdtijChU4YVeiWiNVdeeRUyxleRyK7+Wxlz8xYgbAAarGPSq6Cp4/SrRm0SKcCn03GRThTsSLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw3xMtN6WU+07ctC5Hvgj+RrzlZ5opALa3RraJy8juC4j5ywJA2L34XJ9xXsvjCy+2+H7pV/1ka+cn1Xn9RkfjXlWlzs+pyLNunaNlaNRAXfaec5J2KO2eCcGuCvG035nfQlemvI1HKyRpIgOxwGGRg4PtTYl+arUq5QfOrkcEg55qOFfm6Vx2OxPQeFLcAGopl8meMnrgkmtWGP5ay9U/wBcuPQ01pqLd2KpvWguUkU8qQRXfQSR3FvHPFgh1DA15bdk5rrvAmo+day2bt88R3oP9knn9f51x11eI69PRSRuSQP97OfaqlxJHDC08sgCoMsT0AFXbog72Y8LXJ+M7vdb21hCMNKBJKR/d7D8/wCVcVOnzS5Tnvpc57VL+41u6LPuW2U4ji7Aep96ILEnHFXbO2CqBitW3tx6V6ySirIzMyHTgRyM1egsQvQVz3xe1TUPD3gK81HR5zb3qSwosiojkBpFU4DgjoT1qveeJb7wtpcJvor+61C6mdYLTV5YluJQiAnylsoZAw553AY6kgYrRQcldCckmdl9mwPu00w4rhdK+J93rd7oFtovhl7p9Usvtz5vkj+zoJjE+dy/MBgnjk8DHeug8SeJp7DxRpvh/S9Piu9RvYZLgNc3Jt4lROvzBHJbPYL70/ZyTsxKaJfDGmzaXo6290UM5mmmcoSQTJK7nk9fvVq5rgrv4kC28V2mjtYW88c18NPkuLW4lcQTEfdbdCqZBzwHJwM4rN0v4qNdtpcl7pMFlaajFePFO98WCG3BLbx5YwpA6jJ56VXspvVoXMloepRnmrsHOK8D8WfEe61Xwf4kgtIZdNvLWC1uYbu1nlAkjkmQZRnjjcAg9cYIPBIr2v8AtFYBkgn6UpUnFajU0zfjTI6VKIx6Vh2Ov27ttkyn+8K3oJo5VBQgis7FXGmIYrk/Gsfmaj4WtuMz6qDj2jgmlz/44Pzrtdtcvryed458Lwf8847y7x/uokef/I361cFqS2X3gqB4hWvNH7VVaH1ppAZzQA9qie3B7CtBwBUDsAatIm5nSWYNUprDB3JwfatvIakKKetVYVzm5pms4JZZDhY1LnJwMAZqv4CV7fwdoUTE71sYd3u2wZ/XNW/HMbw+DNeuoo2PlWM7ggdxG2P1q9Z6c9hZwW5Rl8qNY8EHsMd60i7LU3hWTdpGpbSN61p27k96x7Y461qW3atYsc0a1uxHQ1pwNuHPWsq37VpQitYs5JxTLQXnIqRBTYzUoFWYirTxTRThTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACOoZSDyDwa8O12yksdeuLGJbja5cNHER86qRtLZB+Xaw6DnIzXuVeZ/E/TYv7Qgu3VSHAYqSw3leCMrzyCvTqQK58RG6Uux0YeWrj3MvQbdxBI+yARPjlDliRxzgkY/zgVpxR4NN0OGZLIiazjtATuWNZTI3uWJHX86t4wa86W56ENiaMYWsrUUzMPpWqDgVn3Q3TfhR0GtznbuPBNQaLfnTNbt5S2IywV/8AdPB/x/Cr9+oDGud1PjmueS6HZbmjZnsMsMckpy/vtq3DoGnXlsJbm2RpZOfM6Njtg/SsPRrg3Nja3Ln5ngDZ9TgV28K7IUX+6oFXldJSqTk1toeLiG4pI8+1zQ5NKlDoTJbMcK/cH0NQWvavR7iGO4heKZQ0bjDA9xXCarp0ml3W3loW5jf19j712YjD8nvR2FSqX0Yy906y1Sza01O0t7y1cgtDcRLIjYORlSCDzVBPBvhhbdbceHNGFusnmiIWMW0PjG7G3GccZrTt5M1eTkVzxujR6mVaaDpOnyQyWGl2FrJDEYInht0QxxltxRSBwpYk4HGeara3oumaxGker6dZ38cZ3It1AsoU+oDA4Nb7Diqc4xmr13JOYbwxoKXq3iaJpa3asrrMLSMOGX7pDYzkdj2qu2g6PGkKR6Tp6rAJBEFtkAjEnD7eON3fHXvW9N3qnKM1SuGhzo8M6BBBNDFoelxwyqFkRbSMK4B3AEY5APPPerx3SkKAeTwBU03zNtFdd4J0QPINQuV+VT+6U9z/AHvw7e9aRg5uxDkkrlrw14Tgt4kuNRjEk5GREwyqfX1NaGraOBm4sECSDlo1GA30963qK7PYx5eWxhzu9zlLOXzV561gyL53xNg7/ZdHk/Dzpk/+MfpXU6va/ZboXEQxHIcOB2b1/GuY0b/SPiF4in6iKxsbYH0IaeQ/+jF/Ielcns3BtM35rq50TpxVO4worRlwFrLumFTyjuZ8zk+1S6XpMl/OQOEH3nPQf/XqfT9PlvbjaBhR1OOAK7K0t47WFYohhR+p9a3p0+bVmcp22KNpodjbqo8kSsP4pOc/h0q0un2atuW1gDeojFWqK6lFLoZXZyfxSwfAt/Bxi6eC0x0z5s8ceP8Ax+urZQylWAIPUEVynxGJkstEtRj/AEjWrHjPXy5lm/8AaX+RmuspiMfUNBtbgFoFEEvUFRwfqKwDby2s5imUhh+vuK7eq17aR3ce1x8w+6w6iocF0NoVXHR7GDbdq04BVNbd4Jdjjkd/WtCBaSHJliMVMKYg4qQDitDFhiloooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXM/ECxW80IltwMbg7l6rnjI/Eg/hXTVR1u3a60i8hQZd4m2j/axx+tRUXNFoum+WSZx1sS1um5txA5OOtNcYNVtKnDwLzVmQivJZ6qVmJniqc5/fH2WrBcVSmkHmOfbFSVbUy9SPWuY1RvlOa6HUHzmuYvVe6u4raDmSVwi/UnFYyOyGi1PVPDcZOhaMvqiZ/GvQBXI6Ogglt7fHyptC+wyBXXV15TrGcu7PCxLvJBVe+tIr22eGcZU9COoPqKsUV6rV9Gcx5/c20un3TQzdRyrdmHqKswS8V1ep2Ed/bmOThhyrDqprjrmCaynMU67WHII6Eeorz6tHkd1sdMKnMtS6zgiqdwcioTcYGM1BJMWqFEq5FMeapzN6VNK2an0zTZtQuBHEB6knoo9TVqPQlsd4d0htSuwHyIV+aRvb0/GvSIo0ijVI1Coo2gDoBUGnWUVharBCOBySerH1q1XbThyIwlK7CiiitCSG7gW4t3ibow6+h7GvNPDExtfEHi95opNzamkKsgyuEtYO/ruLfhivUa4rwTB9t0DWbgctcazfuh/653Lxj8CIx+BrOpDmRUZWC41BWGFV8/7tael6X9pgjuJyQr8hR1/E1HJCktksmBkVs6Pxp8S/wB3I/U1lTgr6lyk7aFqGJIYwkShVHYVla54n0DQJYo9d1zS9MklBaNLy7jhLgdSAxGRWxXkvxK8PeIrn4oeHde0S11ZrKzsJ7eafSpLITozkYAW6Owg9ziukyPVbO5gvbSG6s54ri2mQSRTROHSRSMhlYcEEc5FPlkSGJ5JXVI0BZnY4CgdST2FeF/EHR/iVdv4hPh1ddZdR0mySyYanBA9rcJIpm3hZVVHZQwJiBU5xnFSyeGPHN5401BZhq1xot8lxE8l/qLW8dqphKIIVt7phICxJy8KsODkHkAHqtzbWXiYaDqVjqEU9laXf26OS3ZZI7j91LGAGBxjMm7I/u471uV842nhDx7p3w40DQdJ0XVrO8gjuI7u5XXH3RyFR5bxJHeRp5ZOMZJ2kOfK5+fo9A0bx2uq6NP4yt9e1OzTSreLydL1dLY290pHmNOFmj83OM5BcYyMc0AeqeHvEmk+IdMl1HSLxZ7KKWSF5WRowrocODuAPBHXpV7Tr+01OyivNNure8s5hmOe3kEkbjOMhgSD+FeE+B/A/jbw9f8Ah+WCO/tYDqGqPqcC6iphMMgJt2MXmFd249VG4d+gqhq/h74sS+DdEsLe21MavBpjebfx605m+1ecxCOPtUcZBTHzlZeoGB2APoqaISrz1HQ1Qnv7KxubW2vLy2gubtilvFLKqvMwGSEBOWIHPFeL3Xhn4ly3Wo6glzq63g1TT5rSNdWAiNuIwLkeX5mzbu6qRz2HJz1Xxe8I6hrnifwVq+n2N9fQaXdyG7hs7/7NKI2TAZCZEGQRyQwbHHIoHc9O4VST0HNZvhfX9M8UaFa6zoVz9q0253GKby2TdtYqflYAjlSOR2rx+LQ/iSnieGGT+1n05PFU9+9z/aaGF9OcDZFtMu/auD+7K4GeM81z/gLwP8TNG8PaZp2lx3uhT2mlX0NybrUUmtp7iR2aAxRJI4QruBL7V5z17gj6Voryr4MaN4v0q6vW8WXWsPHLbQjyb50ljWZRh2jk+1zvzySNqL0IUdB6rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnOu2baRq77QRbTkyRnsCeo/P8ASoTLuHWvQdTsINRtHt7pdyN0I4KnsR71wuoeGdVsmP2VRdw9ipAYD3B/pmvOr4eSd47Ho0K8ZK03ZlJ5KoTycsc0XMWpRHD2N0p/65N/hVOKz1TUNws7KeTB2khcAH0JNcnLJ6WO1SitbooalcBVPNaXw+0j7ReSapcjiMYhB7k5Bb8MEVs6B8P7q5uEn17EUCnPkK2Wf6kcAfTn6V01vbJFfXMcKKkanaqqMAAE4FFShONNyZlVxMZe5Ant0BvYXHZlH6iukrDhT99Dx/y0H863K6crjy05ep5td3aCiiivTMAqveWkN5F5c6Bh2PcfQ1YooauByt14Yk3k206lPSQYP5jrVdPDV4WwxhA9dx/wrsqKy9jEvnZzNr4WjB3XUxP+zGMfqa6C1tobWLy7eNUT0Hepq57xx4nTwhoU+r3Ol6hf2VujSXDWZhzCgGSxEkiZHsuT7VcYKOxLbe50NFczoXjTTNTs4Zr3/iTTT25vIrXUbm3WZ7baG88Kkj4TBOSSMYOQKmbxt4VWWKNvE2hiSXyzGpv4sv5gymBu53Dkeo6VQjoKKwW8ZeGFsheN4j0UWZlaATm+i8syKMlN27G4Dkjriku/GnhaztLS7u/EuiQWt2rNbTS38SpOFOGKMWwwB4OOlAG/XJ/Co7/h7o1xz/pcTXmT3852lz+O/NaF74v8NWFwtvfeIdHtp2CMsc17EjEPyhALZ+bt69qhj8W6ND/aovrq00220ucW0s1zeW6xhiMj7shKfRwre2KAJ5Y/LluYOx+dfoef8as6K+Y5I+6kN+BH+INZuqa3pH9kQa/HqunnSMYa9Fwhg2k4B8zO3G7jr1NZ2ieMfDb6msEHiHR5Hnk+zxql7ExeUEfIAG5bnp15rJaSL3R2tFY58T6ANUl0w65pY1GFWeS0+1x+aiqMsSmcgAcnI4FUx498HmN5B4r0AogUs39ow4UN93J3cZ7etakHSUVwlv8AEnSh4+1vw1qk1jposFtfIuri9RPtjToWCIrAcjHYnOe1btz4z8L2st1Fc+JNFhltSy3CSX0SmEqQrBwW+XBZQc92HrQBvUVgjxj4YOnxX48R6MbGWQwx3AvovLeQDJUNuwWA5x1p9x4t8N2+l2+p3HiDSItNuCRDdvexrFKR1CuWwfwNAG3RTIJoriCOa3kSWGRQ6SIwZWUjIII6gin0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc/4JH/ABKpn/vXEh/Wugb7prA8Ef8AIDHvLJ/6FQBv1l20H+mXLerH+ZrUqKJArufU1nUgpqzKi7EJgG5D/dYGrdNYcU4UU6apqyE3cKKKK0EFFFFABRRRQAVh+OdA/wCEp8IavoX2n7L/AGhbvb+f5e/y9wxnbkZ+mRW5RQB4z8WPhje+IdJ8EabpBl+0aey6feahG6RbLFovLnypbLbgBhRnqfrVvxR8GINam8TG21ZLK31iPT4ooRZ7xaraYwB843BgMdse9et0UAeHeK/hdrkPiyz1bw7cw3L3XiVNXmaaEBLJBEUyy+aplGccKVJ/WrE/wTvj4Yi0S28ZXcVnIt0b2H7O6Q3Es5J8wJFMhAXPCOzqe4617TRQB4xefA/7Voeqac/iH/j+0Ww0jzDZZ2fZih8zHmc7tn3cjGepq7cfB5m1O51O310JfHWItYtvMs/MijdIvL2OnmDeD1yCpHavWqKAOP8AHPhK88ZfDq/8N6pqdvFeXqKsl7b2bLGCsgcERNIT0UD759favOdT+FAurzVrptYETX2o2N4yi0z5P2VdpX7/ADu5OeMe9e7VkapDtn3D7sowfZh/iP5VnO+6Kj2PMoPgjBBq93dRatHNazXdzewpdR3LyW8kykMUK3KxHr1aIkjgk8YavwPAsEtj4gB2+GG8ObvsXrMZPOx5nvjZ+O7tXrGkTeZaBG+9F8h+nb9KvVad1ck8Y1b4J3GovqsLeJUj03VrbT7W9iGn5mZbRVA8uTzcIWK5OVbGcfXT/wCFSeRF4ruNM1oWGua3qD3keqw2QFxaxOVLQB928qdpyVZDz27+qUUwPHNE+Cradf2d3L4g894deGusDbSHe2zaU3STO/J53MzH1z1qr/woeOO100Qa+wuLKe9cZgmSJ47k/NGVhnjcYHGQ4BHBBHFe20UAZHhHRI/DnhrTtHh8ny7OIRL5KuqYH90O7sB9Xb61r0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB6VgeCf+QKV/uzSD9a36xvC8Jtra6iI6XDkUAbNIBjNLRQAGiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKgvIBcW7J0bqp9D2qeihq4GBbTtbT+aQdv3JVHYjv+HNbysGAKkEHkEVl6pD5chmA+SThvY9j/T8qm0V91oUzny2K/h1/rWcLp8pT1Vy/RRRWhIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUFvGI5JcfxNuqekHWgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGyIsiMjgFSMEGoLKzS037Gdt+M7jVmilbqAUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29541=[""].join("\n");
var outline_f28_54_29541=null;
var title_f28_54_29542="Acquired disorders of the complement system";
var content_f28_54_29542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired disorders of the complement system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29542/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29542/contributors\">",
"     M Kathryn Liszewski, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29542/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29542/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29542/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29542/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29542/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/54/29542/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies in complement proteins may be inherited or acquired (secondary). Secondary causes of complement deficiency will be presented in this topic review. Inherited disorders of the complement system, as well as a description of the complement pathways and the clinical evaluation of complement, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H308902\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired deficiencies in complement proteins are much more common than inherited complement disorders. Reductions in complement secondary to acquired disease processes are usually only partial and affect several complement components at once. As an example, approximately 50 percent of patients with systemic lupus erythematosus (SLE) will have reductions in C4 and C3.",
"   </p>",
"   <p>",
"    Such secondary complement deficiencies are most commonly encountered in diseases featuring autoantibodies. In many diseases, such as milder forms of SLE, augmented hepatic synthesis of components may be sufficient to maintain the levels in the normal range. The current management of most all acquired disorders of the complement system featuring excessive activation focuses on the treatment of the underlying disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7564840\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACQUIRED COMPLEMENT DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired deficiencies in complement proteins may result from several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accelerated consumption by immune complexes (common)",
"     </li>",
"     <li>",
"      Reduced hepatic synthesis (uncommon)",
"     </li>",
"     <li>",
"      Loss of complement components the in urine (rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCREASED CONSUMPTION BY IMMUNE COMPLEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the diseases in which complement activation is sufficient to reduce plasma levels are characterized by excessive immune complexes. The disease that best illustrates this point is SLE.",
"   </p>",
"   <p>",
"    In a large Japanese series of patients with low C4, C3, and total hemolytic complement (THC or CH50), SLE accounted for approximately two-thirds of the cases while other vasculitic syndromes accounted for another approximately 20 percent (",
"    <a class=\"graphic graphic_table graphicRef56322 \" href=\"UTD.htm?14/23/14716\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/1\">",
"     1",
"    </a>",
"    ]. By requiring both a low C4 and C3, the authors selected for patients with classical pathway activation. By comparison, the concentration of the lectin pathway initiating factors, such as MBL, are relatively fixed compared to antibodies that activate the classical pathway, and are insufficient to substantially decrease C4 and C3 in blood. The pattern of normal C4 and a low C3, which is uncommonly encountered, indicates alternative pathway activation. Diseases to consider with this profile would be glomerulonephritis, partial lipodystrophy, acute rheumatic fever, and some forms of vasculitis and glomerulonephritis. In these disorders, immune complexes preferentially activate the alternative pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low C4 and C3 occur in about 50 percent of patients with SLE, reflecting in most cases activation of the classical complement pathway by immune complexes. Accelerated consumption outstrips synthesis and is the cause of hypocomplementemia in about 90 percent of such cases, while the remaining 10 percent also show signs of reduced hepatic synthesis.",
"   </p>",
"   <p>",
"    The usual pattern of complement activation in SLE involves the classical pathway, leading to low C3 and C4, while factor B of the alternative pathway is normal. However, a small percentage of patients (approximately one in 20 to 30) demonstrate predominant alternative pathway activation, as evidenced by normal C4 but low C3 and factor B.",
"   </p>",
"   <p>",
"    Immune complex deposition has been implicated in the pathogenesis of tissue damage in most organs afflicted in SLE, particularly the skin, kidneys, joints, and serosal surfaces. Low complement values tend to correlate with more severe SLE, especially with renal disease, and with antibodies to double-stranded DNA. A return to normal levels with treatment is a good prognostic sign. If a patient with SLE presents with low C4 and C3 levels that improve with treatment in parallel with other parameters, then C4 and C3 may become a valuable biomarker of disease activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with SLE may be susceptible to infection with encapsulated bacteria because of immunosuppressive medications, functional asplenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypocomplementemia, although the relative contribution of hypocomplementemia is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Vaccination and prophylaxis of SLE patients against infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A developing area of research involves the measurement of complement fragment deposition (such as C3d and C4d) on peripheral blood cells (ie, red blood cells, platelets, and lymphocytes) as a biomarker of lupus disease activity, analogous to the use of HbA1c in diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. An acquired reduction in the levels of complement receptor one (CR1, also known as CD35 and the C3b receptor) on erythrocytes commonly occurs in immune complex-mediated syndromes and may be a marker of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4305048\">",
"    <span class=\"h3\">",
"     Anticardiolipin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticardiolipin syndrome can be associated with hypocomplementemia, analogous to what is seen in SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/7\">",
"     7",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoglobulins are serum proteins that precipitate at subphysiologic temperatures. Mixed cryoglobulins commonly consist of immune complexes that contain immunoglobulins, antigen, rheumatoid factor, and complement components (particularly fragments of C3 and C4). Cryoglobulinemia may be either essential (no underlying identifiable disease process) or secondary (in association with another disease). Chronic hepatitis B and C account for most all of the formerly idiopathic cases of mixed cryoglobulinemia. Monoclonal paraproteins that precipitate in the cold may also activate complement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual complement profile in the setting of essential or secondary cryoglobulinemia is that of classical pathway activation. The complement profile shows decreased levels of C4 and C2 with normal or slightly lowered C3. C3 levels are usually only modestly altered, because it is harder to form C3 convertases on a soluble or precipitated immune complex than on a cell membrane.",
"   </p>",
"   <p>",
"    In rheumatic disorders, the presence of cryoglobulins is usually associated with a more severe disease. As an example, in SLE there is a correlation of mixed cryoglobulins with renal involvement, vasculitic manifestations and hypocomplementemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vasculitic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many vasculitic syndromes are caused by immune complexes. In these disorders, classical pathway activation by immune complexes initiates inflammatory processes and tissue destruction, primarily affecting blood vessels. Complement activation is usually not as marked as in SLE, although up to 50 percent of patients with polyarteritis may have decreased serum complement levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in SLE, complement values can be helpful in assessing the clinical course, especially the response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466898\">",
"    <span class=\"h2\">",
"     Renal diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many nephritides result from an inflammatory reaction within the kidney glomerulus that features leukocyte infiltration and cellular proliferation. Antibodies in the kidney may result from local immune complex formation or originate in the circulation as immune complexes that then lodge in the glomerulus. In either instance, the result can be activation of the complement system, with recruitment of inflammatory cells and subsequent tissue damage.",
"   </p>",
"   <p>",
"    The complement system is involved in multiple renal diseases including acute poststreptococcal nephritis, IgA nephropathy, membranous nephropathy, types I and II membranoproliferative glomerulonephritis, SLE nephritis, tubulointerstitial nephritis, and Goodpasture's syndrome. Immunohistochemical analyses for complement activated fragments in renal biopsy specimens are often helpful in establishing that complement activation is occurring. In these renal diseases, neither serum hypocomplementemia nor the quantity of C3 fragments deposited is as dramatic as in SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=see_link\">",
"     \"Pathogenesis of tissue injury in glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     C3 nephritic factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary C3 deficiency may arise when an autoantibody stabilizes the alternative pathway C3 convertase, increasing the half-life of the convertase and causing excessive C3 activation. The autoantibody against the alternative pathway convertase is called C3 nephritic factor. The typical complement profile is a normal C4 with a low C3, factor B, and alternative pathway CH50, indicating alternative pathway activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with C3 nephritic factor typically present in childhood with membranoproliferative glomerulonephritis that may be accompanied by partial lipodystrophy, as well as frequent infections with encapsulated bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/8\">",
"     8",
"    </a>",
"    ]. Nephritic factor levels do not correlate predictably with disease activity and progressive renal damage can occur in patients who are persistently normocomplementemic. The clinical features of glomerulonephritis associated with C3 nephritic factor are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dense deposit disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dense deposit disease (DDD) is a rare but devastating glomerular illness that primarily affects children. Dysregulation of the alternative pathway of complement has been associated with pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/9\">",
"     9",
"    </a>",
"    ]. Most patients with DDD present with hypocomplementemia that persists throughout the course of disease. C3 and factor B levels are low, while C4 is normal. More than 80 percent of patients demonstrate a C3 nephritic factor. Genetic analyses have identified mutations in complement regulatory proteins (factors H and I) in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=see_link\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     C4 nephritic factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;C4 nephritic factor is an autoantibody that reacts with an epitope expressed on C4 within the classical pathway convertase (C4b2a). The C4 nephritic factor has been found in a few patients with post-streptococcal glomerulonephritis and SLE, although its role in pathogenesis has not yet been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749094\">",
"    <span class=\"h2\">",
"     Autoimmune hemolytic anemia (AIHA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cold agglutinin disease, IgM autoantibodies react with RBC antigens at reduced body temperatures such as in the extremities. The antibodies activate the classical pathway leading to the deposition of large quantities of C4, C3b and C5b-9. The RBC may be either phagocytosed or lysed. Cold agglutinins are associated with lymphoid malignancy (chronic cold agglutinin syndrome) or arise transiently following viral and mycoplasma infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749108\">",
"    <span class=\"h2\">",
"     IgG4&ndash;positive multiorgan lymphoproliferative syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;This relatively recently defined syndrome features IgG",
"    <sub>",
"     4",
"    </sub>",
"    complement fixing autoantibodies that react with an unknown antigen on a variety of tissues including the pancreas (autoimmune pancreatitis &ndash; AIP) and salivary glands in Mikulicz&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29542/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A variety of other idiopathic inflammatory conditions including sclerosing cholangitis, autoimmune hypophysitis, retroperitoneal and mediastinal fibrosis, interstitial nephritis and others have also been associated with these autoantibodies. A hallmark pathologically is IgG",
"    <sub>",
"     4",
"    </sub>",
"    positive plasma cell infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749122\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B and C infections are associated with immune complex formation secondary to the release of antigen from the infected liver. These immune complexes often manifest as cryoglobulins. Also, other viral infections such as parvovirus infections featuring large antigenic load can develop a transient hypocomplementemia as the antibodies combine with viral antigen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acquired angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inherited deficiency of C1 inhibitor causes the autosomal dominant disorder hereditary angioedema. C1 inhibitor deficiency also can be acquired (acquired angioedema, AAE). AAE has mostly been reported in patients with malignant B-cell lymphoproliferative disorders who present with new-onset swelling of the skin, abdominal viscera,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    larynx. More than one mechanism has been implicated in the complement abnormalities seen in AAE. Most patients demonstrate an autoantibody to the C1-inhibitor that blocks its function or causes its premature removal. Others feature a monoclonal autoantibody on the B-cell surface that activates C1 and consumes C1 inhibitor.",
"   </p>",
"   <p>",
"    AAE should be considered in patients with angioedema in which complement studies show low C4, low C1q, and low or normal C1 inhibitor antigenic levels, but reduced C1 inhibitor function. C1q levels are normal in the hereditary form; otherwise, complement profiles are similar in HAE and AAE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1748991\">",
"    <span class=\"h1\">",
"     REDUCED HEPATIC SYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the synthetic site of most complement components and inhibitors, and reduced hepatic synthesis may lead to hypocomplementemia in various types of advanced liver disease. As an example, low C3 and C4 levels may be seen in alcoholic liver disease. However, liver disease must be severe before there is a detectable decrease in plasma levels. For this reason, the coagulation system provides a more clinically useful measurement of hepatic synthetic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link&amp;anchor=H5#H5\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'Coagulation factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, some patients with SLE demonstrate decreased hepatic synthesis of complement components. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Systemic lupus erythematosus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749018\">",
"    <span class=\"h1\">",
"     LOSS OF COMPLEMENT COMPONENTS IN THE URINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe forms of nephrotic syndrome, several complement components can be lost in the urine, although factor D is the only component that can be lost in substantial amounts. Factor D has a molecular weight of 25,000 Daltons, and is the smallest component of the alternative pathway. Its loss would be detected as a decrease in the alternative pathway CH50 titer. No clinical consequences have been reported in association with this laboratory observation. In primary forms of hypocomplementemia, reduced alternative pathway functional activity is associated with infections (primarily Neisseria). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link&amp;anchor=H12#H12\">",
"     \"Inherited disorders of the complement system\", section on 'Alternative pathway deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7564817\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired complement disorders are much more common than inherited complement disorders. The mechanisms responsible to acquired complement disorders are accelerated consumption by immune complexes (common), reduced hepatic synthesis (uncommon), and loss of complement components the in urine (rare). (See",
"      <a class=\"local\" href=\"#H7564840\">",
"       'Mechanisms of acquired complement disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common mechanism of secondary hypocomplementemia is increased consumption by immune complexes. The disease that best illustrates this process is systemic lupus erythematosus (SLE). The usual pattern of complement activation in such disorders involves activation of the classical pathway, leading to low C3 and C4, while factor B of the alternative pathway is normal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Increased consumption by immune complexes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduced hepatic synthesis is an uncommon cause of hypocomplementemia that is seen in various types of advanced liver disease. The liver is the synthetic site of most complement components and inhibitors, but liver disease must be severe before there is a detectable decrease in plasma levels. (See",
"      <a class=\"local\" href=\"#H1748991\">",
"       'Reduced hepatic synthesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rare cause of secondary hypocomplementemia is loss of complement proteins in the urine. Factor D can be reduced in severe nephrotic syndrome, although this laboratory finding is of uncertain clinical significance. (See",
"      <a class=\"local\" href=\"#H1749018\">",
"       'Loss of complement components in the urine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/1\">",
"      Saeki T, Ito T, Yamazaki H, et al. Hypocomplementemia of unknown etiology: an opportunity to find cases of IgG4-positive multi-organ lymphoproliferative syndrome. Rheumatol Int 2009; 30:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/2\">",
"      Gilliland WR, Tsokos GC. Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 2002; 61:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/3\">",
"      Hepburn AL, Davies KA. Infection and SLE. Ann Rheum Dis 2002; 61:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/4\">",
"      Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005; 17:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/5\">",
"      Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006; 54:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/6\">",
"      Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/7\">",
"      Shinzato MM, Bueno C, Trindade Viana VS, et al. Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus 2005; 14:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/8\">",
"      Walport MJ, Davies KA, Botto M, et al. C3 nephritic factor and SLE: report of four cases and review of the literature. QJM 1994; 87:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/9\">",
"      Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens 2007; 16:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/10\">",
"      Ohi H, Yasugi T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 1994; 95:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/11\">",
"      Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29542/abstract/12\">",
"      Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol 2010; 37:1380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3930 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29542=[""].join("\n");
var outline_f28_54_29542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7564817\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H308902\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7564840\">",
"      MECHANISMS OF ACQUIRED COMPLEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCREASED CONSUMPTION BY IMMUNE COMPLEXES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4305048\">",
"      - Anticardiolipin syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vasculitic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466898\">",
"      Renal diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - C3 nephritic factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dense deposit disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - C4 nephritic factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749094\">",
"      Autoimmune hemolytic anemia (AIHA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749108\">",
"      IgG4&ndash;positive multiorgan lymphoproliferative syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749122\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acquired angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1748991\">",
"      REDUCED HEPATIC SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1749018\">",
"      LOSS OF COMPLEMENT COMPONENTS IN THE URINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7564817\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/23/14716\" title=\"table 1\">",
"      Causes of acquired hypocomplementemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=related_link\">",
"      Dense deposit disease (membranoproliferative glomerulonephritis type II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32312?source=related_link\">",
"      Epidemiology and laboratory diagnosis of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=related_link\">",
"      Pathogenesis of tissue injury in glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_54_29543="Proximal humeral fractures in adults";
var content_f28_54_29543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proximal humeral fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29543/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29543/contributors\">",
"     Rebecca Bassett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29543/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29543/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/54/29543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal humerus fractures occur most commonly in the elderly and their incidence is increasing steadily. Fractures of the humerus can occur proximally, in the shaft (diaphysis), or distally. The majority of both proximal and midshaft humerus fractures are nondisplaced and can be treated conservatively (nonsurgically).",
"   </p>",
"   <p>",
"    Proximal fractures of the humerus will be reviewed here. Nonstress and stress fractures of the shaft of the humerus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27510?source=see_link\">",
"     \"Midshaft humeral fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43812?source=see_link\">",
"     \"Stress fractures of the humeral shaft\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humerus is the largest bone in the upper extremity. The proximal humerus articulates with the glenoid of the scapula to form the glenohumeral (shoulder) joint (",
"    <a class=\"graphic graphic_figure graphicRef81764 \" href=\"UTD.htm?32/20/33093\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54102 \" href=\"UTD.htm?27/60/28613\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69995 \" href=\"UTD.htm?27/6/27748\">",
"     figure 3",
"    </a>",
"    ). The muscles and tendons of the rotator cuff, the acromion, and ligamentous attachments, such as those between the coracoid process of the scapula and the acromion, both stabilize the glenohumeral articulation and provide for the shoulder&rsquo;s wide range of motion. The distal humerus articulates with the radius and ulna at the elbow.",
"   </p>",
"   <p>",
"    According to the Neer classification, the proximal humerus is divided into four sections: the anatomical neck, the surgical neck, the greater tuberosity, and the lesser tuberosity (",
"    <a class=\"graphic graphic_figure graphicRef67578 \" href=\"UTD.htm?19/55/20339\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neer classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anatomical neck consists of the widened articular surface of the humeral head.",
"     </li>",
"     <li>",
"      The surgical neck is located at the constriction distal to the humeral head and tuberosities. The surgical neck is where the articular capsule attaches and several penetrating arteries enter to provide part of the vascular supply to the humeral head.",
"     </li>",
"     <li>",
"      The greater and lesser tuberosities are the sites of attachment for the tendons of the rotator cuff muscles (",
"      <a class=\"graphic graphic_figure graphicRef72027 \" href=\"UTD.htm?15/1/15378\">",
"       figure 5",
"      </a>",
"      ). The greater tuberosity is located lateral to the humeral head on the superior aspect of the humerus. It provides the attachment for three of the rotator cuff muscles: supraspinatus, infraspinatus, and teres minor. The lesser tuberosity is located on the anterior surface of the humerus and provides the attachment for the subscapularis muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The humeral shaft supplies the attachment for a number of powerful muscles. The pectoralis major inserts on the proximal shaft while the deltoid muscle attaches to the midshaft. The biceps brachialis and triceps muscle groups attach more distally.",
"   </p>",
"   <p>",
"    The tendon of the long head of the biceps brachialis muscle passes between the lesser and greater tuberosities as it courses in a shallow groove on the anterior surface of the humerus. The long head tendon attaches to the scapula on the superior portion of the glenoid where its fibers merge with those of the fibrocartilaginous superior glenoid labrum.",
"   </p>",
"   <p>",
"    The proximal humerus receives its blood supply from branches of the axillary artery. Two branches, the anterior and posterior humeral circumflex arteries, originate distal to the anatomic neck and travel proximally to supply the humeral head (",
"    <a class=\"graphic graphic_figure graphicRef71903 \" href=\"UTD.htm?14/37/14931\">",
"     figure 6",
"    </a>",
"    ). Thus, fractures occurring at the anatomic neck can disrupt the blood supply and result in osteonecrosis (avascular necrosis) of the humeral head. The humeral shaft is supplied by the axillary and the brachial artery, which branches distally to become the radial and ulnar arteries. This vascular supply can be disrupted by a humeral shaft fracture if there is considerable displacement of fragments.",
"   </p>",
"   <p>",
"    Proximity of the humerus to the axillary nerve and brachial plexus accounts for the risk of neurologic injury complicating humerus fractures (",
"    <a class=\"graphic graphic_figure graphicRef71903 \" href=\"UTD.htm?14/37/14931\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 7",
"    </a>",
"    ). Nerve injuries are more likely if there is a proximal humeral fracture that is significantly displaced or a concomitant humeral dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/2\">",
"     2",
"    </a>",
"    ]. The axillary and subscapular nerves are most often affected. Radial nerve injuries may occur with significant displacement of mid to distal shaft fractures. Median and ulnar nerve injuries are uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal humerus fractures account for four to five percent of all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/3\">",
"     3",
"    </a>",
"    ] and are the third most common fracture in elderly patients after those of the hip and distal radius. The incidence of proximal humerus fractures increases with age, with more than 70 percent occurring in patients over 60 years of age and the highest incidence among 73 to 78 year olds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/4\">",
"     4",
"    </a>",
"    ]. Proximal humerus fractures are three to four times more common in females than males [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/5\">",
"     5",
"    </a>",
"    ]. The major risk factors are frequent falls and low bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In elderly individuals, falls are the most common cause of proximal humerus fractures; approximately 87 to 93 percent of fractures occur after a fall from standing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. Less often, these fractures occur from a direct blow or violent muscle contraction (eg, seizure). Anterior or posterior dislocations of the humeral head can occur in association with proximal humeral fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with proximal humeral fractures present with moderate to severe shoulder pain that increases with shoulder movement. Patients tend to hold the affected arm adducted against their side. Swelling and ecchymosis may be apparent shortly after injury. Gross shoulder deformities can occur, particularly if the fracture is associated with an anterior or posterior dislocation of the humeral head.",
"   </p>",
"   <p>",
"    There are no specific examination tests for the diagnosis of proximal humeral fractures. Suspect this fracture in elderly patients who have fallen and present with the symptoms or findings described here. Although overlying musculature makes palpation difficult, patients typically have focal tenderness at the proximal humerus.",
"   </p>",
"   <p>",
"    Distal pulses and nerve function must be evaluated, although assessment of motor function is often limited due to pain. Neurovascular injury occurs most often with displaced fractures or fracture-dislocations and usually involves the axillary or suprascapular nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Axillary nerve injury manifests as deltoid muscle weakness and diminished sensation over the mid-deltoid region. Suprascapular nerve injury can manifest as supraspinatus and infraspinatus muscle weakness (ie, weakness with initiation of abduction and external shoulder rotation respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain x-rays of the shoulder that include a true anteroposterior (AP) view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73366 \" href=\"UTD.htm?42/44/43725\">",
"     image 1",
"    </a>",
"    ), an axillary view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53879 \" href=\"UTD.htm?41/38/42605\">",
"     image 2",
"    </a>",
"    ), and a scapular-Y view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51351 \" href=\"UTD.htm?30/36/31311\">",
"     image 3",
"    </a>",
"    ) should be obtained if a proximal humeral fracture is suspected. This is the standard trauma series of radiographs. A Velpeau view, in which the patient's arm is held in internal rotation and the x-ray is oriented superior to inferior while the patient leans backward, is acceptable if an axillary view is unobtainable (",
"    <a class=\"graphic graphic_figure graphicRef71805 \" href=\"UTD.htm?38/47/39678\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A CT scan with three-dimensional reconstructions is recommended if the trauma series of plain radiographs described above is non-diagnostic or if further information is necessary regarding the amount of displacement or rotation of a fracture fragment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/8\">",
"     8",
"    </a>",
"    ]. CT scans are also recommended for fracture dislocations, humeral head-splitting fractures, and comminuted fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fracture patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the many classification systems proposed for proximal humerus fractures, the AO and Neer classification schemes are most commonly used. Of these two, the Neer system is most often used in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/9\">",
"     9",
"    </a>",
"    ]. The AO classification system is based on vascular anatomy. The Neer classification is based on biomechanical forces and displacement, and is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neer classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Neer classification system is based upon the anatomical relationship of the four major segments of the proximal humerus: the anatomical neck, the surgical neck, the greater tuberosity, and the lesser tuberosity (",
"    <a class=\"graphic graphic_figure graphicRef67578 \" href=\"UTD.htm?19/55/20339\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66167 \" href=\"UTD.htm?5/56/6024\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/1\">",
"     1",
"    </a>",
"    ]. Fractures are classified according to whether one or more of these four segments (or fragments) have been displaced. Displacement exists when a segment is angulated more than 45 degrees or displaced more than one centimeter from a normal anatomic position.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One-part fractures are defined as fractures in which no fragments are displaced (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64768 \" href=\"UTD.htm?40/60/41921\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Two-part fractures are defined by one displaced fragment (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59038 \" href=\"UTD.htm?0/30/495\">",
"       image 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Three-part fractures are defined by two displaced fragments but the humeral head remains in contact with the glenoid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50923 \" href=\"UTD.htm?2/11/2239\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Four-part fractures are defined by three or more displaced fragments and dislocation of the articular surface from the glenoid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60812 \" href=\"UTD.htm?13/23/13695\">",
"       image 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One and two-part fractures occur most commonly. Two-part fractures of the surgical neck are the most common displaced fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of proximal humerus fractures are non-displaced or minimally displaced (ie, one-part) and can be treated conservatively by primary care clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/6\">",
"     6",
"    </a>",
"    ]. However, fractures of the anatomic neck have a high rate of subsequent osteonecrosis and patients with this type of fracture should be referred to an orthopedic surgeon even if there is no significant displacement of the fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Fracture patterns'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A nonoperative approach to one-part fractures is supported by the findings of an observational study of 507 patients with minimally displaced humerus fractures treated conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/11\">",
"     11",
"    </a>",
"    ]. At one year follow-up, 88 percent of patients had good or excellent results according to the Neer criteria; no patients developed a nonunion. Another study of 54 patients with one-part humerus fractures treated conservatively found similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/12\">",
"     12",
"    </a>",
"    ]. All patients had clinical union of the fracture and symptom scores at one year were similar to preinjury levels. Forward flexion was not diminished but there was a 2 to 7 degree loss of internal and external rotation.",
"   </p>",
"   <p>",
"    Surgical intervention is generally needed for significantly displaced multi-part fractures and thus all displaced fractures should be referred to an orthopedic surgeon for evaluation. Treatment options include percutaneous pinning, open reduction and internal fixation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77998 \" href=\"UTD.htm?9/55/10111\">",
"     image 8",
"    </a>",
"    ), and hemiarthroplasty (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60512 \" href=\"UTD.htm?6/46/6895\">",
"     image 9",
"    </a>",
"    ). Further indications for referral include fracture-dislocations and joint instability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/13\">",
"     13",
"    </a>",
"    ]. Emergency referral is indicated for all nerve and vascular injuries, open fractures, and fracture dislocations.",
"   </p>",
"   <p>",
"    Three systematic reviews have assessed the outcomes of studies comparing conservative and surgical management of complex proximal humerus fractures and evaluating different surgical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. One systematic review suggests that patients with displaced fractures treated conservatively experience more pain and greater loss of motion but other reviews do not concur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/14\">",
"     14",
"    </a>",
"    ]. Another review found inadequate evidence to confirm that surgery is preferable to conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/16\">",
"     16",
"    </a>",
"    ]. All reviews determined that there is insufficient evidence from randomized controlled trials to determine which interventions are best for the management of different types of proximal humeral fractures. Therefore, we believe that patients with two to four-part proximal humerus fractures or those with anatomic neck fractures should be referred to an orthopedic surgeon to review treatment options, which are based upon the fracture type and patient characteristics.",
"   </p>",
"   <p>",
"    Small, primarily observational studies suggest that good outcomes may be achieved using nonoperative management of displaced fractures when necessary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 160 patients with humerus fractures treated conservatively showed that a majority had good outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/17\">",
"       17",
"      </a>",
"      ]. The study consisted of 75 one-part, 60 two-part, 23 three-part, and 2 four-part fractures. Immobilization averaged three weeks. The mean difference in Constant scores (an assessment of shoulder function) between the affected and unaffected side was 8.2 points (95% CI 7.3-13.1). The risk of delayed and nonunion was 7 percent and 41 of 42 employed patients returned to work.",
"     </li>",
"     <li>",
"      A prospective study of 126 elderly patients with displaced two-part fractures treated conservatively reported that 64.5 percent achieved good or excellent results [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/18\">",
"       18",
"      </a>",
"      ]. There was no correlation between fracture translation or angulation and the patient&rsquo;s ability to return to daily activities. At one year follow-up, no difference in shoulder function (using Neer scores) was found when these patients were compared to a cohort of surgically treated patients.",
"     </li>",
"     <li>",
"      In one of the few randomized, prospective studies to look at complex proximal humerus fractures, 40 patients (mean age 74) with three and four-part fractures were treated either with tension band wiring or nonoperative management [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/19\">",
"       19",
"      </a>",
"      ]. At one year, no significant difference in pain, range of motion, abduction or flexion power, or the ability to perform activities of daily living was found between the two groups. Although the position of the fracture fragments improved in the operative group, this did not correlate with better function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute treatment for one-part fractures includes immobilization in a standard sling or collar and cuff sling (",
"    <a class=\"graphic graphic_figure graphicRef68874 \" href=\"UTD.htm?33/29/34270\">",
"     figure 10",
"    </a>",
"    ). A standard sling is recommended for impacted fractures. A collar and cuff sling may aid in reduction of minimally displaced fragments. Swathes (",
"    <a class=\"graphic graphic_figure graphicRef78370 \" href=\"UTD.htm?26/7/26736\">",
"     figure 11",
"    </a>",
"    ) can be used for pain control but are otherwise not necessary unless the shoulder is unstable. Ice can be used to reduce pain and swelling; pain medications are generally necessary for the first week of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H8#H8\">",
"     \"Splinting of musculoskeletal injuries\", section on 'Upper extremity splints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17318?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles of acute fracture management\", section on 'Pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients generally prefer to sleep semirecumbent (eg, in a reclining chair or propped up with pillows or a wedge in bed) with a sling. Repeat clinical evaluation and radiographs are performed at one week. Careful attention should be paid to the skin, especially in elderly patients with swelling and ecchymosis.",
"   </p>",
"   <p>",
"    Several muscles have insertions on the proximal humerus and the forces exerted by these muscles make it difficult to maintain reductions of proximal humerus fractures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The supraspinatus and infraspinatus pull the greater tuberosity superiorly",
"     </li>",
"     <li>",
"      The subscapularis pulls the lesser tuberosity medially",
"     </li>",
"     <li>",
"      The pectoralis major adducts the humeral shaft",
"     </li>",
"     <li>",
"      The deltoid abducts the humeral shaft",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, closed reduction of fracture fragments is NOT recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total healing time is typically 6 to 12 weeks for proximal humerus fractures. Early callus formation usually occurs at four to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Duration of immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder rehabilitation is important after proximal humerus fractures; however, the optimal timing for the start of rehabilitation remains uncertain. Most experts agree that range of motion exercises should be initiated by two weeks but some argue this should occur sooner. The following clinical studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective study assigned 85 patients to one or three weeks of immobilization, to be followed by rehabilitation with shoulder and other motion exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/13\">",
"       13",
"      </a>",
"      ]. For the initial three months of treatment, shoulder function scores were better in patients who initiated motion at day seven. However, there was no difference in function between the two groups at 6, 12, and 24 months.",
"     </li>",
"     <li>",
"      A similar trial of 74 patients compared aggressive early mobilization at 72 hours to standard mobilization at three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/20\">",
"       20",
"      </a>",
"      ]. Initially, Constant scores (assessment of shoulder function), pain scores, and mobility were better in the early mobilization group, but at six months no significant differences were noted.",
"     </li>",
"     <li>",
"      In a subsequent study, 86 patients with two-part fractures of the proximal humerus were randomly assigned to begin range of motion exercises within the first week after injury or to continue shoulder immobilization for three weeks before beginning rehabilitation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/21\">",
"       21",
"      </a>",
"      ]. The group that started early therapy had significantly less pain and better function four months after the fractures occurred. However, there was no statistically significant difference between the two groups at one year.",
"     </li>",
"     <li>",
"      An uncontrolled study of 104 patients with minimally displaced (one-part) proximal humerus found no difference in fracture healing but significantly better overall function and external rotation in those patients who started supervised physical therapy by day 14 compared with those who started after day 14 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/22\">",
"       22",
"      </a>",
"      ]. The mean duration of follow-up was 41 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, it appears that for patients with nondisplaced or minimally displaced one or two-part fractures, a shorter period of immobilization, perhaps as little as one week, does not adversely affect fracture healing and may be associated with better short term pain control and shoulder function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reevaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are seen again within four to seven days of their initial visit and plain radiographs are obtained to reevaluate for significant displacement. If pain is well controlled and no displacement of fragments is noted, pendulum exercises can be initiated in the sling to avoid loss of shoulder motion (",
"    <a class=\"graphic graphic_figure graphicRef72763 \" href=\"UTD.htm?12/33/12831\">",
"     figure 12",
"    </a>",
"    ). Passive elbow range of motion as well as isometric strengthening exercises for the biceps and triceps should be initiated early.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subsequent visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first of a series of two-week follow-up visits focuses on pain control and upper extremity range of motion. Patients are encouraged to discontinue their sling within two to four weeks of the injury, and to perform gentle, passive range of motion exercises of the elbow and shoulder. Pendulum (",
"    <a class=\"graphic graphic_figure graphicRef72763 \" href=\"UTD.htm?12/33/12831\">",
"     figure 12",
"    </a>",
"    ) and wall climb (",
"    <a class=\"graphic graphic_figure graphicRef58175 \" href=\"UTD.htm?23/44/24256\">",
"     figure 13",
"    </a>",
"    ) exercises should be done at least twice daily. If patients are unable to perform these exercises, a referral to physical therapy for assistance improving passive range of motion is necessary.",
"   </p>",
"   <p>",
"    The goal of shoulder rehabilitation is to restore strength and mobility, including abduction, flexion, extension, and rotation. Exercises in which the patient places their hand on a wall or holds a ball against a wall to improve motion can begin within two to four weeks. Patients can initiate these motions against gravity at four weeks and progress to elastic band or resistance exercises once adequate motion has been achieved and there is sufficient evidence of healing by radiographs. The details of rehabilitation for proximal humeral fractures are beyond the scope of this monograph, but the systematic review cited here emphasizes the importance of early mobilization and outlines a program suitable for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After eight weeks, the time between visits may be increased to every three to four weeks. The focus of these visits is to further improve shoulder range of motion and overall function. Functional measures of motion include the ability to touch the neck and lower back and to abduct the arm overhead.",
"   </p>",
"   <p>",
"    Over subsequent weeks, the patient follows a progression of exercises designed to maximize shoulder mobility and strength. Most patients with nondisplaced or minimally displaced fractures of the proximal humerus who adhere to a well-designed rehabilitation program regain over 90 percent of the function and 85 percent of the motion of their unaffected shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of shoulder mobility is among the more common complications of proximal humerus fractures. The decrease in motion ranges from the clinically insignificant to adhesive capsulitis (frozen shoulder), in which shoulder movement is painful and limited in all orientations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of shoulder motion and function is more likely to develop in patients who do not perform range of motion exercises during recovery.",
"   </p>",
"   <p>",
"    Severely displaced or angulated fractures can cause neurovascular injury, most commonly to the circumflex artery and the axillary or suprascapular nerve. One prospective study of 142 patients with proximal humerus fractures found evidence of some denervation using an electromyogram in 67 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/2\">",
"     2",
"    </a>",
"    ]. Injury to the axillary nerve accounted for 58 percent of cases, while injury to the suprascapular nerve accounted for 48 percent. All patients recovered full function of the nerve and muscles.",
"   </p>",
"   <p>",
"    Proximal humerus fractures are sometimes associated with dislocations of the humeral head or rotator cuff tears, which can cause significant loss of motion or instability. Studies using dynamic ultrasound have found that 20 to 50 percent of patients with proximal humerus fractures have associated rotator cuff tears [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A prospective study involving magnetic resonance imaging reported that 71 percent of patients had rotator cuff abnormalities and 40 percent had at least one torn or avulsed tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29543/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although osteonecrosis of the humeral head is not common, it can occur, especially in fractures involving the anatomic neck or severely displaced fractures. Other complications include nonunion and impingement from avulsed fracture fragments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051038\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to work typically occurs two to three weeks after a proximal humerus fracture, provided the patient can return in the sling and the job does not require full use of the affected arm. Patients whose jobs include two-handed labor or lifting will likely not be able to return for eight to twelve weeks.",
"   </p>",
"   <p>",
"    Criteria for return to work include adequate range of motion and strength as well as stable callus formation on radiographs. The same criteria are used to determine the return to sports. Cardiovascular fitness after a proximal humeral fracture can be maintained by low impact activities such as walking or use of an elliptical trainer or stationary bike.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal humerus fractures account for four to five percent of all fractures and the incidence increases with advancing age. They often occur as a result of falling from a standing height. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Swelling and ecchymosis may be apparent soon after the injury. Gross deformity of the shoulder suggests an associated anterior or posterior dislocation. Concomitant neurologic or vascular injury should be suspected and neurovascular integrity clinically assessed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Neer classification system is often used for proximal humerus fractures. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Neer classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complex proximal humerus fractures (ie, Neer two-part to four-part fractures) and fractures that involve the anatomical neck should be referred to an orthopedic surgeon. These are initially managed with immobilization using a standard sling, or if unstable a sling and swathe. Closed reduction of the fracture is",
"      <strong>",
"       NOT",
"      </strong>",
"      recommended prior to orthopedic referral.",
"     </li>",
"     <li>",
"      Approximately 80 percent of proximal humerus fractures are impacted or nondisplaced (Neer one-part fractures) and are amenable to closed management. Orthopedic referral is not required for one-part fractures unless the fracture involves the anatomic neck, there are neurovascular complications, there is a concomitant shoulder dislocation, or the treating clinician is not experienced in fracture management. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonoperative management of one-part fractures includes initial immobilization with a standard or collar and cuff sling, ice, and analgesics. Neither splinting nor casting is required. We suggest that early mobilization with pendulum exercises be performed in the sling beginning one to two weeks after the injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic follow-up visits allow assessment of range of motion, muscle strength, and function. Generally, the first appointment occurs one week following the injury, with subsequent follow-up every two weeks for two months, followed by visits every three to four weeks until complete radiographic healing is documented. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Return to work can be expected in two to three weeks if the patient can perform the required duties while in a sling. Return to occupations that require full use of the shoulder or to sports is not advised until strength and range of motion are acceptable and stable healing is apparent on radiographs. (See",
"      <a class=\"local\" href=\"#H3051038\">",
"       'Return to sport or work'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/1\">",
"      Neer CS 2nd. Displaced proximal humeral fractures. I. Classification and evaluation. J Bone Joint Surg Am 1970; 52:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/2\">",
"      Visser CP, Coene LN, Brand R, Tavy DL. Nerve lesions in proximal humeral fractures. J Shoulder Elbow Surg 2001; 10:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/3\">",
"      Court-Brown CM, Garg A, McQueen MM. The epidemiology of proximal humeral fractures. Acta Orthop Scand 2001; 72:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/4\">",
"      Palvanen M, Kannus P, Niemi S, Parkkari J. Update in the epidemiology of proximal humeral fractures. Clin Orthop Relat Res 2006; 442:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/5\">",
"      Chu SP, Kelsey JL, Keegan TH, et al. Risk factors for proximal humerus fracture. Am J Epidemiol 2004; 160:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/6\">",
"      Lee SH, Dargent-Molina P, Br&eacute;art G, EPIDOS Group. Epidemiologie de l'Osteoporose Study. Risk factors for fractures of the proximal humerus: results from the EPIDOS prospective study. J Bone Miner Res 2002; 17:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/7\">",
"      Perlmutter GS. Axillary nerve injury. Clin Orthop Relat Res 1999; :28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/8\">",
"      Robinson BC, Athwal GS, Sanchez-Sotelo J, Rispoli DM. Classification and imaging of proximal humerus fractures. Orthop Clin North Am 2008; 39:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/9\">",
"      Sidor ML, Zuckerman JD, Lyon T, et al. The Neer classification system for proximal humeral fractures. An assessment of interobserver reliability and intraobserver reproducibility. J Bone Joint Surg Am 1993; 75:1745.",
"     </a>",
"    </li>",
"    <li>",
"     Fracture Management for Primary Care, Eiff P, Hatch R, Calmbach W.  (Eds), Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/11\">",
"      Gaebler C, McQueen MM, Court-Brown CM. Minimally displaced proximal humeral fractures: epidemiology and outcome in 507 cases. Acta Orthop Scand 2003; 74:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/12\">",
"      Tejwani NC, Liporace F, Walsh M, et al. Functional outcome following one-part proximal humeral fractures: a prospective study. J Shoulder Elbow Surg 2008; 17:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/13\">",
"      Kristiansen B, Angermann P, Larsen TK. Functional results following fractures of the proximal humerus. A controlled clinical study comparing two periods of immobilization. Arch Orthop Trauma Surg 1989; 108:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/14\">",
"      Misra A, Kapur R, Maffulli N. Complex proximal humeral fractures in adults--a systematic review of management. Injury 2001; 32:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/15\">",
"      Lanting B, MacDermid J, Drosdowech D, Faber KJ. Proximal humeral fractures: a systematic review of treatment modalities. J Shoulder Elbow Surg 2008; 17:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/16\">",
"      Handoll HH, Ollivere BJ, Rollins KE. Interventions for treating proximal humeral fractures in adults. Cochrane Database Syst Rev 2012; 12:CD000434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/17\">",
"      Hanson B, Neidenbach P, de Boer P, Stengel D. Functional outcomes after nonoperative management of fractures of the proximal humerus. J Shoulder Elbow Surg 2009; 18:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/18\">",
"      Court-Brown CM, Garg A, McQueen MM. The translated two-part fracture of the proximal humerus. Epidemiology and outcome in the older patient. J Bone Joint Surg Br 2001; 83:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/19\">",
"      Zyto K, Ahrengart L, Sperber A, T&ouml;rnkvist H. Treatment of displaced proximal humeral fractures in elderly patients. J Bone Joint Surg Br 1997; 79:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/20\">",
"      Lefevre-Colau MM, Babinet A, Fayad F, et al. Immediate mobilization compared with conventional immobilization for the impacted nonoperatively treated proximal humeral fracture. A randomized controlled trial. J Bone Joint Surg Am 2007; 89:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/21\">",
"      Hodgson SA, Mawson SJ, Stanley D. Rehabilitation after two-part fractures of the neck of the humerus. J Bone Joint Surg Br 2003; 85:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/22\">",
"      Koval KJ, Gallagher MA, Marsicano JG, et al. Functional outcome after minimally displaced fractures of the proximal part of the humerus. J Bone Joint Surg Am 1997; 79:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/23\">",
"      Hodgson S. Proximal humerus fracture rehabilitation. Clin Orthop Relat Res 2006; 442:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/24\">",
"      Wilmanns C, Bonnaire F. Rotator cuff alterations resulting from humeral head fractures. Injury 2002; 33:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/25\">",
"      Nanda R, Goodchild L, Gamble A, et al. Does the presence of a full-thickness rotator cuff tear influence outcome after proximal humeral fractures? J Trauma 2007; 62:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29543/abstract/26\">",
"      Gallo RA, Sciulli R, Daffner RH, et al. Defining the relationship between rotator cuff injury and proximal humerus fractures. Clin Orthop Relat Res 2007; 458:70.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 217 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29543=[""].join("\n");
var outline_f28_54_29543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fracture patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neer classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Duration of immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reevaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subsequent visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3051038\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/217|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/44/43725\" title=\"diagnostic image 1\">",
"      Adult shoulder normal AP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/38/42605\" title=\"diagnostic image 2\">",
"      Adult shoulder axillary xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/36/31311\" title=\"diagnostic image 3\">",
"      Adult shoulder scapular Y",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/60/41921\" title=\"diagnostic image 4\">",
"      Humeral fracture proximal one-part",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/30/495\" title=\"diagnostic image 5\">",
"      Adult proximal humerus fracture 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/11/2239\" title=\"diagnostic image 6\">",
"      Adult three part humerus fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/23/13695\" title=\"diagnostic image 7\">",
"      Proximal humerus fracture-dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/55/10111\" title=\"diagnostic image 8\">",
"      Fixation of proximal humerus fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/46/6895\" title=\"diagnostic image 9\">",
"      Adult shoulder hemiarthroplast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/217|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/20/33093\" title=\"figure 1\">",
"      Shoulder anatomy anterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/60/28613\" title=\"figure 2\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27748\" title=\"figure 3\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/55/20339\" title=\"figure 4\">",
"      Proximal humerus fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/1/15378\" title=\"figure 5\">",
"      Rotator cuff muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/37/14931\" title=\"figure 6\">",
"      Anterior view of proximal humerus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 7\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/47/39678\" title=\"figure 8\">",
"      Velpeau xray technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/56/6024\" title=\"figure 9\">",
"      Neer classification of proximal humerus fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34270\" title=\"figure 10\">",
"      Collar and cuff sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/7/26736\" title=\"figure 11\">",
"      Sling and swathe splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/33/12831\" title=\"figure 12\">",
"      Pendulum exercises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/44/24256\" title=\"figure 13\">",
"      Wall climb exercises",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17318?source=related_link\">",
"      General principles of acute fracture management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27510?source=related_link\">",
"      Midshaft humeral fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43812?source=related_link\">",
"      Stress fractures of the humeral shaft",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_54_29544="Pathogenesis of herpes simplex virus type 1 infection";
var content_f28_54_29544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of herpes simplex virus type 1 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29544/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29544/contributors\">",
"     Robyn S Klein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29544/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29544/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/54/29544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) is a member of the family of herpesviruses that includes HSV-1, herpes simplex virus type 2 (HSV-2), cytomegalovirus, Epstein Barr virus, and human herpesviruses 6, 7, and 8. This family of viruses is further classified into three subfamilies that include alpha, beta, and gamma herpesviridae. HSV-1 and HSV-2 belong to the alpha herpesviridae subfamily and the genus Simplexvirus, which are characterized by their variable host range, short replication cycle, and the ability to destroy infected cells and establish latent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/1\">",
"     1",
"    </a>",
"    ]. While members of the herpesvirus family share certain structural features, the spectrum of clinical illness induced varies considerably.",
"   </p>",
"   <p>",
"    The pathogenesis of infection due to HSV-1 and viral mechanisms to avoid the humoral and cellular components of the immune system will be reviewed here. The epidemiology, clinical manifestations, diagnosis and treatment of infection by HSV-1 and other members of the herpesvirus family are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38021?source=see_link\">",
"     \"Epidemiology of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39669?source=see_link\">",
"     \"Prevention of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE AND LIFE CYCLE OF HSV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 is a double-stranded DNA-enveloped virus, with a central core containing the viral DNA, an inner core surrounded by envelope derived from both host cellular membranes and viral glycoproteins, and an icosahedral capsid composed of viral proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/1\">",
"     1",
"    </a>",
"    ]. Between the capsid and the envelope lies the tegument, a proteinaceous structure containing two proteins important in the pathogenesis of HSV-1 infection, alpha-transinducing factor (alpha-TIF) (aka: VP16 and Vmw65) and virion host shut-off protein (VHS). VP16 is a transcriptional activator protein that forms a complex with host cell factor (HCF), which localize within the nucleus. These proteins, together with the host transcription factor, octamer-binding protein 1(OCT1), enable the recruitment of other host factors that stimulate transcription of immediate-early (IE) viral gene products [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral glycoproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-TIF activates the viral replication cascade, and VHS shuts off host cell macromolecular synthesis (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Approximately 1,000 molecules of alpha-TIF and 200 copies of VHS are present in the tegument and packaged in the virion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Thus, these proteins can act early as virus particles enter the cells and uncoat. The viral glycoproteins embedded in the lipid envelope mediate attachment to host cell receptors, fusion of viral and host cell membranes, and envelopment and emergence of virus as newly formed nucleocapsids bud from host cell nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. These glycoproteins are also the major targets of humoral and cellular immune responses and viral immune escape mechanisms by binding both complement and anti-HSV IgG molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral replication takes approximately 24 hours and begins with the attachment of viral glycoproteins to cell-surface receptors, including glycosaminoglycan (GAG) heparan sulfate and the immunoglobulin-like cellular receptors (designated nectin1-alpha and delta and nectin2-beta) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Glycoproteins gC and gB interact with GAG heparan sulfate, while gD provides a stable attachment to cellular receptors. Glycoprotein gC also binds complement protein C3b and inhibits complement activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/9\">",
"     9",
"    </a>",
"    ]. HSV strains with mutations in the gC gene are more susceptible to neutralization by human serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cell entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five glycoproteins have been implicated in the entry of HSV-1 into target cells, gB, gC, gH, and gL, and gC; only the last protein is considered dispensible for entry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Initial interactions, however, are mediated by heparan sulfate proteoglycans (HSPGs), which interact first with gB (or gC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/11\">",
"     11",
"    </a>",
"    ]. An additional receptor for gB, paired immunoglobulin-like receptor (PILR)-alpha, is expressed by monocytes, macrophages, and dendritic cells and plays a role in both binding and fusion of virions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Membrane fusion involves gB, gD, gH and gL. gD binds several receptors including nectin-1 and -2, herpesvirus entry mediator (HVEM) and 3-O sulfated heparan sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Most investigators agree that during membrane fusion, gD undergoes a conformational change after receptor binding and then interacts with a heterodimer composed of",
"    <span class=\"nowrap\">",
"     gH/gL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. Fusion domains of the",
"    <span class=\"nowrap\">",
"     gH/gL",
"    </span>",
"    complex and gB enable the virus to penetrate into cells. The viral envelope and plasma membrane fuse, and capsid and tegument proteins are released into the cytosol. The capsid travels to the nucleus via the cytoskeleton where it docks at nuclear pore complexes (NPCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/16\">",
"     16",
"    </a>",
"    ]. The binding of capsid to NPCs triggers the release of viral genome into the nucleus, leaving empty capsids behind in the cytoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Virus-cell interaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once inside the cell, the viral tegument proteins VHS and alpha-TIF begin the work of taking over host cell function. VHS degrades and destabilizes mRNA, interrupting host cell protein synthesis, and alpha-TIF forms a complex with host-cell transcription factors which then binds to cis-acting sites on viral gene promoters [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The IE genes are then upregulated to produce five alpha proteins, designated infected cell polypeptides (ICP) 0, 4, 8, 22, 27, and 47 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. ICP0 and ICP4 are potent trans-activators of early (E) and late (L) viral proteins, and ICP22 and ICP27 modulate the transactivating activity of ICP0 and ICP4. ICP47 binds to and prevents",
"    <span class=\"nowrap\">",
"     TAP1/TAP2",
"    </span>",
"    from allowing the transport of antigenic peptides into the endoplasmic reticulum for ultimate presentation at the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral replication is somewhat sensitive to the presence of interferon (IFN), and ICP0 appears to play a role in bypassing this sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/18\">",
"     18",
"    </a>",
"    ]. Another ICP (ICP 34.5) has been implicated in the enhancement of neurovirulence through its effects on IFN-inducible double stranded RNA-dependent protein kinase R [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/19\">",
"     19",
"    </a>",
"    ]. Beta genes encode polypeptides like thymidine kinase and DNA polymerase, whose expression correlates with viral DNA synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. Gamma genes code for structural proteins like VHS, alpha-TIF, capsid proteins and envelope glycoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. Six genes are required for cleavage of viral concatemeric DNA into unit-length genomes and packaging of the virus genomes into preformed capsids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Budding and cell-to-cell spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;After synthesis, glycoproteins attach to the outer surface of the nuclear membrane, and VHS and alpha-TIF attach to the inner surface. A newly formed nucleocapsid will bud only where these viral proteins are present. After exiting the nucleus, the virion travels through the cytoplasm in a vesicle, which then fuses with the plasma membrane to release the virus into the extracellular space or to enable cell-to-cell spread [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. The latter is accomplished via interactions between viral glycoproteins and receptors at cell junctions, depending on the same gD interactions with its receptors required for initial cell entry.",
"    <span class=\"nowrap\">",
"     gE/gI",
"    </span>",
"    complex and gM, which are not required for initial cell entry of virions, interact with these receptors and facilitate spread of the virus along the basolateral surface of polarized cells, achieving cell-to-cell spread. In addition, gK plays a critical role in cell-to-cell spread in corneal and trigeminal ganglia cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 causes both acute and recurrent disease. The most common clinical manifestation is herpes labialis, but HSV-1 also causes serious disease elsewhere (eg, the eye) and is the virus most responsible for sporadic cases of encephalitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infection with HSV-1 may induce disease through direct destruction of tissues or through the induction of immunopathologic responses (see below). Tissue destruction, which is the direct consequence of replicating virus, results in mucocutaneous HSV-1. Visceral infections with HSV-1, such as pneumonitis, encephalitis, and hepatitis, also reflect virus-induced cytopathogenicity, which occurs through the same mechanisms as herpes labialis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rapid viral replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with HSV-1 begins with an acute phase during which virus rapidly replicates at the site of contact. Dermal keratinocytes and other epithelial sites are the principal sites of viral replication in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/5\">",
"     5",
"    </a>",
"    ]; infected gingival tissue has been shown to be a source of HSV-1 shedding into the oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nervous system invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;While local replication does not determine the extent of mucosal inflammation or clinical symptoms, it does determine neuroinvasiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/23\">",
"     23",
"    </a>",
"    ]. The virus first enters neuronal termini and is transported to sensory ganglia via intra-axonal flow [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/5\">",
"     5",
"    </a>",
"    ]. Herpesvirus nucleocapsids have been shown to travel within axons in the retrograde direction at a rate of 2",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/24\">",
"     24",
"    </a>",
"    ]. Ganglia generally become infected within 24 hours of exposure, with further acute viral replication and the establishment of latency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Latency'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animal models, infectious virus and viral antigens can be detected in neurons for approximately 10 days after inoculation at peripheral sites; after this time, replication ceases and latency ensues [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. In the case of herpes labialis, the trigeminal ganglia are considered to be the site of virus reactivation and the source of infectious viral particles in recrudescent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/22\">",
"     22",
"    </a>",
"    ]. The rate of establishment of latent foci is related to the dose of the inoculum. HSV-1 remains latent in the trigeminal ganglia for life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible mechanism of nervous system invasion is viremia. HSV has been identified by culture in the blood or neonates and immunocompromised patients and, by polymerase chain reaction, in the blood of immunocompetent adults with gingivostomatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent HSV-1 infection is a chronic, intermittent disease characterized by both clinical and subclinical episodes of productive viral infection. During the cycle of recurrent disease, the virus undergoes repeated reactivations from latent infection in trigeminal ganglia neurons with anterograde axonal transport to new sites of replication in epithelial cells. Epithelial cell infection may not necessarily have to occur in order to establish latency since mutant viruses that are unable to produce skin lesions have been found in ganglia after peripheral inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .) Some preliminary data suggest that the frequency of HSV recurrences may be related to the patient's genetic background; in a study of 421 members of 39 large families, herpes susceptibility was linked to the long arm of human chromosome 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Latency",
"    </span>",
"    &nbsp;&mdash;&nbsp;During latent infection, viral DNA remains episomal within neuronal nuclei, and no infectious virions are produced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ]. Infectious virus cannot be detected in neuronal or epithelial tissue; however, explanted sensory ganglia are able to yield infectious virus after one week in culture, demonstrating the presence of infectious virus. Consistent with this, recent studies have shown that lytic gene expression and reactivation do occur in a minority of neurons within infected ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/29\">",
"     29",
"    </a>",
"    ]. The only viral gene products found during latency are the latency-associated transcripts (LATs) located in the nuclei of latently-infected neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6,22,30\">",
"     6,22,30",
"    </a>",
"    ]. LATs are unsuitable for translation because they are not polyadenylated at their 3' end and lack a methyl-7-guanosine cap at their 5' end. Although these transcripts were first described over ten years ago, their function remains poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]. Most studies suggest that transcription within the HSV-1 LAT genomic focus facilitates latency through repression of ICP0 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other experiments have shown that LAT promotes neuronal survival by blocking apoptosis, allowing infected neurons to persist [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/31\">",
"     31",
"    </a>",
"    ] and by increasing the numbers of neurons in which latency is established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/32\">",
"     32",
"    </a>",
"    ]. Separate LAT genes also appear to be responsible for maintaining latency and for initiating reactivation (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/33\">",
"     33",
"    </a>",
"    ]. Nerve growth factor (NGF) also appears to be involved in the mechanics of maintaining viral latency. A host transcription factor, Oct-2, has been shown to repress viral alpha gene expression and NGF has been shown to upregulate Oct-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection of mouse trigeminal ganglia by HSV induces cytokine expression that persists long after primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/35\">",
"     35",
"    </a>",
"    ]. A possible role of the immune system in regulating viral replication and maintaining latency in the sensory neurons has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/36\">",
"     36",
"    </a>",
"    ]. Expression of the T cell chemokine, RANTES, and other antiviral cytokines are detectable in latently infected ganglia after HSV-1 infection of the cornea where both CD4 and CD8 T cells accumulate within latently infected ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Viral reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAT genes have been linked to reactivation of HSV through various animal studies. Their absence produces an 80 percent reduction in the rate of spontaneous reactivation without affecting the ability of the virus to establish and maintain latency or the severity of lytic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/38\">",
"     38",
"    </a>",
"    ]. Some studies suggest that a protein product of the LAT genome is linked to viral reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In addition, the number of HSV-1 genome copies in individual neurons may correlate with reactivation from latency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/41\">",
"     41",
"    </a>",
"    ]. The viral tegument proteins VHS and alpha-TIF also appear to be important for the reexpression of viral proteins. VHS deficient viruses are unable to reactivate in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/5\">",
"     5",
"    </a>",
"    ], and alpha-TIF can initiate reactivation through mechanisms that require the presence of certain host proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other stimuli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, the latent state may periodically break down in response to certain stimuli and lead to reactivation of virus and shedding of virions at the periphery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/5\">",
"     5",
"    </a>",
"    ]. There is evidence from human studies that acute and chronic psychological stress is associated with reactivation of both oral and genital herpes viruses as demonstrated by increases in antibody levels to HSV-1 and recrudescence associated lymphokines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/42\">",
"     42",
"    </a>",
"    ]. A murine model of psychological stress, applied in the form of physical restraint, has demonstrated that suppression of various immune functions are the probable cause of the observed increases in viral replication during stressful circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H18\">",
"     'Influence of stress on response to the virus'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Certain studies suggest that elevations in prostaglandins (PGE) are associated with recurrence of HSV-1. Various forms of skin trauma, which cause reactivation of HSV in humans and mice, have been shown to be associated with local elevations of prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/3\">",
"     3",
"    </a>",
"    ]. In vitro studies have found that the PGE inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , inhibits HSV reactivation from latently infected mouse and rabbit ganglia, viral replication in lymphoid cells, and reduces the size of HSV-induced plaques on Vero cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/3\">",
"     3",
"    </a>",
"    ]. In vivo studies with guinea pigs and humans have demonstrated a decrease in herpetic recurrences in individuals treated with indomethacin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/3\">",
"     3",
"    </a>",
"    ]. Further studies are needed to evaluate the therapeutic value of PGE inhibitors in the treatment of herpetic recurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMMUNE RESPONSE TO HSV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other viral infections, the successful clearance of HSV-1 depends upon the generation of a T helper cell-associated immune response with expansion of the appropriate CD4+ and CD8+ T cell subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/44,45\">",
"     44,45",
"    </a>",
"    ] and the initiation of a macrophage response [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/46\">",
"     46",
"    </a>",
"    ]. In the case of ocular infection with HSV-1, the generation of high titers of neutralizing antibodies is also crucial for protection against lethal challenge and ocular scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/44\">",
"     44",
"    </a>",
"    ]. The generation of durable HSV-specific cytotoxic T lymphocyte (CTL) responses does not appear to depend upon viral replication, as demonstrated by the immune responses generated by replication deficient HSV-1 mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, despite these vigorous HSV-specific immune responses, viral replication may proceed to lesion formation and clinical symptoms. When lesions occur, a dermal mononuclear cell infiltrate is present as early as the second day of lesion formation. The infiltrate contains mostly CD4+ lymphocytes during the first few days and equal numbers of CD4+ and CD8+ lymphocyte in later lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/48\">",
"     48",
"    </a>",
"    ]. HSV-specific CD4+ lymphocyte proliferative responses and natural killer (NK)-like cytotoxic responses are present at all stages of herpetic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cytotoxic T lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coincident with the initial CD4+ infiltration is the appearance of IFN-gamma in infected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/49\">",
"     49",
"    </a>",
"    ]. IFN-gamma has been shown to increase the susceptibility of infected keratinocytes to lysis by CTL; this effect is maximal at the time when CD8+ cells are infiltrating [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/50\">",
"     50",
"    </a>",
"    ]. Viral clearance from the lesion site is associated with a high level of local HSV-specific CTL activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/48\">",
"     48",
"    </a>",
"    ]. The CTL may strike early, before virions are produced and before cells are disabled by infection. Thus, CTL may be containing the spreading lesion. In addition, IFN-gamma appears to counteract the blocks to antigen presentation afforded by both VHS and ICP47, producing increased recognition by CTL. This may be due to the fact that IFN-gamma upregulates the expressions of class I, TAP, and other components of the antigen presentation pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cell receptor",
"    <span class=\"nowrap\">",
"     (TCR)-gamma/delta",
"    </span>",
"    cells also appear to have a role in the regulation of HSV-1 infections. In two mouse models of HSV-1 infection,",
"    <span class=\"nowrap\">",
"     TCR-gamma/delta",
"    </span>",
"    cells limited severe HSV-1 induced epithelial lesions and prevented the development of lethal viral encephalitis by arresting both viral replication and neurovirulence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/51\">",
"     51",
"    </a>",
"    ]. Once cleared, HSV persists in a latent state without further viral replication (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Influence of stress on response to the virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to mount an immune response to infection with HSV-1 may be inhibited by stress. Using a murine model of acute footpad HSV infection, mice subjected to restraint or mild electric footshock have been shown to develop lower levels of HSV-specific memory CTL activity, lower levels of NK activity, lower levels of anti-HSV serum IgM levels, and decreased production of cytokines associated with CTL activation and function (interleukin [IL]-6 and IFN-gamma) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. These changes were correlated with increased viral titers in stressed mice compared to controls. Thus, stress is associated with depressed HSV-specific cellular and humoral immunity and is associated with increased pathogenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Avoidance of immune recognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 displays a number of mechanisms for avoiding immune recognition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Class I MHC",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-infected dermal fibroblasts use various indirect and direct mechanisms to escape recognition by the CD8+, class I MHC-restricted arm of the immune response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two HSV-encoded proteins that interfere with host protein synthesis produce a reduction in class I expression. This inhibition occurs within three hours after infection and is mediated by the VHS and the immediate-early protein ICP47. However, CD8+ T cell stimulation requires only low levels of epitope expression for functionality [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VHS has been shown to reduce the synthesis of MHC class I heavy chains and beta-2 microglobulin in mice and of HLA class I expressed on the surface of human dermal fibroblasts [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/53\">",
"       53",
"      </a>",
"      ]. Cells without class I expression become resistant to lysis by HSV-specific CTL clones [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/49,53\">",
"       49,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The production of ICP47 requires gene expression and occurs late during infection (see above). This protein binds to and interferes with the peptide translocation function of TAP (a transporter protein that transports 8 to 15 amino acid peptides to MHC for antigen presentation), so that human fibroblasts infected with HSV retain class I MHC molecules in the endoplasmic reticulum, rendering antigen presentation impossible [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Protection of virus within neurons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virus is also able to avoid immune recognition by escaping into neurons, resulting in infection by direct transfer between neuronal target cells. This limits cytolytic effector function of NK cells and CTL, which are unable to become activated and recognize viral products via antigen presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/49\">",
"     49",
"    </a>",
"    ]. This loss of CTL lysis is not necessarily detrimental to the host, since it may prevent spread of virions and subsequent infection (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Cytotoxic T lymphocytes'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immune-mediated complications of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain complications of infection with HSV-1 are immune-mediated. HSV-associated erythema multiforme (HAEM) is a polymorphic, self-limited, often recurring cutaneous eruption composed of macules, papules, bullae, and target lesions in an acral symmetrical distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/54\">",
"     54",
"    </a>",
"    ]. The pathogenesis of HAEM results from a combination of viropathic effects mediated by HSV proteins, notably DNA polymerase, and an immunologic reaction to viral antigens. HSV-1 DNA has been detected by polymerase chain reaction (PCR) in acute and healed HAEM skin lesions, and viral gene expression is associated with lesion development [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clearance of HSV-1 DNA from the skin may be delayed in patients with HAEM. Viral DNA and proteins ingested by macrophages at HSV lesion sites are processed and presented to T cells with HSV memory. NK cells, macrophages and activated CTL directed against antigen targets in epidermal cells are recruited to the skin site, resulting in the generation of an inflammatory cascade.",
"   </p>",
"   <p>",
"    Another example of autoimmune disease precipitated by HSV-1 infection is autoimmune herpes stromal keratitis. Intravitreal anti-CD11b monoclonal antibody therapy, which broadly depletes many effector cells including macrophages, granulocytes, NK cells and CTL, had been shown to suppress HSV-1 induced contralateral disease in a murine model of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/55\">",
"     55",
"    </a>",
"    ]. An epitope expressed by a coat protein of HSV-1 can be recognized by autoreactive T cells that target corneal antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29544/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=see_link\">",
"     \"Herpes simplex keratitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11926776\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes simplex virus type 1 (HSV-1) is a member of the family of herpesviruses that includes HSV-1, herpes simplex virus type 2 (HSV-2), cytomegalovirus, Epstein Barr virus, and human herpesviruses 6, 7, and 8. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV-1 is a double-stranded DNA-enveloped virus with an inner core surrounded by envelope derived from host cellular membranes and viral glycoproteins. Viral replication takes approximately 24 hours and begins with the attachment of viral glycoproteins to cell-surface receptors. Once inside the cell, the viral machinery takes over host cell function. After viral synthesis, glycoproteins attach to the outer surface of the nuclear membrane. After exiting the nucleus, the virion travels through the cytoplasm in a vesicle, which then fuses with the plasma membrane to release the virus into the extracellular space enabling cell-to-cell spread. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Structure and life cycle of HSV-1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute infection with HSV-1 may induce disease through direct destruction of tissues or through the induction of immunopathologic responses. During latent infection, no infectious virions are produced. Certain stimuli (such as stress) may lead to reactivation of virus and shedding of virions at the periphery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with other viral infections, the successful clearance of HSV-1 depends upon the generation of a T-helper cell-associated immune response. HSV-1 displays a number of mechanisms for avoiding immune recognition, such as reduction of human leukocyte antigen (HLA) class I expression or through viral escape into neurons. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Immune response to HSV-1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain complications of infection with HSV-1 are immune-mediated. HSV-associated erythema multiforme manifests as a cutaneous eruption composed of macules, papules, bullae, and target lesions in an acral symmetrical distribution, which can be self-limited or recurrent. Autoimmune herpes stromal keratitis is characterized by recurrent corneal inflammation with scarring, which can lead to decreased vision or blindness. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Immune-mediated complications of infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/1\">",
"      Riley LE. Herpes simplex virus. Semin Perinatol 1998; 22:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/2\">",
"      Wysocka J, Herr W. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci 2003; 28:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/3\">",
"      Kwong AD, Kruper JA, Frenkel N. Herpes simplex virus virion host shutoff function. J Virol 1988; 62:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/4\">",
"      Wu TJ, Monokian G, Mark DF, Wobbe CR. Transcriptional activation by herpes simplex virus type 1 VP16 in vitro and its inhibition by oligopeptides. Mol Cell Biol 1994; 14:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/5\">",
"      Strelow LI, Leib DA. Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. J Virol 1995; 69:6779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/6\">",
"      Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/7\">",
"      Rajc&aacute;ni J, Vojvodov&aacute; A. The role of herpes simplex virus glycoproteins in the virus replication cycle. Acta Virol 1998; 42:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/8\">",
"      Cocchi F, Menotti L, Dubreuil P, et al. Cell-to-cell spread of wild-type herpes simplex virus type 1, but not of syncytial strains, is mediated by the immunoglobulin-like receptors that mediate virion entry, nectin1 (PRR1/HveC/HIgR) and nectin2 (PRR2/HveB). J Virol 2000; 74:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/9\">",
"      Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004; 6:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/10\">",
"      Campadelli-Fiume G, Amasio M, Avitabile E, et al. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol 2007; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/11\">",
"      O'Donnell CD, Shukla D. A novel function of heparan sulfate in the regulation of cell-cell fusion. J Biol Chem 2009; 284:29654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/12\">",
"      Satoh T, Arii J, Suenaga T, et al. PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 2008; 132:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/13\">",
"      Tiwari V, ten Dam GB, Yue BY, et al. Role of 3-O-sulfated heparan sulfate in virus-induced polykaryocyte formation. FEBS Lett 2007; 581:4468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/14\">",
"      Atanasiu D, Whitbeck JC, Cairns TM, et al. Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A 2007; 104:18718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/15\">",
"      Akhtar J, Tiwari V, Oh MJ, et al. HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium. Invest Ophthalmol Vis Sci 2008; 49:4026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/16\">",
"      Ojala PM, Sodeik B, Ebersold MW, et al. Herpes simplex virus type 1 entry into host cells: reconstitution of capsid binding and uncoating at the nuclear pore complex in vitro. Mol Cell Biol 2000; 20:4922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/17\">",
"      Hagglund R, Roizman B. Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1. J Virol 2004; 78:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/18\">",
"      Mossman KL, Saffran HA, Smiley JR. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 2000; 74:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/19\">",
"      Leib DA, Machalek MA, Williams BR, et al. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci U S A 2000; 97:6097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/20\">",
"      Reynolds AE, Fan Y, Baines JD. Characterization of the U(L)33 gene product of herpes simplex virus 1. Virology 2000; 266:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/21\">",
"      David AT, Baghian A, Foster TP, et al. The herpes simplex virus type 1 (HSV-1) glycoprotein K(gK) is essential for viral corneal spread and neuroinvasiveness. Curr Eye Res 2008; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/22\">",
"      Scott DA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus type 1: a review. J Oral Pathol Med 1997; 26:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/23\">",
"      Fleck M, Podlech J, Weise K, et al. Pathogenesis of HSV-1/2 induced vaginitis/vulvitis of the mouse: dependence of lesions on genetic properties of the virus and analysis of pathohistology. Arch Virol 1993; 129:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/24\">",
"      Kristensson K. Retrograde transport of macromolecules in axons. Annu Rev Pharmacol Toxicol 1978; 18:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/25\">",
"      Stanberry LR, Floyd-Reising SA, Connelly BL, et al. Herpes simplex viremia: report of eight pediatric cases and review of the literature. Clin Infect Dis 1994; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/26\">",
"      Harel L, Smetana Z, Prais D, et al. Presence of viremia in patients with primary herpetic gingivostomatitis. Clin Infect Dis 2004; 39:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/27\">",
"      Steiner I, Spivack JG, Deshmane SL, et al. A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J Virol 1990; 64:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/28\">",
"      Hobbs MR, Jones BB, Otterud BE, et al. Identification of a herpes simplex labialis susceptibility region on human chromosome 21. J Infect Dis 2008; 197:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/29\">",
"      Margolis TP, Elfman FL, Leib D, et al. Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia. J Virol 2007; 81:11069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/30\">",
"      Millhouse S, Wigdahl B. Molecular circuitry regulating herpes simplex virus type 1 latency in neurons. J Neurovirol 2000; 6:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/31\">",
"      Perng GC, Jones C, Ciacci-Zanella J, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 2000; 287:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/32\">",
"      Thompson RL, Sawtell NM. The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J Virol 1997; 71:5432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/33\">",
"      Alvira MR, Goins WF, Cohen JB, Glorioso JC. Genetic studies exposing the splicing events involved in herpes simplex virus type 1 latency-associated transcript production during lytic and latent infection. J Virol 1999; 73:3866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/34\">",
"      Wood JN, Lillycrop KA, Dent CL, et al. Regulation of expression of the neuronal POU protein Oct-2 by nerve growth factor. J Biol Chem 1992; 267:17787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/35\">",
"      Chen SH, Garber DA, Schaffer PA, et al. Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation. Virology 2000; 278:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/36\">",
"      Liu T, Tang Q, Hendricks RL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J Virol 1996; 70:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/37\">",
"      Theil D, Derfuss T, Paripovic I, et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003; 163:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/38\">",
"      Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998; 37:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/39\">",
"      Thomas SK, Gough G, Latchman DS, Coffin RS. Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency. J Virol 1999; 73:6618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/40\">",
"      Goldenberg D, Mador N, Ball MJ, et al. The abundant latency-associated transcripts of herpes simplex virus type 1 are bound to polyribosomes in cultured neuronal cells and during latent infection in mouse trigeminal ganglia. J Virol 1997; 71:2897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/41\">",
"      Sawtell NM, Poon DK, Tansky CS, Thompson RL. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Virol 1998; 72:5343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/42\">",
"      Bonneau RH, Sheridan JF, Feng NG, Glaser R. Stress-induced suppression of herpes simplex virus (HSV)-specific cytotoxic T lymphocyte and natural killer cell activity and enhancement of acute pathogenesis following local HSV infection. Brain Behav Immun 1991; 5:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/43\">",
"      Kusnecov AV, Grota LJ, Schmidt SG, et al. Decreased herpes simplex viral immunity and enhanced pathogenesis following stressor administration in mice. J Neuroimmunol 1992; 38:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/44\">",
"      Ghiasi H, Wechsler SL, Cai S, et al. The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge. Immunology 1998; 95:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/45\">",
"      Ghiasi H, Perng G, Nesburn AB, Wechsler SL. Either a CD4(+)or CD8(+)T cell function is sufficient for clearance of infectious virus from trigeminal ganglia and establishment of herpes simplex virus type 1 latency in mice. Microb Pathog 1999; 27:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/46\">",
"      Irie H, Koyama H, Kubo H, et al. Herpes simplex virus hepatitis in macrophage-depleted mice: the role of massive, apoptotic cell death in pathogenesis. J Gen Virol 1998; 79 ( Pt 5):1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/47\">",
"      Brehm MA, Bonneau RH, Knipe DM, Tevethia SS. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. J Virol 1997; 71:3534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/48\">",
"      Koelle DM, Posavad CM, Barnum GR, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/49\">",
"      Tigges MA, Leng S, Johnson DC, Burke RL. Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol 1996; 156:3901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/50\">",
"      Symington FW, Santos EB. Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-gamma-treated keratinocytes. J Immunol 1991; 146:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/51\">",
"      Sciammas R, Kodukula P, Tang Q, et al. T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. J Exp Med 1997; 185:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/52\">",
"      Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol 2004; 5:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/53\">",
"      Burgert HG. Subversion of the MHC class I antigen-presentation pathway by adenoviruses and herpes simplex viruses. Trends Microbiol 1996; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/54\">",
"      Aurelian L, Kokuba H, Burnett JW. Understanding the pathogenesis of HSV-associated erythema multiforme. Dermatology 1998; 197:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/55\">",
"      Berra A, Rodriguez A, Heiligenhaus A, et al. The role of macrophages in the pathogenesis of HSV-1 induced chorioretinitis in BALB/c mice. Invest Ophthalmol Vis Sci 1994; 35:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29544/abstract/56\">",
"      Zhao ZS, Granucci F, Yeh L, et al. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998; 279:1344.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8294 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29544=[""].join("\n");
var outline_f28_54_29544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11926776\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE AND LIFE CYCLE OF HSV-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral glycoproteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral replication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cell entry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Virus-cell interaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Budding and cell-to-cell spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rapid viral replication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nervous system invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Latency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Viral reactivation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other stimuli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMMUNE RESPONSE TO HSV-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cytotoxic T lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Influence of stress on response to the virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Avoidance of immune recognition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Class I MHC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Protection of virus within neurons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immune-mediated complications of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11926776\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38021?source=related_link\">",
"      Epidemiology of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39669?source=related_link\">",
"      Prevention of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_54_29545="Lichen sclerosus vulvar";
var content_f28_54_29545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85726%7EOBGYN%2F78574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85726%7EOBGYN%2F78574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus of the vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rodriguez MI, Leclair CM. Benign vulvar dermatoses. Obstet Gynecol Surv 2012; 67:55. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29545=[""].join("\n");
var outline_f28_54_29545=null;
var title_f28_54_29546="Lipid abnormalities after renal transplantation";
var content_f28_54_29546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid abnormalities after renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Krista L Lentine, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/54/29546/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/54/29546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of post-transplant cardiovascular disease (CVD) most likely involves traditional and non-traditional risk factors. Although lipid abnormalities and cardiovascular disease are common complications of kidney transplantation, a causal association of dyslipidemias with cardiovascular risk has not been proven in this patient population.",
"   </p>",
"   <p>",
"    However, extrapolation from general population studies and some data in kidney transplant patients supports the view that the assessment and treatment of dyslipidemias should be part of routine post-renal-transplant care. Since immunosuppressive medications often cause secondary dyslipidemias, medication regimens should be individualized to minimize the competing risks of rejection and cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=see_link\">",
"     \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the high incidence of atherosclerotic disease events in the renal transplant population, we and several national groups suggest that patients with kidney transplants should be considered to be in the highest cardiovascular disease (CVD) risk group with respect to risk factor management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. Renal transplantation should therefore be considered a coronary heart disease equivalent risk. The prevalence and ability to modify dyslipidemias therefore render lipid modification a potentially important intervention for improving outcomes after kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the causes and management of lipid abnormalities in an attempt to lower cardiovascular risk in renal transplant recipients. The evidence concerning other putative benefits of lipid-lowering therapy among renal transplant recipients including preservation of renal function and lower acute rejection risk will also be discussed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     PREVALENCE",
"    </strong>",
"    &mdash; Dyslipidemia is defined by elevated plasma total cholesterol, elevated LDL, elevated triglycerides,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low HDL, all factors that may contribute to the development of atherosclerosis. Dyslipidemia is a frequent complication prior to and after kidney transplantation, even when allograft function is normal or near normal.",
"   </p>",
"   <p>",
"    Increases in total cholesterol and LDL levels are most common abnormalities, with elevated hypertriglyceride levels also usually noted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. Historically, single- and multi-center reports have estimated that, by one year post-transplant, 80 to 90 percent of adult recipients have total cholesterol levels &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and 90 to 97 percent have LDL levels &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Mean reported triglyceride levels values ranged from 160 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8 to 2.26",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. However, a more recent multi-center prospective cohort study reported LDL levels &gt;100",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    among 45 percent of patients, and mean triglyceride levels of 142",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    at six-months post-transplant, patterns that likely reflect use of modern immunosuppression as well as concomitant statin treatment in 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/11\">",
"     11",
"    </a>",
"    ]. HDL levels &lt;40",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    have been estimated in 14 to 48 percent of transplant recipients at one year or later post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive agents, particularly corticosteroids, calcineurin inhibitors, and rapamycin, have well-known dose-related effects on serum lipid levels. Other secondary causes in this patient population may include the nephrotic syndrome, hypothyroidism, diabetes mellitus, excessive alcohol intake, obesity, and chronic liver disease. Genetic predisposition and low daily exercise also contribute to dyslipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids alter lipoprotein metabolism to cause dyslipidemia, particularly elevated cholesterol levels, via multiple indirect pathways. These include hyperinsulinemia-mediated stimulation of hepatic VLDL synthesis and down-regulation of LDL receptors, possibly via ACTH suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trial data demonstrate that steroid withdrawal may lower total cholesterol and possibly triglyceride levels. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest multicenter placebo-controlled trial of steroid discontinuance, 500 patients administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and steroids were randomly assigned to no change or to low dose corticosteroids followed by complete tapering after 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/13\">",
"       13",
"      </a>",
"      ]. Steroid discontinuance was associated with stabilization of total cholesterol and triglyceride levels (average &lt;5 percent change by one year post-enrollment) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast, the 248 control participants experienced average increases of 29 and 10 percent in total cholesterol and triglyceride levels, respectively, at one year after transplant. However, at 6 months, the withdrawal group had significantly more biopsy-proven acute rejection episodes than the control group at both 6 (23 versus 14 percent) and 12 months (25 versus 15 percent).",
"     </li>",
"     <li>",
"      Another large prospective multi-center trial evaluated dyslipidemia and acute rejection rates among 266 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and corticosteroids who were randomly assigned to late steroid complete withdrawal or to a taper to a baseline",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose of 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/14\">",
"       14",
"      </a>",
"      ]. Over a period of observation from 3 months to 1 year post-transplant, the late steroid complete withdrawal group had an average 13.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.35",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      reduction in total cholesterol levels compared with the baseline steroid use group [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/14\">",
"       14",
"      </a>",
"      ]. There was no significant difference in average triglyceride levels. However, after 266 patients were enrolled, the patient enrollment was stopped because of excess rejection in the withdrawal group.",
"     </li>",
"     <li>",
"      In the open-label non-inferiority FREEDOM trial with a primary endpoint of 12-month GFR, 336 de novo transplant recipients were randomly assigned to steroid avoidance, early steroid withdrawal by seven days post-transplant, or \"standard-steroids\" in the context of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      induction,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/15\">",
"       15",
"      </a>",
"      ]. Median triglyceride levels at 12 months were significantly lower in the steroid-withdrawal compared to standard-steroids group (1.6 versus 1.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      but did not differ significantly between the steroid-free and standard-steroids group. Total, LDL, and HDL cholesterol levels were not significantly different among the study arms, but use of lipid-lowering therapy was lower in the steroid-withdrawal compared to the standard group (37 versus 52 percent). The incidence of the composite outcome of acute rejection, graft loss, or death was less favorable in the steroid-free (36 percent, p = 0.007 versus standard steroids) and steroid withdrawal (30 percent, not significant compared with standard steroids) compared to standard steroids group (19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a randomized, double-blinded, placebo-controlled trial, 386 patients were randomly assigned to corticosteroid withdrawal by day seven or to corticosteroid continuance, in which corticosteroids were tapered slowly to 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by day 180 and followed for five years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/17\">",
"       17",
"      </a>",
"      ]. Corticosteroid withdrawal but not corticosteroid continuance was associated with improved serum triglycerides (evaluated by mean and median change from baseline) at 12 months but not thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/17\">",
"       17",
"      </a>",
"      ]. There were no significant changes in total cholesterol, HDL, LDL, Framingham risk points, or cardiovascular serious adverse events at any time point in either the corticosteroid withdrawal group or the corticosteroid continuance group. There was no difference in the proportion of patients receiving dyslipidemia therapy in either the corticosteroid withdrawal or corticosteroid continuance group at baseline (30.4 and 28.7 percent, respectively) or at five years (62.1 and 73.5 percent, respectively). However, the proportion of patients who required institution of dyslipidemia therapy and remained on dyslipidemia therapy at the end of the study was higher in corticosteroid continuance group compared with the corticosteroid withdrawal group (67 percent versus 50.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits in terms of improved lipid levels with steroid withdrawal must therefore be considered in the context of higher acute rejection risk as well as a possible increased risk of allograft loss and recurrent glomerulonephritis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/13,14,18\">",
"     13,14,18",
"    </a>",
"    ]. In addition, steroid elimination may not yield a net benefit in the overall lipid profile, since it may depress protective HDL levels to the same extent as total cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/19\">",
"     19",
"    </a>",
"    ]; as a result, the HDL to total cholesterol ratio remains unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/19\">",
"     19",
"    </a>",
"    ]. Nonetheless, reducing steroids may have other cardioprotective benefits, including improved blood pressure and glucose tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    can directly cause post-transplant hypercholesterolemia, an effect that is independent of concurrent corticosteroid use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/20\">",
"     20",
"    </a>",
"    ]. The impact of cyclosporine upon lipid levels appears dose-dependent as trough blood levels of the agent correlate with elevations in total and LDL cholesterol concentrations and with reductions in HDL levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose-responsiveness of lipid levels was suggested in a trial of late",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    reduction among patients also being administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/22\">",
"     22",
"    </a>",
"    ]. In this study, 64 patients were randomly assigned to either continue their stable-maintenance cyclosporine dose or to lower their cyclosporine dose by 50 percent over a two month period. Cyclosporine reduction at one-year post-transplant produced a mean 29 percent reduction in triglycerides and a trend towards a modest reduction in total cholesterol after six months compared to baseline levels, versus no change among controls. No episode of acute rejection or graft loss occurred in either group.",
"   </p>",
"   <p>",
"    Converting from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may provide significant benefits in serum lipid levels. In a multicenter investigation, 124 patients at least one-year post-transplant were randomly assigned to the continuation of cyclosporine at target trough levels of 50 to 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    versus conversion to tacrolimus at target trough levels of 5 to 8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/23\">",
"     23",
"    </a>",
"    ]. After six months, participants in the tacrolimus group experienced significant mean reductions in LDL and triglycerides of 134 to 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.48 to 3.11",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and 186 to 152",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.11 to 1.72",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively. In addition, tacrolimus-related LDL reductions were confined to patients not using statins, the administration of which was not regulated.",
"   </p>",
"   <p>",
"    Several smaller randomized trials have also shown consistent reductions in total and LDL cholesterol after the conversion from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    among stable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lipid profiles may also be favorable among patients treated from the time of transplantation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    compared to those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two-year, intention-to-treat follow-up of 459 patients randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and steroids in the European Tacrolimus versus Cyclosporine A Microemulsion Renal Transplantation Study found significantly lower cholesterol and triglyceride levels in the tacrolimus arm [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/26\">",
"       26",
"      </a>",
"      ]. These differences occurred despite more frequent use of hypolipemic medications in the cyclosporine group (32 versus 16 percent).",
"     </li>",
"     <li>",
"      In the ELITE-Symphony study, 1645 kidney transplant recipients were randomly assigned to standard-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and corticosteroids, or to daclizumab induction, mycophenolate, and corticosteroids in combination with low-dose cyclosporine, low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , or low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/27\">",
"       27",
"      </a>",
"      ]. At 12 months, there were favorable prevalence estimates in the low-dose tacrolimus group concerning hyperlipidemia (10 versus 13 to 16 percent), hypercholesterolemia (5 versus 10 to 10 percent), and hypertriglyceridemia (3.5 versus 3.7 to 6.8 percent), although these proportions were not compared for statistical differences [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A follow-up observational study of Symphony trial participants reported that new onset hyperlipidemia developed within one to three years after transplant in 35 to 36 percent of patients who were initially assigned to receive cyclosporine (standard or low-dose) verus 26 percent of patients who were assigned to low-dose tacrolimus [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/28\">",
"       28",
"      </a>",
"      ]. Details concerning the ELITE-symphony study are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rapamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapamycin is frequently associated with dyslipidemias post-transplantation, particularly hypertriglyceridemia. The mechanism of action includes blocking insulin-stimulated lipoprotein lipase, as shown in an animal study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/29\">",
"     29",
"    </a>",
"    ]. This is also supported by the finding of fractional reductions in the catabolism of apoB100-containing lipoproteins in kidney transplant recipients with rapamycin-related hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of two similar multicenter, open-label pilot trials comparing rapamycin to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    as part of triple-drug combinations with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and antimetabolite agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ) for rejection prevention reveal the time course and degree of dyslipidemia that may occur in association with rapamycin as part of immunosuppression regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 83 participants being administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      were randomly assigned at the time of transplantation to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (initial target trough level of 200 to 400",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for two months, then 100 to 200",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      or rapamycin (target trough level 30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for two months, then 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      thereafter) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/31\">",
"       31",
"      </a>",
"      ]. At two months, the group receiving rapamycin had significantly higher mean triglyceride (469 versus 180",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and total cholesterol levels (355 versus 247",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      However, differences narrowed over the course of the study and became non-significant for total cholesterol by six months. Use of lipid-lowering therapy was also more common in the rapamycin group (39 versus 14 percent). Target rapamycin levels are now much lower, but dyslipidemia remains common with this drug.",
"     </li>",
"     <li>",
"      In another study that used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      as the anti-metabolite, 78 participants were randomly assigned at the time of transplantation to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or rapamycin according to the same target-level protocol as the previous study [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/32\">",
"       32",
"      </a>",
"      ]. Average total cholesterol and triglyceride levels were significantly higher among rapamycin-treated patients for the first 6 months, but not at 12 months (mean total cholesterol levels of 243 versus 222",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and mean triglycerides 193 versus 184",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in rapamycin and cyclosporine groups, respectively). Lipid-lowering therapy was used by a significantly higher proportion of patients receiving rapamycin versus cyclosporine (62 versus 29 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because neither pilot trial stratified analyses according to therapy for dyslipidemias, it is unclear whether the improvements in lipid levels with time in the rapamycin groups resulted from reductions in target trough levels or the use of adjuvant drugs.",
"   </p>",
"   <p>",
"    In the CONVERT trial, which randomly assigned 830 stable kidney transplant recipients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    to rapamycin conversion or continued use of calcineurin inhibitor, LDL cholesterol, HDL cholesterol and triglyceride levels peaked at two months after rapamycin conversion and then declined to month 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/33\">",
"     33",
"    </a>",
"    ]. Despite the decline, rapamycin conversion was associated with higher prevalence of hypertriglyceridemia (54 versus 26 percent) and hypercholesterolemia (42 and 12 percent) by month 24, even in the context of more common use of lipid-lowering therapy (78 and 55 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other secondary causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant patients should also undergo evaluation for other remediable secondary causes including nephrotic syndrome, hypothyroidism, diabetes, obesity, excessive alcohol administration, chronic liver disease, as well as a review of their medication list for drugs known to be associated with dyslipidemia. There are no published trials evaluating the impact of proteinuria reduction, as by angiotensin II-converting enzyme inhibition, on serum lipids in renal allograft recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2525201\">",
"    <span class=\"h2\">",
"     Isolated low HDL-cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;An isolated low HDL cholesterol concentration is generally defined as &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    However when considered as part of the metabolic syndrome, low HDL concentrations are defined by gender: &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for men and &lt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H3#H3\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on '2001 National Cholesterol Education Program/ATP III'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated low HDL cholesterol is primarily associated with high triglyceridemia and is commonly associated with uncontrolled diabetes, obesity, and low daily exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain immunosuppressive agents and other secondary causes have well-known dose-related effects on serum lipid levels. Balancing risks of rejection, immunosuppressive therapy, cardiovascular risks, and treatment options is complex.",
"   </p>",
"   <p>",
"    Given that allograft failure is the principal risk to a patient's health, dyslipidemia may be tolerated even if it cannot be treated optimally and is related to immunosuppressive therapy. Thus, if the perceived risks of dyslipidemia are less than the risk of alternative immunosuppression associated with decreased adverse lipid effect, immunosuppressive therapy should take precedence over dyslipidemic therapy. In general, we are inclined to replace",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    if dyslipidemia occurs, and continue low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 5 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lipid levels may fluctuate in the first months after transplantation with changes in nutritional status, renal function and medications, baseline lipid profiling should be undertaken to avoid delaying therapy in patients for whom it is indicated. Serum concentrations of fasting total cholesterol, LDL, HDL, and triglycerides should therefore be evaluated at patient presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The working group from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (NKF-K/DOQI)",
"    </span>",
"    recommends remeasurement of lipid profiles within 6 months of transplant, at one-year post transplant, and annually thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. Further testing should also be performed with changes in immunosuppressive therapy, graft function or other cardiovascular disease (CVD) risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our current policy is to assess for dyslipidemias at the time of transplant evaluation, upon presentation for transplantation, and quarterly thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF DYSLIPIDEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our general approach to treating dyslipidemias in adult kidney transplant recipients is consistent with that advanced by the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    working group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ], and incorporated in the 2009 KDIGO clinical practice guidelines for the management of kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/35\">",
"     35",
"    </a>",
"    ] and the 2012",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    Scientific Statement on Cardiac disease evaluation and management among kidney and liver transplantation candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/36\">",
"     36",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines in turn largely parallel the recommendations of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/37\">",
"     37",
"    </a>",
"    ] for the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .) In this topic review, there is a particular emphasis given to the high CVD risk associated with kidney transplantation and the prevalence of immunosuppression-related hypertriglyceridemia.",
"   </p>",
"   <p>",
"    Based almost entirely upon adverse results and benefits with therapy in the general population, four subgroups of renal allograft recipients with distinct lipid profiles are distinguished for particular anti-dyslipidemic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triglyceride levels &gt;500",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&gt;5.65",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      independent of elevated cholesterol levels",
"     </li>",
"     <li>",
"      LDL levels &gt;100",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&gt;2.59",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL levels &lt;100",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&lt;2.59",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      triglycerides levels &gt;200",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&gt;2.26",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and non-HDL cholesterol levels &gt;130",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&gt;3.36",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Isolated low HDL levels &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.03",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Very high triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some renal allograft recipients have very high triglyceride levels due primarily to the consequences of immunosuppressive medications. Because of the risk of pancreatitis with triglyceride levels that are greater than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;5.65",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    measures aimed at lowering such triglyceride levels take precedence over those that target elevated LDL cholesterol levels (See subsequent sections) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial attempt to lower triglyceride levels to less than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;5.65",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    should focus upon lifestyle changes such as abstinence from alcohol, treatment of hyperglycemia, increased physical activity, weight reduction, and possibly low-fat diets. However, diets should be used judiciously, if at all, in patients with protein-energy malnutrition. In addition, because kidney transplant recipients frequently have other nutritional concerns, dietary modification requires consultation with a dietitian experienced in the care of these patients. Alternatives to medications known to aggravate lipid levels should also be considered.",
"   </p>",
"   <p>",
"    If triglyceride levels remain greater than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;5.65",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    despite changes in life style and correction of secondary causes, drug treatment with the cholesterol uptake inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    or nicotinic acid should be initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       Ezetimibe",
"      </a>",
"      has triglyceride lowering effects when used as a single agent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/38-41\">",
"       38-41",
"      </a>",
"      ]. As an example, in one retrospective study of eight renal transplant recipients, ezetimibe as single agent therapy lowered triglyceride levels from 543",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      to 188",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/40\">",
"       40",
"      </a>",
"      ]. Although published trial evaluation of ezetimibe in the transplant population is currently limited, we support the use of this agent for hypertriglyceridemia based on extrapolation from general population studies and, in our experience, the absence of significant toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/38-40,42\">",
"       38-40,42",
"      </a>",
"      ]. The 2004",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines, by comparison, stated that ezetimibe should probably not be used in the transplant setting, until its safety was established [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nicotinic acid lowers triglycerides and LDL-cholesterol and raises HDL-cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"       \"Lipid lowering with drugs other than statins and fibrates\"",
"      </a>",
"      .) Although nicotinic acid is associated with a high incidence of side effects including flushing and hyperglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/44\">",
"       44",
"      </a>",
"      ], there are scant data on whether side effects are more common among patients with renal impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally avoid fibrates given the potential toxicity associated with these agents, particularly fibrate-related myositis and rhabdomyolysis. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Anti-dyslipidemic drug interactions and side effects'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .) Associations of fibrate therapy with 30 to 40 percent elevations in serum creatinine concentrations have also been noted in retrospective studies among patients with baseline renal dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    solid organ transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. While such changes are often reversible and their relation to true alterations of glomerular filtration rate is unclear, such elevations may complicate the assessment of other conditions such as acute rejection. A unique nephrotoxicity attributed to fibrates has also been described. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Anti-dyslipidemic drug interactions and side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among the different fibrates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , may pose the least risk of creatinine elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/45\">",
"     45",
"    </a>",
"    ]. Because this is the only agent of its class that does not require dose adjustment for renal impairment, it is probably the fibrate of choice for patients with chronic kidney disease. If administered, we use gemfibrozil at a dose of 600 mg twice a day.",
"   </p>",
"   <p>",
"    Other agents are also less desirable in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The triglyceride-lowering effects of statins are generally weak and they are not a first-line choice for this indication.",
"     </li>",
"     <li>",
"      Because bile acid sequestrants exacerbate hypertriglyceridemia in some patients, these drugs are",
"      <strong>",
"       contraindicated",
"      </strong>",
"      in patients with triglycerides &gt;400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and are relatively contraindicated in those with triglycerides &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/37\">",
"       37",
"      </a>",
"      ]. In addition, bile acid sequestrants may interfere with the absorption of immunosuppressive medications, although the data on drug interactions are limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with triglyceride levels &gt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;5.65",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    we first attempt lifestyle modifications in an attempt to decrease levels to less than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;5.65",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    If such lifestyle changes are inadequate after three months, we try monotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    (10 mg daily) or nicotinic acid (beginning with 250 mg per day and advancing slowly to 2 grams per day). We usually start with ezetimibe unless insurance or costs necessitate the use of nicotinic acid. As previously mentioned, we avoid fibrates, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , given the potential toxicity associated with these agents. In addition, the 2004",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines stated that ezetimibe should probably not be used in the transplant setting, until its safety was established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Elevated LDL-cholesterol levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The work group for",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    recommends treating renal transplant recipients with LDL levels that are greater than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to a goal LDL-cholesterol of less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines have also been incorporated in the 2009 KDIGO clinical practice guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/35\">",
"     35",
"    </a>",
"    ], and parallel the recommendations of the ATP III for the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the ATP III and",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines were published before newer lipid-lowering data were published that suggest even lower levels may be beneficial in the general patient population. Some experts now recommend a lower goal of less than 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for secondary prevention of coronary heart disease among the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .) We feel that these more aggressive guidelines may also be applicable for all renal transplant recipients, given that such patients are considered a high risk equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/47\">",
"     47",
"    </a>",
"    ]. However, recommendations for more aggressive lipid lowering have not been adopted by the 2009 KDIGO guidelines.",
"   </p>",
"   <p>",
"    In the general population, improvements in outcome with lipid-lowering therapy have almost entirely been demonstrated with statins. In addition, among heart transplant patients, statins are associated with significant mortality benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=see_link\">",
"     \"Lipid abnormalities after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, there are",
"    <strong>",
"     no",
"    </strong>",
"    definitive data of statin-related improvement in CVD outcomes in patients with kidney transplants, although there is suggestive evidence of some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     A",
"    </strong>",
"    ssessment of",
"    <strong>",
"     LE",
"    </strong>",
"    scol in",
"    <strong>",
"     R",
"    </strong>",
"    enal",
"    <strong>",
"     T",
"    </strong>",
"    ransplantation (ALERT) is the only randomized controlled trial on the effect of dyslipidemia management on CVD outcomes after kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/49\">",
"     49",
"    </a>",
"    ]. In this study, 2101 renal transplant recipients with total cholesterol levels between 154 and 347",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.0 to 9.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/49\">",
"     49",
"    </a>",
"    ]. After a mean follow-up of 5.1 years, the statin group achieved a 32 percent lower mean LDL level compared to the placebo group (average difference of 38",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    There was a non-significant trend with active therapy towards a reduction in the primary composite outcome of cardiac death, non-fatal myocardial infarction or coronary interventions (risk ratio of 0.83, 95% CI 0.64-1.06). In addition, significantly fewer cardiac deaths or non-fatal myocardial infarction, a secondary outcome, were observed with fluvastatin (70 versus 104, RR of 0.65, 95% CI 0.48-0.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2009 Cochrane meta-analysis of 16 studies including 3229 kidney transplant recipients compared statins with placebo (15 studies) or another statin (one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/52\">",
"     52",
"    </a>",
"    ]. There were nonsignificant trends towards a benefit of statins in terms of cardiovascular mortality (13 studies: RR 0.68, 95% CI 0.46-1.03) and non-fatal cardiovascular events (1 study: RR 0.70, 95% CI 0.48-1.01). Statins were not associated with lower all-cause mortality compared with placebo (14 studies: RR 1.30, 95% CI 0.54-3.12) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that included 3297 transplant recipients showed an uncertain impact of statin use versus placebo or no treatment on overall mortality (RR 1.05, 95% CI 0.84 to 1.31) but a possible reduction in cardiovascular mortality (RR 0.68, 95% CI 0.45 to 1.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the number of events was low.",
"   </p>",
"   <p>",
"    By comparison, significant long-term benefits in the primary composite outcome with statin therapy were observed in an extension of the ALERT study, in which all patients initially enrolled were offered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    for an additional two years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/50\">",
"     50",
"    </a>",
"    ]. At a mean total follow-up of 6.7 years, the group initially randomized to active therapy, compared to the original placebo group, had a significantly lower risk of the primary cardiac composite outcome (HR of 0.79, 95% CI 0.63-0.99). However, there was no significant difference in overall mortality and rate of allograft loss.",
"   </p>",
"   <p>",
"    Observational and post-hoc studies have also found that statins are associated with significant benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 2041 kidney allograft recipients (302 patients used statins while 1739 did not), multivariate analysis found that statin use was associated with significantly decreased all-cause mortality (0.65, 95% CI 0.48-0.86) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/54\">",
"       54",
"      </a>",
"      ]. There was no significant improvement in long-term allograft survival.",
"     </li>",
"     <li>",
"      Post-hoc analysis of the ALERT study found that the initiation of statin therapy early after transplantation provided more benefit than that observed with late initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/55\">",
"       55",
"      </a>",
"      ]. Compared with beginning statin therapy &gt;6 years post-transplant, initiation of therapy between years zero to two post-surgery lowered the risk of cardiac death and non-fatal myocardial infarction by 59 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of additional trials have evaluated the impact of statin therapy on indirect markers of atherosclerotic vascular disease risk in renal allograft recipients, including lipid profiles and measures of endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/56-63\">",
"     56-63",
"    </a>",
"    ]. Statin doses were low to moderate in all studies. A summary of some of the findings of these studies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average range in reductions in lipid levels was 18 to 33 percent for total cholesterol, 20 to 42 percent for LDL-cholesterol, and 0 to 23 percent for triglycerides, while average increases in HDL levels were 0 to 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/56-59\">",
"       56-59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Statin-related improvements have been noted in ultrasonographic measures of endothelial function [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/60\">",
"       60",
"      </a>",
"      ], in biopsies showing a decreased incidence of kidney transplant vasculopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/63\">",
"       63",
"      </a>",
"      ], and in the progression of atherosclerosis based upon carotid intima-media dimensions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also need for clinical trials investigating the safety and efficacy of new lipid-lowering agents in renal transplant recipients, such as the cholesterol uptake inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    . Published trial evaluation of ezetimibe in the transplant population is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/38,40,64,65\">",
"     38,40,64,65",
"    </a>",
"    ]. A prospective study of 18 renal transplant recipients with uncontrolled cholesterol levels despite statin therapy found that the combination of ezetimibe plus statin therapy significantly lowered LDL cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/64\">",
"     64",
"    </a>",
"    ]; ezetimibe therapy was stopped in two patients because of nausea and muscle pain without elevations in CK levels. We support the use of this agent as a second choice for renal transplant patients with high LDL-cholesterol levels based largely on extrapolation from general population studies and, in our experience, the absence of significant observed toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]. The 2004",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, by comparison, stated that ezetimibe should probably not be used in the transplant setting, until its safety was established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    in the non-transplant patient population is evolving. A surrogate endpoint trial, ENHANCE, involved 720 patients with heterozygous familial hypercholesterolemia who were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    80 mg daily with or without ezetimibe 10 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/7\">",
"     7",
"    </a>",
"    ]. Decreases in LDL-C were greater in patients treated with combination therapy (56 versus 39 percent) as were increases in HDL-C (10 versus 8 percent). Despite this, there was no statistically significant difference in the primary outcome of change from baseline in carotid intima-media thickness (0.0111 versus 0.0058 mm, p = 0.29) after two years. There did not appear to be a difference between the two arms in the small number of cardiovascular events (10 versus 7 events). The precise role of ezetimibe relative to other lipid-lowering drugs is unclear in non-transplant and transplant populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, the available body of evidence shows a consistent benefit of statin therapy upon cardiovascular risk surrogates and possibly upon clinical cardiac events in kidney transplant patients. However, a major concern in the transplant recipient has been a relatively high incidence of a clinically significant myopathy in patients also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Starting with a low statin dose substantially decreases the risk of muscle toxicity, and individual statins have different degrees of muscle toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Anti-dyslipidemic drug interactions and side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Issues surrounding the choice of a particular statin in the transplant population therefore involve balancing the relative risk of adverse effects (including adverse drug interactions) with efficacy (particularly in terms of cardiovascular benefit). As discussed elsewhere within this topic review, the largest experience in the kidney transplant population is with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    in the ALERT study, which found a non-significant trend with active therapy towards a reduction in the primary composite outcome and no difference in side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to the general population, a number of statins have shown substantial benefit in terms of cardiovascular mortality, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    . By comparison, there is a paucity of data concerning the efficacy of this agent in the kidney transplant population. Despite this, our statin of choice is atorvastatin because of superior results compared to other statins in non-transplant recipients, increased potency compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , and, in our experience, very few adverse events or drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with LDL &ge;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&ge;2.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    beginning at 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    We aim for a goal LDL-cholesterol of less than 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for secondary prevention of coronary heart disease. To attain this level, we increase atorvastatin to a maximum dose of 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or only to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in those also receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . If this dose fails to lower LDL-cholesterol levels adequately, we add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    as an additional agent. If myopathy or drug interactions occur, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    may be considered instead of atorvastatin, because these alternative statins have little or no muscle toxicity and are not metabolized by CYP3A4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , others prefer to initiate statin therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    instead of atorvastatin. Due to the frequent side effects associated with fibrates and nicotinic acid, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    as either an additional agent when necessary or as our second choice when a statin is not tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/42\">",
"     42",
"    </a>",
"    ]. As previously stated, the 2004",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, by comparison, stated that ezetimibe should probably not be used in the transplant setting, until its safety was established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, as noted in the non-transplant population, the precise role of ezetimibe relative to other lipid-lowering drugs is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Elevated non-HDL cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HDL-cholesterol is defined as the difference between the total cholesterol and HDL-cholesterol. Non-HDL-cholesterol includes all cholesterol present in lipoprotein particles that is considered atherogenic, including LDL, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As part of the \"metabolic syndrome\", elevations of non-HDL cholesterol levels plus triglycerides are linked with CVD risk in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Thus, based in part upon guidelines for the general population as suggested from the ATP III, we and the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines recommend that, among patients with LDL &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;2.59",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    triglyceride levels &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;2.26",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and non-HDL cholesterol &gt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;3.36",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    non-HLD cholesterol should be lowered to less than 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;3.36",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This pattern of dyslipidemia is managed with life style modifications including moderation of alcohol intake, exercise, and glycemic control. A statin is recommended for patients not already being administered this class of medication for treatment of LDL. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (beginning at 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    as our statin of choice because of the reasons previously delineated. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Elevated LDL-cholesterol levels'",
"    </a>",
"    above.) If goal levels are not met with the initial dose, we increase atorvastatin to a maximum dose of 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or only to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in those also receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . If myopathy or drug interactions occur, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    may be considered instead of atorvastatin, because these alternative statins have little or no muscle toxicity and are not metabolized by CYP3A4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .) Others prefer to initiate statin therapy with fluvastatin or pravastatin given these properties. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Anti-dyslipidemic drug interactions and side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For those who do not achieve goals with statins, the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines advise stopping the statin and treating with a fibrate. However, because of the frequent side effects associated with fibrates and nicotinic acid, we use the combination of a statin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    if goals are not met. If statins are not tolerated, we also prefer ezetimibe monotherapy as the alternative agent. However, the 2004",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, by comparison, stated that ezetimibe should probably not be used in the transplant setting, until its safety was established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Isolated low HDL-cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, epidemiologic studies have identified HDL cholesterol &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    levels as an independent risk factor for coronary heart disease even after adjustment for LDL cholesterol levels. In a single center study, low HDL (defined as &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in men or &lt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in women) was identified in 58 percent of renal allograft recipients at an average of 30 weeks after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/68\">",
"     68",
"    </a>",
"    ]. Low HDL was associated with approximately twice the odds of major adverse cardiovascular events (adjusted OR 1.92, 95% CI 1.15-3.20), a relationship that was statistically significant with or without other concomitant findings of \"metabolic syndrome.\"",
"   </p>",
"   <p>",
"    The first line of treatment for this pattern of dyslipidemia is therapeutic lifestyle modification, including regular aerobic exercise (at least 30 minutes per day), weight reduction to target normal body mass index (18.5 to &lt;25",
"    <span class=\"nowrap\">",
"     kg/m2),",
"    </span>",
"    smoking cessation, and mild-to-moderate alcohol consumption (no more than one to two drinks per day).",
"   </p>",
"   <p>",
"    Evidence for the efficacy of pharmacologically-induced HDL elevation to decrease adverse cardiovascular outcomes has been less consistent to date and is based entirely upon the non-transplant population. Agents that have been used include nicotinic acid, fibrates, and, to a lesser extent, statins. A phase 3 trial also evaluated torcetrapib. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No studies have been performed in kidney transplant patients with isolated low HDL-cholesterol levels. Given the frequent side effects associated with fibrates in transplant recipients, our current approach for kidney transplant patients with low HDL cholesterol after attempted lifestyle modification is to administer statin therapy to target an LDL-to-HDL cholesterol ratio &lt;2.0, if possible. By contrast, current",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines state that the risks of current pharmacological therapy to raise HDL (in the absence of high LDL or high triglycerides) probably outweigh the benefits in patients with kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other possible indications for lipid-lowering therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prevention of acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suggestion that statins may reduce rejection rates after solid organ transplantation comes from an observational study among patients with lung transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/6\">",
"     6",
"    </a>",
"    ]. This was also supported by findings from clinical trial data among heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to kidney transplantation, a number of randomized clinical trials have reported conflicting results concerning the impact of statin therapy on acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/7,8,69-71\">",
"     7,8,69-71",
"    </a>",
"    ]. The first published randomized trials of statins for prevention of acute rejection after kidney transplantation reported treatment-related absolute risk reductions of approximately 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, these positive conclusions are suspect because these studies were small in size, and had very high control acute rejection rates and design flaws. By comparison, three subsequent larger trials found no effect on acute rejection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. A 2009 Cochrane review found no difference in the risk of acute rejection with statin use compared with placebo (5 studies: RR 0.61; 95% C.I.0.32-1.16) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these trials, there is inadequate evidence to support the use of statins for lowering the risk of acute allograft rejection after kidney transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Preservation of renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have reported links between dyslipidemias and decreased renal function in non-renal transplant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .) A paucity of data exists concerning the preservation of renal function in renal transplant recipients and treatment of dyslipidemias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single center study reported favorable creatinine clearance estimates and reduced histological markers of interstitial fibrosis over the first year post-transplant among 44 statin-treated renal allograft recipients compared to 33 untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/72\">",
"       72",
"      </a>",
"      ]. However, interpretation of these findings is limited by the retrospective design, small sample, and lack of adjustment for potential confounding.",
"     </li>",
"     <li>",
"      In the previously mentioned ALERT trial, there was no difference in the secondary end-points of graft loss, doubling of serum creatinine concentration, and decline in glomerular filtration rate between patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/49,73\">",
"       49,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single-center retrospective study of 615 consecutive kidney transplant recipients (1998-2002) found no association of statin use (defined by reported use at two or more quarterly followup visits) with either graft or patient survival within the first year [",
"      <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anti-dyslipidemic drug interactions and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the statins, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , are metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) hepatic enzyme system. This enzyme system is also responsible for the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Despite the shared metabolic pathway, it is the level of the statins that tends to be most affected (raised) with concurrent therapy with both classes of agents and not that of the immunosuppressive agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    increases blood levels of essentially all statins investigated, regardless of the pathway of statin metabolism. This can be associated with significant myopathy, including rhabdomyolysis, although myopathy is rare with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clearances of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    do not rely upon CYP3A4, but increased levels of all these drugs have been reported with co-administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in kidney",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heart transplant recipients. In pharmacokinetic studies limited to patients with kidney transplants, statin levels increased 3- to 20-fold and elevations appeared greatest for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The randomized controlled trials of statin use (low to moderate doses) among renal allograft recipients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based immunosuppression for the reduction of CVD risk surrogates or events, or for the prevention of acute allograft rejection have reported some adverse events or safety markers, although some variability in ascertaining such events were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/7,8,49,56-62,69-71\">",
"     7,8,49,56-62,69-71",
"    </a>",
"    ]. The ALERT trial, by enrolling the largest sample for the longest follow-up (over 10,000 patient-years), afforded the greatest power for detecting drug-related side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/49\">",
"     49",
"    </a>",
"    ]. This study found no difference in the frequencies of total or types of adverse events among patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    compared with placebo, including no difference in rates of infections and malignancies.",
"   </p>",
"   <p>",
"    Although interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and statins are well described, limited data are available on potential interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and statins. A pharmacokinetics study examined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    levels in 13 healthy volunteers after four days of statin treatment and short (12 hour) concomitant exposure to cyclosporine or tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/75\">",
"     75",
"    </a>",
"    ]. Systemic exposure to atorvastatin and its metabolites was increased when atorvastatin was administered with cyclosporine, but not when administered with tacrolimus. In a small study of 24 tacrolimus-treated kidney transplant recipients, the addition of atorvastatin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    did not change tacrolimus pharmacokinetics or creatinine kinase levels, although the effect of tacrolimus use on statin levels was not studied [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of fibrate-related myositis and rhabdomyolysis are higher in patients with CKD. The safety of combining fibrates with statins has not been well-studied in patients with CKD and should be",
"    <strong>",
"     avoided",
"    </strong>",
"    pending more clinical information.",
"   </p>",
"   <p>",
"    A unique nephrotoxicity attributed to fibrates has also been described. Acute renal failure due to biopsy-verified proximal tubule dysfunction was reported in three renal transplant recipients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/77\">",
"     77",
"    </a>",
"    ]. Renal dysfunction was not thought to be due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    as serum levels of these agents were in the therapeutic range. Renal dysfunction resolved with discontinuation of fenofibrate. Additional case reports and case series have described fenofibrate-associated increases in serum creatinine levels in a variety of patient populations, with a suggestion that the risk may be higher in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible mechanisms for the nephrotoxicity attributed to fibrates may include direct increases in skeletal muscle creatinine production and alteration of renal hemodynamics. In a small study of 26 hyperlipemic patients administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    200 mg daily for two weeks, treatment was associated with increased creatininemia compared to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/79\">",
"     79",
"    </a>",
"    ]; however, since this was countered by increased creatinine excretion, creatinine clearance remained unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?28/54/29546/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although lipid abnormalities are common complications of kidney transplantation, a causal association of dyslipidemias with cardiovascular risk has not been proven in this population. However, due to the high incidence of atherosclerotic disease events in the renal transplant population, we and several national groups consider renal transplantation to be a coronary heart disease equivalent risk. Thus, the assessment and treatment of dyslipidemias in kidney transplant patients should be part of routine post-renal-transplant care. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive medications, particularly corticosteroids, calcineurin inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      more than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and rapamycin, frequently cause secondary dyslipidemias. Regimens should therefore be individualized to minimize competing risks of rejection and cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Causes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=see_link\">",
"       \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We assess for dyslipidemias at the time of transplant evaluation, upon presentation for transplantation, and quarterly thereafter. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific interventions aimed at lifestyle modification, such as abstinence from alcohol, treatment of hyperglycemia, increased physical activity, weight reduction, and possibly low-fat diets requires consultation with a dietician experienced in the care of kidney transplant recipients. Issues related to glycemic control are also specifically discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"       \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with triglyceride levels &gt;500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;5.65",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we first recommend attempting lifestyle modifications and correction of secondary causes in an attempt to decrease levels to less than 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;5.65",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If such interventions are inadequate after three months, we initiate therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      alone. If insurance or cost is an issue, we use nicotinic acid alone as the alternative agent. We suggest NOT administering fibrates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Very high triglycerides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with LDL &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;2.6",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend life style modifications and statin therapy to lower LDL cholesterol levels (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , which is our statin of choice (beginning at 10",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      We aim for a goal LDL-cholesterol of less than 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      To attain this level, we increase atorvastatin to a maximum dose of 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or rarely above 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in those also receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . If this dose fails to lower LDL-cholesterol levels adequately, we suggest administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      as an additional agent. If myopathy or drug interactions occur, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      may be considered instead of atorvastatin, because these alternative statins have little or no muscle toxicity and are not metabolized by CYP3A4. Others prefer to initiate statin therapy with fluvastatin or pravastatin, rather than atorvastatin, given these properties. When statins are not tolerated, we administer ezetimibe alone. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Elevated LDL-cholesterol levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with LDL &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;2.6",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      triglycerides &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.26",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and non-HDL cholesterol &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;3.36",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend the institution of life style modifications and the administration of a statin (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our goal is to lower the non-HDL cholesterol level to less than 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.36",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      We suggest the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (beginning at 10",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which is our agent of choice. To attain goal levels, we increase atorvastatin to a maximum dose of 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or rarely above 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in those also receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . If myopathy or drug interactions occur, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      may be considered instead of atorvastatin, because of these properties. Others prefer to initiate statin therapy with either fluvastatin or pravastatin given that these drugs have little or no muscle toxicity and are not metabolized by CYP3A4. We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      as an additional agent if goals are not met with statin therapy alone. If statins are not tolerated, we also prefer ezetimibe monotherapy as the alternative agent. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Elevated non-HDL cholesterol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with isolated low HDL levels &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.03",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we suggest the institution of lifestyle modifications. Our goals are to raise the HDL cholesterol above 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in men and above 55",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in women and to lower the non-HDL cholesterol level to less than 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.36",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      For those in whom we are unable to achieve these goals, we suggest the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (beginning at 10",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which is our agent of choice. To attain goal levels, we increase atorvastatin to a maximum dose of 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or rarely above 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in those also receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . If myopathy or drug interactions occur, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      may be considered instead of atorvastatin, because of these properties. Others prefer to initiate statin therapy with either fluvastatin or pravastatin, given that these drugs have little or no muscle toxicity and are not metabolized by CYP3A4.",
"     </li>",
"     <li>",
"      Significant drug interactions and adverse effects are associated with the combination of a number of lipid-lowering agents and immunosuppressive agents. This includes significant myopathy and rhabdomyolysis. The safety of combining fibrates with statins has not been well-studied in patients with CKD and should be",
"      <strong>",
"       avoided",
"      </strong>",
"      pending more clinical information. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Anti-dyslipidemic drug interactions and side effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/1\">",
"      Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 Suppl 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/2\">",
"      Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/3\">",
"      LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/4\">",
"      Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/5\">",
"      Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/6\">",
"      Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/7\">",
"      Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. Transplantation 1996; 61:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/8\">",
"      Tuncer M, S&uuml;leymanlar G, Ersoy FF, Yakupolu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc 2000; 32:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/9\">",
"      Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc 1992; 67:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/10\">",
"      Moore R, Thomas D, Morgan E, et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc 1993; 25:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/11\">",
"      Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/12\">",
"      Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/13\">",
"      Vanrenterghem Y, Lebranchu Y, Hen&eacute; R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/14\">",
"      Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/15\">",
"      Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8:307.",
"     </a>",
"    </li>",
"    <li>",
"     Cantarovich, D, Rostaing, L, Kamar, N, et al. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed. Transpl Int; 2009 Oct 19 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/17\">",
"      Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/18\">",
"      Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/19\">",
"      Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/20\">",
"      Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 18:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/21\">",
"      Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994; 57:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/22\">",
"      Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/23\">",
"      Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/24\">",
"      McCune TR, Thacker LR II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998; 65:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/25\">",
"      Kohnle M, Zimmermann U, L&uuml;tkes P, et al. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transpl Int 2000; 13 Suppl 1:S345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/26\">",
"      Kr&auml;mer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005; 20:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/27\">",
"      Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/28\">",
"      Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/29\">",
"      Kraemer FB, Takeda D, Natu V, Sztalryd C. Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. Metabolism 1998; 47:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/30\">",
"      Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001; 72:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/31\">",
"      Groth CG, B&auml;ckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/32\">",
"      Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/33\">",
"      Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/34\">",
"      Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/35\">",
"      KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation 2009; 9:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/36\">",
"      Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2012; 60:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/37\">",
"      Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/38\">",
"      Puthenparumpil JJ, Keough-Ryan T, Kiberd M, et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/39\">",
"      Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/40\">",
"      Buchanan C, Smith L, Corbett J, et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/41\">",
"      Yoon HE, Song JC, Hyoung BJ, et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med 2009; 24:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/42\">",
"      Abbud-Filho M, Adams PL, Alber&uacute; J, et al. A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation 2007; 83:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/43\">",
"      Lal SM, Hewett JE, Petroski GF, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis 1995; 25:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/44\">",
"      Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995; 99:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/45\">",
"      Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/46\">",
"      Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/47\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/48\">",
"      Lentine KL, Brennan DC. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant 2004; 19:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/49\">",
"      Holdaas H, Fellstr&ouml;m B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/50\">",
"      Holdaas H, Fellstr&ouml;m B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/51\">",
"      Jardine AG, Holdaas H, Fellstr&ouml;m B, et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/52\">",
"      Navaneethan SD, Perkovic V, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009; :CD005019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/53\">",
"      Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/54\">",
"      Wiesbauer F, Heinze G, Mitterbauer C, et al. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol 2008; 19:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/55\">",
"      Holdaas H, Fellstr&ouml;m B, Jardine AG, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005; 20:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/56\">",
"      Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993; 8:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/57\">",
"      Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/58\">",
"      Renders L, Mayer-Kadner I, Koch C, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/59\">",
"      Santos AF, Keitel E, Bittar AE, et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc 2001; 33:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/60\">",
"      Hausberg M, Kosch M, Stam F, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001; 59:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/61\">",
"      Cofan F, Gilabert R, Zambon D, et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc 2002; 34:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/62\">",
"      Asberg A, Holdaas H, Jardine AG, et al. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplant 2003; 17:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/63\">",
"      Ser&oacute;n D, Oppenheimer F, Pallard&oacute; LM, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation 2008; 86:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/64\">",
"      Kohnle M, Pietruck F, Kribben A, et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006; 6:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/65\">",
"      Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006; 81:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/66\">",
"      Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81:7B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/67\">",
"      Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/68\">",
"      Barn K, Laftavi M, Pierce D, et al. Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients. Transpl Int 2010; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/69\">",
"      Kasiske BL, Heim-Duthoy KL, Singer GG, et al. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/70\">",
"      Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001; 60:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/71\">",
"      Sahu K, Sharma R, Gupta A, et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant 2001; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/72\">",
"      Masterson R, Hewitson T, Leikis M, et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 2005; 80:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/73\">",
"      Fellstr&ouml;m B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/74\">",
"      Younas N, Wu CM, Shapiro R, et al. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival. BMC Nephrol 2010; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/75\">",
"      Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005; 5:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/76\">",
"      Katsakiori PF, Papapetrou EP, Goumenos DS, et al. Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. Indian J Pharmacol 2011; 43:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/77\">",
"      Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am J Kidney Dis 2004; 44:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/78\">",
"      McQuade CR, Griego J, Anderson J, Pai AB. Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health Syst Pharm 2008; 65:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/54/29546/abstract/79\">",
"      Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92:536.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7303 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29546=[""].join("\n");
var outline_f28_54_29546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rapamycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other secondary causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2525201\">",
"      Isolated low HDL-cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF DYSLIPIDEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Very high triglycerides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Elevated LDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Elevated non-HDL cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Isolated low HDL-cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other possible indications for lipid-lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prevention of acute rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Preservation of renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anti-dyslipidemic drug interactions and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=related_link\">",
"      Lipid abnormalities after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=related_link\">",
"      Risk factors for cardiovascular disease in the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_54_29547="Dx criteria generalized anxiety";
var content_f28_54_29547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for generalized anxiety disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Excessive anxiety and worry about a number of events",
"or activities, occurring more days than not for at least six months,",
"that are out of proportion to the likelihood or impact of feared events.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. The worry is pervasive and difficult to control.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        3. The anxiety and worry are associated with three (or",
"more) of the following six symptoms (with at least some symptoms",
"present for more days than not for the past six months):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Restlessness or feeling",
"keyed up or on edge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Being easily fatigued",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Difficulty concentrating or mind going blank",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Muscle tension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sleep disturbance",
"(difficulty falling or staying asleep, or restless unsatisfying sleep)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. The anxiety, worry, or physical symptoms cause",
"clinically significant distress or impairment in social, occupational,",
"or other important areas of functioning.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29547=[""].join("\n");
var outline_f28_54_29547=null;
var title_f28_54_29548="Maternal analyte changes associated w adverse pregnancy outcome";
var content_f28_54_29548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Associations between maternal serum markers for aneuploidy and adverse outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preeclampsia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Birthweight less than 10th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preterm birth",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fetal death at or before 24 wk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fetal death after 24 wk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAPP-A (&lt;0.42 MoM)",
"       </td>",
"       <td>",
"        +/++",
"       </td>",
"       <td>",
"        ++/+++",
"       </td>",
"       <td>",
"        <p>",
"         + (32 wk or less)",
"        </p>",
"        <p>",
"         ++ (less than 34 wk)",
"        </p>",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++/+++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Free &beta;-hCG (&lt;0.21 MoM)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -/++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AFP (&gt;2.0 MoM)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        <p>",
"         - (32 wk or less)",
"        </p>",
"        <p>",
"         + (37 wk)",
"        </p>",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -/+++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        hCG (&gt;2.0 MoM)*",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         - (greater than 24 wk)",
"        </p>",
"        <p>",
"         +++ (greater than 500 g)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        uE3 (&lt;0.5 MoM)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibin A (&gt;2.0 MoM)",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: adjusted odds ratio (OR) greater than 1.0; ++: adjusted OR greater than 2.0; +++: adjusted OR greater than 3.0; -: adjusted OR not significant (P &ge;.05); PAPPA: pregnancy-associated plasma protein-A; MoM: multiples of the median; AFP: alpha-fetoprotein; uE3: unconjugated estriol.",
"     <br>",
"      * Although an isolated human chorionic gonadotropin (hCG) was not significantly associated with the adverse outcomes, a hCG level greater than 2.0 MoM was significantly associated with preeclampsia, birth weight less than the 10th percentile for gestational age, preterm birth 32 weeks or less, and early and late fetal loss.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dugoff L. Society for Maternal-Fetal Medicine: First- and Second-Trimester Maternal Serum Markers for Aneuploidy and Adverse Obstetric Outcomes. Obstet Gynecol 2010; 115:1052. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29548=[""].join("\n");
var outline_f28_54_29548=null;
var title_f28_54_29549="Etiology of chronic meningitis";
var content_f28_54_29549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential causes of chronic meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mycobacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mycobacterium tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Spirochetal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Borrelia burgdorferi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Treponema pallidum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leptospira",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brucella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Francisella tularensis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Actinomyces",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Listeria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ehrlichia chaffeensis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nocardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Whipple's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Human immunodeficiency virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epstein-Barr virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Human T cell lymphotrophic virus I and II",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Enterovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Herpes simplex virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Varicella zoster virus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections (cont.)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cryptococcus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sporothrix",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histoplasma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Blastomyces",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coccidioides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Other (eg, Pseudallescheria, Paracoccidioides, dematiaceous molds)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Parasitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Taenia solium (cysticercosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Angiostrongylus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Schistosoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toxoplasma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acanthamoeba",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Noninfectious conditions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neoplastic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fabry disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Central nervous system vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vogt-Koyanagi-Harada disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chemical or drug-induced meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic (up to one-third of cases)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nonsteroidal antiinflammatory drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intravenous immunoglobulin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intrathecal agents",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29549=[""].join("\n");
var outline_f28_54_29549=null;
var title_f28_54_29550="Postoperative nipple inversion";
var content_f28_54_29550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postoperative nipple inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postoperative inversion of the nipple can occur with reduction mammoplasty. The breast may pull on the nipple-areola complex leading to inversion, particularly if the nipple was inverted or flat initially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29550=[""].join("\n");
var outline_f28_54_29550=null;
var title_f28_54_29551="Partogram form";
var content_f28_54_29551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Primigravid labor record",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 702px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advancement of cervical dilation charted on a partogram.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_54_29551=[""].join("\n");
var outline_f28_54_29551=null;
